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Mutations in MECP2 are responsible for Rett syndrome (RTT), a severe X-linked neurological disorder
characterized by loss of developmental milestones, intellectual disability and motor impairments.
However, molecular insight into how these mutations affect the neuronal transcriptiome, disrupt neuronal
function and contribute to RTT is impeded by the cellular heterogeneity of the mammalian brain. A
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allows the tag to be post-translationally modified with biotin in a cell type-specific manner. Altogether,
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Finally, this genetic strategy circumvents genetic mosaicism associated with female mouse models of
RTT and identifies functionally distinct transcriptional changes between neighboring WT and mutant
neurons, therefore providing key insights into phenotypic severity between RTT-associated mutation
types. By assessing RTT transcriptomes across various neuronal contexts, I propose a novel
contextualized paradigm for MeCP2 function in neuronal cell types that not only hypothesizes how
MeCP2 dysfunction leads to the cellular deficits that give rise to RTT-like phenotypes, but identifies novel
transcriptional and post-transcriptional mechanisms that may be future therapeutic targets for RTT.
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ABSTRACT
CONTEXTUAL INSIGHTS INTO THE RETT SYNDROME TRANSCRIPTOME
Brian S.R. Johnson
Zhaolan Zhou, Ph.D.
Mutations in MECP2 are responsible for Rett syndrome (RTT), a severe X-linked
neurological disorder characterized by loss of developmental milestones, intellectual disability and
motor impairments. However, molecular insight into how these mutations affect the neuronal
transcriptiome, disrupt neuronal function and contribute to RTT is impeded by the cellular
heterogeneity of the mammalian brain. A comparison between gene expression changes in the
striatum, hypothalamus, and cerebellum of MeCP2-null mice revealed that gene expression
changes are distinct between different brain regions, which suggests that MeCP2 function should
be understood in a cell type-dependent context. To accomplish this task, I generated and
phenotypically characterized tagged knock-in mice bearing frequent RTT mutations in Mecp2
(T158M, R106W). Concurrently, I also developed a novel genetic system that allows the tag to be
post-translationally modified with biotin in a cell type-specific manner. Altogether, these mice
allow for molecular profiling of WT and mutant cortical neurons in the mammalian brain. MeCP2dependent gene expression changes vary by age and cell type, and the degree of Pol II-mediated
transcriptional changes genome-wide correlates with the severity of the RTT mutation. I also
detected evidence that supports the post-transcriptional compensation of misregulated long
genes, leading to a reinterpretation of prevailing thought within the RTT research field with
regards to MeCP2 function. Finally, this genetic strategy circumvents genetic mosaicism
associated with female mouse models of RTT and identifies functionally distinct transcriptional
changes between neighboring WT and mutant neurons, therefore providing key insights into
phenotypic severity between RTT-associated mutation types. By assessing RTT transcriptomes
across various neuronal contexts, I propose a novel contextualized paradigm for MeCP2 function
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in neuronal cell types that not only hypothesizes how MeCP2 dysfunction leads to the cellular
deficits that give rise to RTT-like phenotypes, but identifies novel transcriptional and posttranscriptional mechanisms that may be future therapeutic targets for RTT.
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CHAPTER 1: Introduction
1

General Introduction
1.1

THE MECP2 GENE AND PROTEIN
1.1.1

MECP2 Gene and Protein Structure and Function

Methyl-CpG binding protein 2 (MeCP2) was first detected in a biochemical screen to
identify and clone novel protein factors from crude rodent nuclear extracts that were capable of
binding to a single symmetrically methylated CpG (Lewis et al., 1992). In this initial study, MeCP2
was described as an 84kDa protein that demonstrated robust binding to methylated CpG, but
showed weak or undetectable binding for hemi-methylated or non-methylated CpGs, respectively.
Expression cloning was used to identify the ORF from a rat brain cDNA library. Strangely, this
ORF was predicted to encode a protein of 53kDa, suggesting that MeCP2 exhibits lower mobility
on an SDS-PAGE gel than expected. Immunofluorescent staining in cultured rat cells using an
antibody raised against MeCP2 revealed that this protein was likely chromatin bound in the
nucleus, which was confirmed through its release from mouse nuclei following enzymatic digest
of DNA. In addition to being uniformly distributed throughout the mouse nucleus, MeCP2 also
demonstrated strong punctate nuclear staining due to association with pericentromeric chromatin,
which suggested that MeCP2 is distributed over euchromatic and heterochromatic regions. These
nuclear puncta, which was estimated to contain over 40% of all methyl-CpGs in the mouse
nucleus, are enriched for satellite repeat units, each of which are AT-rich and contain at least
seven methylated CpGs per unit. Thus MeCP2 was initially described as a chromatin associated
nuclear protein that binds to methyl-CpG-rich containing DNA.
MeCP2 is a founding member of the methyl-CpG binding domain (MBD) family of
proteins that have binding affinity for methylated DNA (Lewis et al., 1992). In addition to the MBD,
which principally dictates MeCP2 interactions with symmetrically methylated CpGs, MeCP2 also
1

contains a transcriptional repression domain (TRD) which mediates protein-protein interactions
with various histone deacetylase (HDAC) co-repressor complexes, including the NCoR-SMRT
and Sin3A-HDAC1&2 comples (Ebert et al., 2013; Nan et al., 1996, 1997, 1998). Hence MeCP2
is traditionally known to bind to methylated DNA and mediate transcriptional repression in vivo.
MeCP2 also contains a Nuclear Localization Sequence (NLS) within the interior of the TRD and
mediates its localization to the nucleus (Lewis et al., 1992). In addition to the two principal
domains (MBD and TRD) that are critical for MeCP2 function, MeCP2 also has a long C-terminal
Domain (CTD) that, although unstructured, may be important for MeCP2 binding in a methylationindependent manner (Heckman et al., 2014; Nikitina et al., 2007a). The CTD may also play a role
in modulating chromatin structure, as several AT-hook domains, which closely resemble those
found in the family of high-mobility group proteins, are spaced throughout the C-terminal tail and
are required for proper binding of MeCP2 to chromatin in vivo (Baker et al., 2013).
Aside from the well conserved and highly structured MBD domain, more than 60% of
MeCP2 is intrinsically disordered and does not adopt strong secondary protein structure, although
the protein becomes more structured upon binding to methylated DNA (Adams et al., 2007). This
unusual property is thought to underlie the multifunctional roles associated with MeCP2 as a
chromatin-bound architectural protein that can modulate transcription. Like most unstructured
proteins, MeCP2 has thus been shown to interact with multiple protein partners that help define
its function. In addition to the NCoR-SMRT and Sin3a complexes, MeCP2 has also been shown
to interact with additional co-repressors, including cSki, and CoREST (Abuhatzira et al., 2007;
Kokura et al., 2001), transcriptional activators such as CREB (Chahrour et al., 2008), and RNAbinding proteins that may influence RNA splicing, such as YB1 and TDP-43 (Sephton et al., 2011;
Young et al., 2005). MeCP2 is also known for interacting with proteins that regulate epigenetic
alterations to chromatin structure, including, but not limited to, ATRX, Dnmt1, Tet1, and HP1
(Cartron et al., 2013; Chatr-Aryamontri et al., 2013; Kernohan et al., 2014; Nan et al., 2007).
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The human MECP2 gene is mapped to the Xq28 gene locus, and is thus subject to Xinactivation in females. The gene encompasses 152kb of genomic sequence in humans and
123kb of genomic sequence in mice, and is comprised of four coding exons. While exons 1 and 2
are alternatively spliced (described below) and encode the N-terminal domain of MeCP2, exons 3
and 4 encode both halves of the MBD, and exon 4 encodes the NLS, TRD, and remainder of the
C-terminal domain, as well as the 3’-UTR (described below). Transcriptional regulation of MeCP2
is likely to be extensive, as the second intron of MeCP2 (between exons 2 and 3) is atypically
long at 60kb and contains several regions with high evolutionary conservation (Singh et al., 2008)
and likely contains multiple regulatory elements. A recent study performing a comparative
sequence analysis of the MECP2-gene in both human and mice found 170 conserved elements
>50bp in length, five of which are found with MECP2 exon sequences, and 109 of which are
found in untranslated regions and intron sequences (Reichwald et al., 2014).
Exon 1 and exon 2 of the MECP2 gene each contain an ORF and are subject to
alternative splicing, producing two translated protein products that, aside from unique amino
termini that differ in size by 13 amino acids, remain 96% similar in primary sequence. The
MeCP2-e1 isoform (which was previously known as MeCP2B due to its order of discovery, or
MeCP2α), which is derived from exons 1,3, and 4, is 498 amino acids long and is more
abundantly expressed in neurons than glia throughout the mouse brain, although it’s abundance
varies between individual brain regions (Dragich et al., 2007; Kriaucionis and Bird, 2004;
Mnatzakanian et al., 2004; Zachariah et al., 2012). In contrast, the MeCP2-e2 isoform (previously
known as MECP2A or MeCP2β) derived from exons 2-4 is 486 amino acids long, with sequences
in exon 1 contributing to the 5’-UTR that are required for translation of MeCP2-e2 (Saxena et al.,
2006). Although the overall abundance of MeCP2-e2 in the mouse brain is significantly lower
(~10X less abundant) relative to MeCP2-e1, MeCP2-e2 demonstrates a more restricted
spatiotemporal pattern of expression, being widely expressed during early postnatal development
before being restricted to the dorsal thalamus and cortical laver V of the brain (Dragich et al.,
2007). Despite the differences in abundance and patterns of expression, the high similarity in C3

terminal sequence suggests that both isoforms appear to be functionally equivalent, and the
transgenic expression of each isoform in mice demonstrates that one isoform can functionally
compensate for the other (Kerr et al., 2012). However, the lack of pathogenic mutations in exon 2
of the MECP2 gene, in contrast to several that have been identified in exon 1, suggests that
MeCP2-e2 is likely indispensible for function in contrast to MeCP2-e1 (Gianakopoulos et al.,
2012; Itoh et al., 2012; Saunders et al., 2009; Saxena et al., 2006). As a result, the remainder of
this section will only consider MeCP2 in the context of the MeCP2-e1 isoform.
MeCP2 is expressed in multiple tissues and organs of the human and mouse body to a
variable degree. MeCP2 protein expression is highest in the brain, lung, and spleen, lower in the
heart and kidney, and barely detectable in liver, stomach, and small intestine (Shahbazian et al.,
2002b). However, MeCP2 RNA transcripts is detected in all human and mouse tissues, which
suggests that this protein is significantly regulated at a post-transcriptional level (Shahbazian et
al., 2002b). Post-transcriptional regulation likely arises from it’s 3’-UTR in exon 4, which
represents one of the longest 3’-UTRs in the human genome and is subject to alternative
polyadenylation usage, resulting in mRNA transcripts 1.9kb, 5kb, 7.5kb and 10.1kb in size (Coy et
al., 1999; Reichwald et al., 2014; Singh et al., 2008). These transcripts exhibit tissue-specific
expression patterns but have almost identical half lives, and the shortest and longest transcripts
contain AU-rich elements which are known to be associated with reduced RNA transcript stability
(Reichwald et al., 2014). The shortest transcript is detectable in heart, skeletal, muscle, and
spleen tissues, whereas the longest transcript is detectable in skeletal muscle, kidney, pancreas,
and brain (Reichwald et al., 2014). The longest 3’-UTR (10.1kb), exhibits between 52%-74%
sequence homology between human and mice (depending on the study), and exhibits low
ubiquitous expression in early organogenesis but higher expression in the mature brain (Coy et
al., 1999; Reichwald et al., 2014). Furthermore, changes in polyadenylation usage over age result
in the postnatal decrease, than increase in usage of the long 3’-UTR, which negatively correlates
with postnatal changes in MeCP2 expression as mice age (Balmer et al., 2002; Pelka et al., 2005;
Shahbazian et al., 2002b). The evolutionary conservation of the long 3’-UTR is limited to blocks of
4

primary sequences that are highly conserved across mice, humans kangaroo, rat, hamster,
macaque, and chimpanzee sequences and suggests the potential for post-transcriptional
regulation by miRNAs (Coy et al., 1999; Klein et al., 2007). One brain-enriched and activitydependent miRNA, miR-132, has been shown to recognize this long 3’-UTR and downregulate
MeCP2 expression in response to neuronal depolarization in primary cortical neurons (Klein et
al., 2007). Interestingly, this study found that miR-132 expression is induced through activitydependent expression of Bdnf, a well-known MeCP2 target gene, which suggests that MeCP2
may indirectly downregulate its expression in the brain in response to neuronal activity as a
means of homeostatic control. Similar homeostatic loops have been identified for miRNA-212 in
mediating cocaine responses in the striatum, miR-7b during postnatal maturation of Mecp2
expression in neurons, among others (Chen et al., 2014; Im et al., 2010), suggesting complex
neurodevelopmental regulation of MeCP2 expression that may change with age.
MeCP2 protein is highest in post-mitotic neurons of the mammalian brain. Neuronal
MeCP2 is relatively low a birth, but dramatically increases with age as neurons mature and
undergo synaptogenesis (Alvarez-Saavedra et al., 2007; Chen et al., 2015; Kishi and Macklis,
2010; Shahbazian et al., 2002b; Skene et al., 2010). The rapid increase in MeCP2 expression
levels is particularly steep within the mouse neocortex and hippocampus, which undergo
synaptogenesis within the first two weeks of murine post-natal life, whereas the cerebellum
displays a delayed increase in expression after four weeks of age (Mullaney et al., 2004).
Biochemical quantification and comparison of MeCP2 abundance in the adult mouse revealed
that each post-mitotic neuronal nucleus contains 16 million molecules of MeCP2, in contrast to 2
million molecules of MeCP2 in glial nuclei (8 times less abundant) and 500,000 molecules of
MeCP2 in liver hepatocyte nuclei (32 times less abundant) (Skene et al., 2010). This indicates
that post-mitotic neurons contain 1 molecule of MeCP2 for every 2 nucleosomes, enough to
potentially saturate all methyl-CpGs and coat the neuronal genome (Skene et al., 2010).
Subsequent studies have shown that the high expression of MeCP2 protein in the brain is
carefully balanced, as too much (Collins et al., 2004; Friez et al., 2006; del Gaudio et al., 2006;
5

Liu et al., 2016; Meins et al., 2005) or too little (Samaco et al., 2008) MeCP2 protein results in
neurological phenotypes. Thus the high expression of MeCP2 in the brain, which is tightly
regulated by a complex array of transcriptional and post-transcriptional mechanisms that differ
between brain regions, argues for MeCP2 playing an important role in CNS function.

1.2

THE CLINICAL RELEVANCE OF MECP2
1.2.1

Clinical Features of Rett Syndrome

Rett syndrome (RTT) is named after the Austrian pediatrician Dr. Andreas Rett, who first
described a curious condition among 22 patients that resulted in severe brain atrophy and
relentless hand-wringing behavior, which he, at the time, attributed to hyperammonemia (Rett,
1966). However, this syndrome went overlooked until 1983, when Swedish neurologist Dr. Bengt
Hagberg reported 33 clinical cases across three different countries, all of which exhibited a
uniform and strikingly progressive X-linked encephalopathy reminiscent of what had been
described 17 years prior (Hagberg et al., 1983). The specific clinical features that were described,
combined with the identification of additional patients worldwide, further established RTT as a
clinical syndrome. However, the molecular etiology of the disorder was unknown until 1999, when
pediatric neurologist Dr. Huda Zoghbi and her lab discovered both rare familial and common
sporadic de novo mutations that associate with RTT, which were quickly followed by the
discovery of additional mutations and genomic aberrations at this gene locus (Amir et al., 1999).
Since then, research interest has exploded in order to discover the exact nature of MeCP2
function within the CNS, and how molecular dysfunction of this protein leads to neuronal deficits
and human disease.
RTT is a progressive X-linked neurological disorder that represents one of the most
common causes of mental disability among young girls, occurring in 1 out of every 10,000 female
births. Individuals with RTT exhibit wide variability in the rate of disease progression and severity,
and can broadly be classified into typical (stereotyped RTT progression) and atypical (RTT
variant progression) RTT cases (Cuddapah et al., 2014; Neul et al., 2010). Individuals with typical
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RTT appear asymptomatic during early childhood development. During the initial phase of RTT
onset, which occurs ~6-18 months of age, many of these patients begin to exhibit developmental
delays, including a failure to meet developmental milestones, a deceleration in the rate of head
and body growth appropriate for their age (microcephaly), and reduced muscle tone (hypotonia)
(Chahrour and Zoghbi, 2007; Hagberg et al., 1983; Tarquinio et al., 2012). This is followed by a
phase of rapid developmental regression in which these patients lose acquired developmental
skills over a period of weeks to a year, including purposeful hand use, spoken language, and the
ability to walk. Patients during this period also experience a temporary indifference to the
surrounding environment and unresponsiveness to social cues, which caused RTT to be
characterized as an autistic-spectrum disorder up until it DSM-V was released in 2013. Many of
the characteristic clinical features associated with RTT arise during this regression phase,
including the “hand-wringing” hand stereotypies, impaired motor coordination and ataxia, and
intellectual disability. RTT patients also display severe autonomic dysfunction that is
characterized by irregular respiratory behaviors such as breath holding and hyperventilation
during waking hours, forced expulsion of air and saliva, and sleep apneas (Chahrour and Zoghbi,
2007; Ramirez et al., 2013). After regression, many patients experience a pseudostationary stage
in which symptoms begin to stabilize; some individuals may display subtle improvements and
partially regain previously lost skills (Lombardi et al., 2015; Neul et al., 2010), which suggests that
RTT symptoms may be reversible. Notably, many RTT patients are socially aware of their
environment, which is typified by the appearance of an intense eye-gaze that these patients
display as a method of communication (Kaufmann et al., 2012). A large proportion of RTT
patients also exhibit seizures that begin during early childhood and range from easily controllable
to severe epilepsy, although this symptom may decline in frequency during adolescence (Jian et
al., 2006). From adolescence into adulthood, many patients enter a stationary phase
characterized by scoliosis, increase autonomic dysfunction, and increasing loss of mobility
associated with Parkinsonian-like features (Chahrour and Zoghbi, 2007).
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Atypical RTT patients represent a small proportion of the total RTT patient population
(14% from a 2014 study) can be described as lying on the phenotypic extremes of typical RTT.
There are three associated variants: atypical RTT with preserved speech, early onset seizures, or
congenital variants. Atypical RTT with preserved speech is the least severe variant, which
includes mildly affected individuals who can walk, talk and draw; in contrast, atypical individuals
with the congenital variant never acquire the ability to speak and have difficulty sitting (Ariani et
al., 2008; Artuso et al., 2010; Cuddapah et al., 2014; Renieri et al., 2009; Zappella et al., 2003).
What remains notable about atypical RTT patients is that they exhibit RTT clinical symptoms
despite a failure to detect MECP2 mutations among some individuals. In recent years, however,
additional research has revealed that the early seizure RTT variant is genetically linked to Cyclindependent kinase-like 5 (CDKL5), a protein-kinase in the CNS that may be involved in synaptic
plasticity, and is now recognized as the clinically distinct CDKL5 disorder (Artuso et al., 2010).
Similarly, the congenital RTT variant is genetically linked to Forkhead box G1 (FOXG1), a
transcriptional regulator, and is now recognized as the clinically distinct FOXG1 syndrome (Ariani
et al., 2008).

1.2.2

MeCP2 and the Genetics of Rett Syndrome

More than 95% of RTT clinical cases can be linked to mutations in the MECP2 gene,
which to date total 888 unique nucleotide changes (missense, nonsense, deletions, insertions,
duplications) across the MECP2 gene. However, 58% of RTT cases have 1 of 8 frequent
mutations, which all occur at CpG hotspots and likely arise from the deamination of methylated
cytosines. MeCP2 R106W, R133C, and T158M are missense mutations located in the MBD of
MeCP2 and have been shown to disrupt MeCP2 binding to methylated DNA (Ballestar et al.,
2000; Brown et al., 2015; Ghosh et al., 2008; Ho et al., 2008) by altering the hydrophobic
environment of the ASX-ST motif within the MBD (Ghosh et al., 2008; Ho et al., 2008). R306C is
another missense mutation that resides within the TRD and has been shown to disrupt MeCP2’s
interaction with the Nuclear Receptor Corepressor Complex (NCoR, see section 1.4.3 for more
detailed information) (Brown et al., 2015; Ebert et al., 2013; Lyst et al., 2013). The remaining four
8

mutations are nonsense mutations. R168X is a nonsense mutation that occurs 3’ to the MBD.
R255X and R270X are nonsense mutations that overlap with the NLS sequence (amino acids
255-271), although R270X can still be translocated to the nucleus, while R294X disrupts the TRD.
The majority of MECP2 mutations occurs de novo and arises spontaneously in the
paternal germ line. Because MECP2 is an X-linked gene, most mutations will typically be
inherited by female offspring that are heterozygous for the mutation. Random X-inactivation (XCI)
in females will cause female RTT patients to display variable clinical features that are dependent
on the percentage of somatic cells expressing the wild-type or mutant MECP2 allele, in addition
to the severity of the mutation. In some cases, XCI can be non-random, which skews expression
towards the wild-type or mutant allele and leads to much milder (akin to a mild learning disability)
or more severe clinical symptoms, respectively (Weaving et al., 2003). Familial cases of RTT, as
well as RTT cases among males, are incredibly rare. However, owing to non-random XCI that
skews towards the wild-type allele in germline cells, many mosaic females can become carriers
and pass their MECP2 mutant allele to their offspring. Hemizygous males that inherit MECP2
mutations are severely affected, and either display severe intellectual disability, present with
neonatal encephalopathy and rarely survive beyond two years of age, or die in utero owing to the
nature and severity of the mutation (Meloni et al., 2000; Neul et al., 2010; Zeev et al., 2002, 2002)
XCI confounds many clinical studies that have tried to establish clear genotypephenotype correlations between mutation type/severity and specific RTT clinical outcomes,
especially since assessments of XCI is limited to circulating leukocytes from blood draws, which
may not represent XCI in the tissue of interest (Archer et al., 2007; Cuddapah et al., 2014;
Temudo et al., 2011; Wu et al., 2014). This is compounded by the difficulty in studying rare males
bearing MECP2 mutant alleles that are so severely affected. Nonetheless, broad associations
have emerged that find that the nature of the MECP2 mutation affects RTT severity (Bebbington
et al., 2008; Charman et al., 2005; Cuddapah et al., 2014; Young et al., 2011). Most missense
mutations occur in two broad clusters that overlap with the MBD and the TRD of MeCP2,
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highlighting the functional and clinical importance of these two domains. Several studies have
corroborated that mutations which are predicted to disrupt MeCP2’s ability to bind methylated
DNA are associated with higher clinical severity scores and more severe symptoms that are
diagnosed at earlier ages, on par with deletions, insertions, and splice site mutations that are
damaging for protein function. In contrast, mutations less likely to disrupt binding to methylated
DNA are associated with lower clinical severity scores. Interestingly, the T158M mutation exhibits
the most variability between studies and is classified as a severe mutation in some studies and
an intermediate mutation in others (Bebbington et al., 2008; Charman et al., 2005; Cuddapah et
al., 2014; Young et al., 2011), which might be attributed to the degree of XCI (Archer et al., 2007).

1.3

MODELING MECP2 MUTATIONS IN RETT SYNDROME
1.3.1

Mouse Models of Rett syndrome

Germline and Conditional Deletion of Mecp2
The first mouse models of MeCP2 were generated by either deleting exon 3, which
generated a truncated protein (Chen et al., 2001), or exon 3 and 4, which completely abolished a
detectable protein product (Guy et al., 2001). Notably, in both studies, mice have lost the MBD
domain, resulting in a failure of MeCP2 binding to methylated DNA in vivo. Mecp2-null male mice
display striking physiological changes that began around 4-6 weeks of age, including body
tremors, gain or loss of body weight depending on the genetic background, abnormal gait,
hindlimb clasping, and premature lethality around 2 months of age (Chen et al., 2001; Guy et al.,
2001). In addition to the apparently normal early development prior to symptom onset, these
Mecp2-null mice also displayed reduced brain size and respiratory abnormalities, which are
prominent features that are observed among the RTT patient population (Neul et al., 2010). The
reduced brain size is associated with increase neuronal cell packing without gross changes in
brain anatomy and morphology, suggesting that RTT is not a product of neurodegeneration
(Chen et al., 2001; Guy et al., 2001). In contrast, Mecp2-null female mice display a delayed onset
of RTT-like symptoms (~3-4 months of age), but by 12 months of age display similar features as
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male mice, including tremor, abnormal gain, hypoactivity, hindlimb clasping, and respiratory
abnormalities (Chen et al., 2001; Guy et al., 2001).
Given that germ line loss of MeCP2 in mice results in the appearance of neurological
RTT-like phenotypes, a key question in the field has been whether these phenotypes are
attributed to deficits in neuronal function. A seminal experiment that addressed this question
involved the conditional removal of MeCP2 from the whole brain using a Nestin-Cre driver, which
depletes MeCP2 expression from most post-mitotic neurons and glia in the CNS. Conditional
deletion of MeCP2 from the brain was sufficient to recapitulate the phenotypes observed in germ
line Mecp2-null mice (Chen et al., 2001; Guy et al., 2001), confirming that all RTT phenotypes are
primarily neurological in origin, although mutant glia may also contribute to RTT pathogenesis in
ways that are not fully understood (Lioy et al., 2011).
Given that global loss of MeCP2 is associated with multiple cognitive, motor, and
physiological symptoms, there has been great interest in dissecting the RTT phenotypes even
further and determining whether particular neuronal cell types are responsible for neurological
deficits. Although specific cell populations correlate with specific phenotypes upon loss of MeCP2
(see Table 1.2), most subpopulations of neuronal cells are not sufficient to recapitulate all aspects
of RTT phenotypes and are rather variable. For example, the loss of MeCP2 function from all
GABAergic neurons in the CNS is sufficient to recapitulate all RTT-like phenotypes because
GABAergic neuronal function is important for ensuring that every neuronal circuit in the brain is
functioning in a coordinated fashion (Chao et al., 2010). In contrast, the loss of MeCP2 function
from all forebrain GABAergic neurons results in milder RTT-like phenotypes, likely because
neuronal circuits in the hindbrain are not being affected by lost of GABAergic inhibitory signaling,
which would otherwise impact the autonomic functions of that brain region that largely contribute
to RTT phenotypes (Chao et al., 2010; Ward et al., 2011). In contrast, the loss of MeCP2 function
from all forebrain excitatory neurons only results in mild abnormal cognitive behaviors,
characteristic of those neurons mediating higher order cognitive function (Gemelli et al., 2006).
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Collectively, these studies have found that the variability in RTT phenotypic impairments correlate
with the brain region or circuit that is being adversely affected. However, it remains unclear
whether cell type-specific impairments in neuronal function correlate with cell type-specific gene
expression changes in the absence of MeCP2.

Postnatal Deletion and Re-activation of Mecp2
Postnatal deletion of the Mecp2 gene in late juvenile or adult male and female mice
across three independent studies all result in the same rate of onset of RTT-like symptoms and
premature lethality seen with germ line Mecp2-null male and female mice regardless of the age of
inactivation (Cheval et al., 2012; McGraw et al., 2011; Nguyen et al., 2012). This includes higher
neuronal cell packing density and decreased branch complexity and spine density of neuronal
dendrites which altogether contribute to reduced brain weight (Nguyen et al., 2012) and are
hallmarks of RTT symptoms in human patients. In one of these studies, hippocampal neurons
also display reductions in the protein expression of synaptic genes such as CaMKII α/β, AMPA
and NMDA receptors, and the synaptic vesicle proteins Vglut and Synapsin, which is indicative of
impaired synaptic structural plasticity and overall neuronal function (Nguyen et al., 2012).
Notably, the decreases in synaptic proteins were not reflected among unchanged mRNA levels;
although MeCP2 may be involved in the post-transcriptional regulation of these genes, these
observations are entirely consistent with studies that found that MeCP2 depletion results in
reduced transcription of ribosomal RNAs, leading to global deficits in protein translational rates (Li
et al., 2013a; Yazdani et al., 2012). These observations suggest that MeCP2 transcriptional
regulation may be actively and continuously required to maintain normal neuronal functions.
Inversely, several studies have now demonstrated that RTT-like phenotypes can be
genetically reversed in Mecp2-null male mice. By removing a floxed Stop cassette from the
Mecp2 gene locus (thus reactivating expression from the endogenous mouse gene) or from a
floxed Stop-Mecp2 transgene in combination with various Cre lines (Nestin-Cre: all neurons and
glia starting at embryonic day 10; Tau-Cre: all post-mitotic neurons starting at embryonic day 9.5;
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CaMKII-Cre: postnatal forebrain neurons starting at post-natal day 0-15 or 15-30, depending on
the Cre line), these studies have shown that post-natal restoration of MeCP2 expression in
previously Mecp2-null post-mitotic neurons of male and female mice is sufficient to restore brain
size and body weight (Giacometti et al., 2007; Guy et al., 2007). In female mice, the post-natal
restoration of MeCP2 expression also rescues electrophysiological deficits in long-term
potentiation and synaptic plasticity (Guy et al., 2007). Lifespan is also noticeably extended when
Mecp2 expression is restored in all post-mitotic neurons in the CNS (>8 months survival)
(Giacometti et al., 2007). However, lifespan for CamKII-Cre mice was only extended by ~4
weeks, suggesting that proper MeCP2 expression in hindbrain post-mitoic neurons, such as
HoxB1+ neurons in the brainstem, likely mediate the extensions in lifespan (Giacometti et al.,
2007; Ward et al., 2011).
Interestingly, it has also been found that although Mecp2 expression is low in glia and is
not necessary for initiating RTT phenotypes, the conditional restoration of MeCP2 expression in
glial cells is sufficient to significantly improve locomotion and anxiety levels, restore respiratory
abnormalities, and prolong the lifespan of Mecp2-null animals, along with restoring normal
dendritic morphology and increasing VGLUT1 protein expression (Lioy et al., 2011). This study
suggests that non-cell autonomous effects may also play a role in RTT pathogenesis, and that
the secreted trophic support provided by glia in the CNS may be viable targets for RTT
therapeutics.
Altogether, genetic studies using various mouse models confirm that MeCP2 is involved
in the active and dynamic maintenance of post-mitotic neuronal function, and that the absence of
MeCP2 at earlier stages is not a pre-requisite for manifesting RTT-like phenotypes, nor a barrier
towards the development of therapeutic interventions.

Mecp2 RTT-Associated Point Mutations
Given the difficulty in performing genotype-phenotype correlations among clinically
variable human RTT female patients (Cuddapah et al., 2014), the development of mouse models
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bearing RTT-associated missense and non-sense mutations has expanded our molecular
understanding of MeCP2 function and the impact of individual pathogenic mutations (Figure 1.2,
Table 1.1). These mouse models have been shown to faithfully model the degree of phenotypic
severity observed in human RTT patients, thus providing key insights into the molecular aspects
of RTT.
Mutations in the MBD of MeCP2 are known to variably impact RTT patients (see Figure
1.2), which are likely mediated by differences in MeCP2 binding affinity to methylated DNA. In
vitro studies have shown that MeCP2 R133C binding to methylated CpGs is indistinguishable
from wildtype MeCP2, whereas MeCP2 T158M retains partial affinity, and MeCP2 R106W
completely abolishes interactions between the MBD and methylated CpGs (Ballestar et al., 2000;
Brown et al., 2015; Ghosh et al., 2008; Ho et al., 2008). To date, MeCP2 R133C, T158M, and
T158A knock-in mutations have been modeled in mice (Brown et al., 2015; Goffin et al., 2012).
MeCP2 R133C is noticeably less severe when compared to T158M/A mutations, best
characterized by the differences in symptom onset (R133C: 42 weeks, T158M: 13 weeks, T158A:
16 weeks). The differences in lifespan correlate with the expected impairments in binding to
methylated DNA, suggesting that the severity of mutations in the MBD is dictated by the degree
of impairment to methylated DNA binding. This is further supported by the generation of MeCP2
R111G mutant mice, which appear phenotypically similar to Mecp2-null mice in terms of
symptoms and lifespan (12 weeks), consistent with the complete abolishment of binding to
methylated DNA (Free et al., 2001; Kudo et al., 2003).
Mice bearing RTT-associated point mutations in the TRD of Mecp2 confirm that the
clinical variability associated with this domain is dependent on how much of the TRD function is
conserved (see Table 1.1). Mice with R168X and R255X are predicted to truncate MeCP2 prior to
its NLS, and thus should not be present in the nucleus. However, studies were unable to detect
either full length or partial MeCP2 protein products (Lawson-Yuen et al., 2007; Pitcher et al.,
2015; Wegener et al., 2014). As a result, both R168X and R255X male mice appear
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phenotypically similar to Mecp2-null male mice and display premature lethality, respiratory
abnormalities, and impairments in motor function, effectively making these mutations null alleles
that are consistent with the clinical severity observed in human RTT patients.
In contrast, among three independent lines of mice bearing R306C mutations (Brown et
al., 2015; Heckman et al., 2014; Lyst et al., 2013), retention of the full TRD results in relatively
mild disease severity and increased lifespan when compared to Mecp2-null mice, consistent with
the mild clinical severity of R306C-bearing human patients. However, R306C mice continue to
display deficits in locomotion, motor coordination, and learning and memory, similar to other
Mecp2-mutant mice (Brown et al., 2015; Heckman et al., 2014; Lyst et al., 2013). Interestingly,
two of the three R306C lines display a median lifespan of ~18 weeks (Heckman et al., 2014; Lyst
et al., 2013), whereas the third displays a median lifespan of ~30 weeks (Brown et al., 2015),
highlighting the variability associated with differences in genetic background, gene targeting
strategies, or C-terminal tags (see Table 1.1 for more detailed information). Using these mice, the
partial loss-of-function phenotypes associated with the R306C mutation was linked to a disruption
in protein interaction with the NCoR-SMRT co-repressor complex, resulting in MeCP2 failing to
recruit NCoR-SMRT to chromatin and mediate transcriptional repression (Lyst et al., 2013). Thus
these mutant mice provided critical molecular insights into RTT, highlighting loss of transcriptional
repression by this complex as being critical to disease onset. The relatively mild phenotypic
severity among R306C mice and human patients suggests that loss of transcriptional repression
by NCoR-SMRT may be necessary, but not sufficient, to mediate the full severity of RTT
phenotypes.
In this respect, nonsense mutations in the R270X and G273X mice are particularly
interesting. Boys with the MeCP2 R270X mutation exhibit severe symptoms typical of Mecp2 loss
of function in human males, including neonatal encephalopathy and death before 4 years of age
(Kankirawatana et al., 2006; Venâncio et al., 2007). However, boys with the MeCP2 G273X
mutation live significantly longer with a relatively mild display of neuropsychiatric symptoms (Ravn
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et al., 2003). The strong phenotypic differences associated with the difference in three amino
acids is recapitulated in MECP2 R270X and G273X mutant mice, which exhibit median lifespans
of ~12 and 27 weeks, respectively (Baker et al., 2013). Further molecular investigations using
these mice found that although both mutations abolished transcriptional repressor activity, the
R270X mutation disrupted an AT-hook domain that severely impaired MeCP2’s ability to recruit
the nucleosome remodeler ATRX, cluster nucleosomes, and form higher order structures from
nucleosomal arrays; in contrast, this AT-hook domain was maintained with the G273X mutation,
which exhibited more moderate impairments for the same features (Baker et al., 2013). Thus,
molecular differences in MeCP2’s ability to modulate chromatin structure and mediate
transcriptional repression likely underlie the differences in severity between these two mutations
in both mice and humans.

1.4

UNDERSTANDING THE MOLECULAR FUNCTION OF MECP2
1.4.1

Synaptic Deficits Associated with MeCP2

Without question, the defining feature of the vertebrate brain is its ability to learn and
adapt to changes in its external environment. This occurs through activity-dependent biochemical
processes and structural dynamics in the neuron, resulting in widespread morphological changes
at neuronal dendrites and synapses. Dendrites, which encompass many postsynaptic synapses,
are highly specialized and extraordinarily complex cellular compartments that “branch out” to
receive external excitatory or inhibitory sensory input and help inform an individual neuron as to
whether it should propagate sensory stimuli to surrounding neurons. The ability to scale an
individual neuron’s electrical capacity and activity in response to dynamic changes in overall
network activity encompasses the essence of synaptic plasticity, and has broad implications for
the way that the brain processes and stores information in a higher-order manner.
Synaptic plasticity, which has primarily been studied in excitatory pyramidal neurons, is
affected by both translational and transcriptional mechanisms (Guan et al., 2002; Holtmaat and
Svoboda, 2009). Neuronal depolarization results in the intracellular release of calcium, whose
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cytoplasmic concentration is relatively low under basal conditions. This results in the activation of
multiple signaling pathways mediated by protein kinases (CaMKII, CaMKIV, PKA, MAPK,
ribosomal S6 kinase) and protein phosphatases (calcineurin) that can modulate the activity of
translational and transcriptional regulators (Ebert and Greenberg, 2013). Translational regulation
enacts synaptic plasticity on a more immediate timescale through activation of mTOR and ERK
signaling pathways, resulting in the local translation of previously inert mRNA transcripts that are
localized to dendrites and encode various synaptic proteins; thus, de novo protein synthesis at
the synapse will rapidly influence the compositional structure and function of postsynaptic
structures and modulate signal input (Holtmaat and Svoboda, 2009). Neuronal activity also
regulates transcriptional programs that affect the development and plasticity of the synapse. The
most well described mechanism for activity-dependent transcriptional activation is observed with
cyclic-AMP-dependent-responsive-element binding protein (CREB) activity. Upon
phosphorylation by CaMKIV, CREB binds to specific responsive elements at gene promoters and
recruits CREB-binding protein (p300/CBP), a histone acetyltransferase that post-transcriptionally
modifies histones and alters chromatin structure to promote gene activation through the
recruitment of RNA polymerase II (Ebert and Greenberg, 2013; Guan et al., 2009).
Transcriptional regulation can thus be tailored in response to neuronal activity and regulate the
abundance of mRNAs localized to the synapse, leading to dynamic long-term changes in synaptic
plasticity.
MeCP2-deficient neurons in RTT patients and Mecp2-null animal models consistently
demonstrate neuronal phenotypes that are characteristic of a loss of synaptic plasticity. Symptom
onset among human RTT patients occurs during the first year of life when experience-dependent
neuronal plasticity is guiding synapse development (Alvarez-Saavedra et al., 2007; Chahrour and
Zoghbi, 2007; Chen et al., 2015). Morphologically, pyramidal neurons in post-mortem RTT patient
brains, as well as IPSC-derived RTT patient neurons both show a striking reduction in soma size,
dendritic arborization, disorganized afferent axonal fibers, and reduced dendritic spine density,
consistent with the volumetric decrease of patient brains (Belichenko et al., 1994; Chapleau et al.,
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2009; Kim et al., 2011; Kishi and Macklis, 2010; Marchetto et al., 2010; Murakami et al., 1992;
Reiss et al., 1993). These phenotypes are recapitulated in pyramidal neurons of Mecp2-null mice,
and can be induced through shRNA-mediated downregulation of MeCP2 expression in
hippocampal slice cultures and through in utero neuronal transfections of wild-type mice
(Belichenko et al., 2008, 2009; Chapleau et al., 2009; Landi et al., 2011; Wood et al., 2009). This
suggests that neuronal deficits in plasticity are cell autonomous, which is supported by
transplants of Mecp2-null mutant neurons into the brains of wild-type mice, which fail to rescue
cellular deficits (Kishi and Macklis, 2010).
These morphological deficits are undoubtedly accompanied by abnormal
electrophysiological responses in RTT neurons. Electrophysiological studies in Mecp2-null mice
have shown that excitatory synapse strength is reduced concurrently with reductions in
glutamatergic synapse number, and patch clamp recordings in the somatosensory cortex reveal
decreased excitatory synaptic drive and increased inhibitory drive onto layer V pyramidal neurons
(Chao et al., 2007; Dani et al., 2005). These experiments demonstrate that RTT cortical
pyramidal neurons ultimately become hypoexcitable, as they fire less frequently and respond less
robustly to excitatory input, which can disrupt overall network activity in the brain (Goffin et al.,
2012, 2014; Nguyen et al., 2012). The shift in balance from excitation to inhibition in the brain has
led the field to propose that MeCP2 functions to maintain experience-dependent maturation and
regulation of neuronal circuits. This is supported by both the observation that MeCP2 is
phosphorylated in an activity-dependent manner (Cohen et al., 2011; Ebert et al., 2013; Zhou et
al., 2006), by the induction of RTT-like behavioral and cellular phenotypes upon conditional
postnatal deletion of MeCP2 adult mice (Cheval et al., 2012; McGraw et al., 2011), and by the
partial rescue of RTT-like phenotypes in mice upon conditional expression of MeCP2 in postmitotic neurons of Mecp2-null animals (Alvarez-Saavedra et al., 2007; Giacometti et al., 2007;
Guy et al., 2007; Kerr et al., 2012; Luikenhuis et al., 2004).
Although MeCP2 deficiency is associated with penetrant neuroanatomical features that
are conserved across post-mortem human RTT patients, Mecp2 mutant mice, and cultured
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neurons, studies have also observed a wide degree of variability in the degree to which each
neuron is affected (Belichenko et al., 2008, 2009; Wang et al., 2013). Much of this variability may
be attributed to differences in genetic background, individual brain regions, or cell types, which
suggests that individual neurons may be differentially affected by loss of MeCP2 function.

1.4.2

MeCP2 Interactions with Chromatin

The conserved structure of the methyl-CpG binding domain among MBD family
members, coupled with a transcriptional repression domain and its strong enrichment at
pericentromeric chromatin in the nucleus, supports the hypothesis that MeCP2 binds to
methylated DNA and mediates transcriptional repression in vivo (Nan et al., 1996, 1997, 1998).
As a result, there has been much interest in identifying target genes that are de-repressed in the
absence of MeCP2 function and likely contribute to the etiology of RTT by determining where
MeCP2 binds to chromatin in vivo. Chromatin immunoprecipitation coupled with high-throughput
sequencing (ChIP-seq) has led to the functional identification of multiple DNA-binding proteins
and the biological processes that they participate in (Furey, 2012). However, despite extensive
study using ChIP-seq, the mechanism by which MeCP2 interacts with chromatin in vivo, as well
as its precise localization throughout the neuronal genome, remains poorly understood. MeCP2 is
highly abundant in the brain and is thought to coat the genome; the amount of MeCP2 molecules
per neuron is sufficient to saturate all methyl-CpGs in the genome, and tracks DNA methylation
genome-wide with a particular affinity for high densities of methylated CpGs (Baubec et al., 2013;
Chen et al., 2015; Cohen et al., 2011; Skene et al., 2010). The high nuclear abundance of
MeCP2 in post-mitotic neurons, together with the broad distribution of MeCP2 throughout the
genome via ChIP-seq and its ability to affect higher-order nucleosomal structure, has led to the
reassessment that MeCP2 may function as a global regulator of chromatin structure, rather than
as a classical sequence-specific transcription factor that function at specific genes (Skene et al.,
2010).
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Biochemical assays have consistently demonstrated that MeCP2 preferentially binds to
symmetrically methylated CpGs adjacent to A/T rich sequences in vitro, and prior studies
traditionally assessed MeCP2 repressor function through binding to methylated promoters in vivo
(Klose et al., 2005; Nan et al., 1997; Yu et al., 2000). RTT mutations that disrupt the MBD also
confirm that the recognition of methylated CpGs by a functional MBD remains the primary
determinant of MeCP2 binding in vivo (Baubec et al., 2013). However, recent observations from a
number of studies question whether methyl-CpGs alone are sufficient to mediate MeCP2
interactions with chromatin in a physiological context. In addition to methylated CpGs, studies
have found that methylated DNA in a non-CpG context (methyl-CpH) is highly enriched in the
brain and comprises ~40-50% of methylated cytosines in the mature cortical neurons relative to
other somatic cell types (Lister et al., 2013; Mo et al., 2015). Notably, DNMT3A deposits CpH
methylation early in postnatal neuronal development, and the increase in methyl-CpH levels
correlate with rates of synaptogenesis in the brains of humans and mice (Lister et al., 2013).
Interestingly, MeCP2 expression also rapidly increases during the same developmental period
(Chen et al., 2015; Kishi and Macklis, 2004; Shahbazian et al., 2002b). Methyl-CpH is found
throughout the gene body and is associated with either transcriptional repression or low levels of
expression, and patterns of methyl-CpH vary between individual neuronal cell types and correlate
with cell type-specific gene expression in the mouse brain (Lister et al., 2013; Mo et al., 2015). In
recent years, MeCP2 has been closely associated with the role of methyl-CpH in post-mitotic
neuronal maturation through direct binding to methylated CpH, primarily in a methyl-CpA context,
to mediate transcriptional repression (Chen et al., 2015; Gabel et al., 2015; Guo et al., 2014).
Furthermore, methyl-CpA dinucleotides are enriched for higher MeCP2 ChIP-seq read density
and are positively correlated with gene length, and as a result are throught to mediate the lengthdependent repression of long genes observed across various Mecp2-mutant animal and cell
culture models (Gabel et al., 2015).
In contrast, MeCP2 has also been shown to bind to hydroxymethylated CpGs in the
mouse cerebellum, which is known to be associated with active expressed genes, particularly in a
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cell type-specific context (Mellén et al., 2012). However, subsequent MeCP2 ChIP-seq
experiments have been unable to reproduce or detect MeCP2 enrichment at hydroxymethylated
cytosines in vivo, in contrast with methylated DNA in a CpG/CpH context (Gabel et al., 2015).
MeCP2 may also associate with genomic regions in a methylation-independent manner. One
study recently implicated MeCP2 in binding to GC-rich promoters of the genome in mouse
olfactory epithelial tissue, regardless of the cytosine methylation status (Rube et al., 2016). This is
in line with an early report that performed a genome-wide analysis of MeCP2 binding in the
human neuronal SH-SY5Y cultured cell line and found that 63% of MeCP2-bound promoters
were actively expressed genes, whereas only 6% of promoters were methylated (Yasui et al.,
2007). Together, these studies argue against MeCP2 in silencing methylated promoters.
Additional evidence reveals that, within murine embryonic stem cells where MeCP2 is ectopically
overexpressed, the global loss of CpG methylation results in a redistribution of the protein
towards regions with open accessible chromatin, including regions of increased DNAseI
hypersensitivity, histone H3K4me1 and H3K27ac (Baubec et al., 2013). Although MeCP2 does
exhibit methylation-independent binding to DNA that may be mediated by its C-terminal domain, it
has been hypothesized that these interactions are non-specific and may occur in vivo as a means
of searching for methylated regions of the genome (Hansen et al., 2010; Heckman et al., 2014).
However, it remains an open question whether these marks are reproducible and representative
of Mecp2 binding in vivo, especially in the face of biochemical studies demonstrating MeCP2’s
strong preference for methylated DNA.
Although it is entirely plausible that MeCP2 function varies depending on the surrounding
chromatin structure and methylation status, more research is required to determine where and
how MeCP2 binds to chromatin in vivo, as evidence from current studies probing MeCP2
localization to chromatin currently remain in conflict.
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1.4.3

Post-translational Modifications of MeCP2

Given the high abundance of MeCP2 in the brain, its broad histone-like genomic
distribution, and the synaptic deficits associated with RTT, MeCP2 has been proposed to
modulate chromatin structure and gene expression in an activity-dependent manner through the
use of post-translational modifications (PTMs), similar to histone tail PTMs. Differential
phosphorylation of MeCP2 has been shown to modulate MeCP2 protein interactions, affinity for
methylated DNA and chromatin, gene expression, and neuronal morphology (Cohen et al., 2011;
Ebert et al., 2013; Li et al., 2011; Tao et al., 2009; Zhong et al., 2012; Zhou et al., 2006). Given
the importance of protein-kinase signaling and phosphorylation in synaptic plasticity, subsequent
studies have demonstrated that MeCP2 is phosphorylated on multiple residues in response to
neuronal activity from excitatory synapses (Chen et al., 2003; Zhou et al., 2006). Serine 421 and
Threonine 308 are both phosphorylated in response to neuronal activity. Serine 421 is
phosphorylated as a product of CaMKII kinase signaling and is correlated with MeCP2-mediated
de-repression of Bdnf, which ultimately acts to decrease the number of excitatory synapses and
increase the number of inhibitory synapses (Bloodgood et al., 2013; Zhou et al., 2006). This may
occur through reduced affinity for methyl-CpGs as observed using southwestern blots (Chen et
al., 2003), although ChIP-seq did not reveal extensive changes in MeCP2 binding upon Serine
421 phosphorylation (Cohen et al., 2011). In contrast, Threonine 308 phosphorylation is required
to disrupt the interaction between MeCP2 and the NCoR-SMRT co-repressor complex (Ebert et
al., 2013). Activity-dependent phosphorylation of these two residues may negatively regulate
MeCP2 function by synergistically mediating the de-repression of gene targets, which may be
important for the establishment of proper neuronal connectivity in the brain. In support of this
notion, the S421A mutation in mice, which abolishes Serine 421 phosphorylation, is associated
with cognitive impairments, abnormal behavioral responses to novel experiences, and increased
neuronal dendritic complexity, similar to what is observed with mice that overexpress MeCP2
(Cohen et al., 2011; Collins et al., 2004). In contrast to Serine 421 and Threonine 308, Serine 80
is a residue that is phosphorylated in resting neurons of the mouse brain and becomes
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dephosphorylated in the presence of neuronal activity (Tao et al., 2009). Mutation at this residue
(S80A) leads to decreased association with chromatin in resting neurons, which suggests that
this residue positively regulates MeCP2 function (Tao et al., 2009).
MeCP2 has also been shown to exhibit other PTMs. Small Ubiquitin-like Modifier (SUMO)
is a small protein involved in various cellular processes, including transcriptional regulation,
protein stability, response to stress, and apoptosis (Hay, 2005). MeCP2 is SUMOylated in
response to NMDA, IGF-1, or CRF-mediated neuronal activity in the rat brain, and has been
shown to release CREB from a repressor complex in order to enhance Bdnf mRNA expression
(Tai et al., 2016). Importantly, the re-expression of SUMO-modified MeCP2 in Mecp2-null
neurons can rescue several behavioral and electrophysiological deficits in conditional Mecp2-null
mice, implicating SUMOylation as being a negative regulator of MeCP2 function, together with
phosphorylation at Serine 421 and Threonine 308 (Tai et al., 2016). MeCP2 also undergoes
poly(ADP-ribosyl)ation in vivo, and the loss of poly(ADP-ribosyl)ation on MeCP2 is associated
with an increase in both MeCP2 binding to chromatin and its ability to cluster pericentromeric
heterochromatin in MEF cells, suggesting that poly(ADP-ribosyl)ation negatively regulates
MeCP2-mediated chromatin structural changes (Becker et al., 2016).

1.4.4

MeCP2 and Transcriptional Profiling

Since 2002, multiple MeCP2 gene expression studies have been performed using whole
brain or individual brain regions of MeCP2-null (Ben-Shachar et al., 2009; Chahrour et al., 2008;
Gabel et al., 2015; Jordan et al., 2007; Kriaucionis et al., 2006; Nuber et al., 2005; Tudor et al.,
2002; Urdinguio et al., 2008) or Mecp2-mutant mice bearing RTT missense mutations (Baker et
al., 2013; Gabel et al., 2015). These studies predominantly use male mice because 100% of the
neurons in these mice express the null Mecp2 allele, in contrast to female mice that undergo
random XCI. These studies revealed that MeCP2-mediated gene expression changes are
extraordinarily subtle, as earlier studies using cDNA arrays either failed to identify gene
expression changes in Mecp2-mutant mice, or identified relatively few genes that were
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misregulated in aged symptomatic mice but not early asymptomatic mice. The majority of these
gene expression studies applied > 1.5 fold change cutoffs; by reducing the fold change cutoff to >
1.15, hundreds to thousands of genes were found to be differentially expressed depending on the
brain region profiled (Ben-Shachar et al., 2009; Chahrour et al., 2008). Although many
differentially expressed genes (DEGs) were identified, it still remains unclear how small changes
in gene expression among many individual genes lead to the morphological and physiological
effects seen in Mecp2-null animals, although one hypothesis suggests that neurons may be
sensitive to subtle changes in the dosage of mRNAs (Tudor et al., 2002). As a result, many gene
expression studies have been limited to gene-specific interpretations and candidate gene
experimental approaches. Although a small number of misregulated genes, such as the
corticotropin-releasing hormone (Crh), opioid receptor mu-1 (Oprm1), and Brain-derived
neurotrophic factor (Bdnf) are sufficient to mediate behavioral phenotypes when misregulated in
mice (Samaco et al., 2012; Zhou et al., 2006), these genes tend to encode receptors or secreted
hormones whose expression is known to dramatically influence organism physiology and
behavior.
Furthermore, there is an extraordinary amount of variability among individual DEGs
across multiple studies, mouse lines, and cultured cells. As a result, there are few validated target
genes and no consistent molecular pathways that have been identified. One of the earliest cDNA
microarray studies profiled gene expression changes in human MECP2 wild-type and mutant
fibroblasts and lymphoblastoid cells but found that MeCP2 did not cause reproducible changes in
mRNA transcript levels, even across multiple clones that were derived from the same RTT patient
(Traynor et al., 2002). Another study compared gene expression changes between two germline
Mecp2-null mouse lines (Chen et al., 2001; Guy et al., 2001) using the cerebellum, which is
mostly comprised of excitatory granule neurons and largely limits cellular heterogeneity. Although
three post-natal time points were assessed, with the number of DEGs increasing with age, only
2.6% and 2% of all DEGs found in either mutant mouse line overlapped with the other mutant
mouse line, despite the similarities in phenotype (Jordan et al., 2007). This study observed that
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genetic background, as well as the gene targeting strategy, helps contribute to the large variation
in the types of DEGs that are detected from various Mecp2 mutant mice.
A portion of this variation may be due to the astounding complexity and cellular
heterogeneity of the mammalian CNS. The brain in particularly comprises numerous anatomically
distinct brain regions; each region possesses a myriad of intermixed cell types that differ in
morphology, function, and electrophysiological properties. To accommodate this cellular diversity,
different cell types establish distinctive gene expression profiles that are maintained by a complex
interplay of cell type-specific transcription factors, epigenetic modifications (e.g. methylcytosine,
posttranslational modification of histone tails), and alterations to chromatin accessibility and
structure. Experiments that solely rely on individual brain regions may thus reflect composite
profiles that easily obscure these cell type-specific differences and impede an accurate
assessment of gene regulation and function. Indeed, recent studies that account for CNS
heterogeneity have been able to identify gene expression markers for novel, functionally distinct
neuronal subtypes and have clarified regulatory relationships between intragenic CG/CH
methylation and gene expression (Fuzik et al., 2016; Mo et al., 2015; Tasic et al., 2016; Usoskin
et al., 2015). These studies highlight the need for novel innovations that parse cellular
heterogeneity in exchange for increased biological insight, especially in light of a
neurodevelopmental disease context. In support of this view, it was recently found that manually
sorted Mecp2 mutant neurons displayed gene expression changes that were unique to each cell
type and would have otherwise been undetected using whole tissue homogenates, which
suggests that MeCP2 may modulate gene expression in a cell type-specific manner (Sugino et
al., 2014). This contrasts with previous studies that found similar gene expression within the
hypothalamus and cerebellum and concluded that MeCP2 regulates the same complement of
genes across different brain regions (Ben-Shachar et al., 2009; Chahrour et al., 2008).
Alternatively, the variability in the identity of individual DEGs across different mutant mice
or cell lines may also be a feature of MeCP2 loss-of-function and the RTT phenotype. Because
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this variability, coupled with the high abundance and broad distribution of MeCP2 throughout the
neuronal genome (Cohen et al., 2011; Skene et al., 2010), has made the identification of specific
MeCP2 gene targets exceedingly difficult, researchers have proposed the alternative hypothesis
that MeCP2 may play a global role in transcriptional regulation. Consistent with this hypothesis is
a recent study which found that when genes are sorted by gene length and fold changes are
averaged every 200 genes, MeCP2-deficient neurons display a length-dependent increase in
gene expression specifically within the brain, implicating MeCP2 in mediating the repression of
long genes enriched for methyl-CpA that are important for neuronal function (Gabel et al., 2015;
Sugino et al., 2014). The most notable feature about this study is the conservation of this
phenomenon across Mecp2-null or Mecp2-mutant primary neurons, brain tissue, and individual
cell types from mice, human MECP2 ESC-derived neurons, and RTT patient mutant fibroblasts,
and that such effects can also be recapitulated in conditionally-deleted Dnmt3a-null neurons that
are responsible for methyl-CpA deposition. This study provided strong evidence for MeCP2 in
binding to long genes and mediating global transcriptional repression of long neuronal genes
related to synaptic functions. However, a major question that remains is how the ectopic
upregulation of long neuronal genes genome-wide leads to the reductions in glutamergic synapse
number, reduced dendritic branch complexity, and cell autonomous hypoexcitability of neurons in
RTT, aside from compromising general cellular health. In this respect, the length-dependent derepression of long neuronal genes in the absence of MeCP2 is not completely sufficient to explain
the occurrence of RTT phenotypes.
Finally, gene expression studies from human post-mortem RTT brain tissue reveal
generally larger fold changes in gene expression, in contrast to gene expression changes in
Mecp2-null male mice (Colantuoni et al., 2001; Tudor et al., 2002). Although such differences
may be attributed to evolutionary differences between humans and mice, the majority of
transcriptional and molecular studies rely on male hemizygous Mecp2-mutant mice. Given that
RTT patients are predominantly female, it remains an open question whether gene expression
changes in female heterozygous Mecp2-mutant mice, the most clinically relevant model for RTT,
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will closely resemble those that have been observed in male hemizygous mutant mice.
Transcriptional profiling in female heterozygous Mecp2-mutant mice may thus offer new insights
into RTT pathogenesis and MeCP2 function.

1.4.5

Proposed Roles for MeCP2 Function

MeCP2 as a Transcriptional Repressor
Although in vivo evidence supports a role for MeCP2 in transcriptional repression by
binding to methylated CpA and mediating length-dependent repression of long neuronal genes,
these are relatively recent observations. Historical evidence supporting MeCP2 as a
transcriptional repressor is largely derived from biochemical assays examining its ability to bind to
methylated DNA and interact with transcriptional co-repressors both in vivo and in vitro. Transient
transfection of MeCP2 in heterologous cells indicated that this protein could bind to methylated
promoters and mediate long-range repression of reporter constructs, consistent with the role of a
transcriptional repressor (Nan et al., 1997). It was later found that transcriptional repression by
MeCP2 in vivo required the recruitment of the histone deacetylase co-repressor complex Sin3A
via the MeCP2 TRD (Nan et al., 1998). This was followed by the identification of NCoR-SMRT corepressor recruitment, whose stoichiometric interaction with MeCP2 can be regulated by
phosphorylation on R306 in an activity-dependent fashion (Ebert et al., 2013; Lyst et al., 2013).
Consistent with MeCP2 being a transcriptional repressor via HDAC co-repressor recruitment in
vivo, the loss of Mecp2 function is also associated with a global increase in histone H3 acetylation
in post-mitotic neurons (Shahbazian et al., 2002a; Skene et al., 2010). Although the genomic
locations of this mark and its correlation with gene expression changes is not yet understood, the
increase in global histone acetylation was accompanied by an increase in spurious transcription
of repetitive elements throughout the genome, which may implicate MeCP2 in suppressing
transcriptional noise (Skene et al., 2010). However, given that transcriptional repression by
MeCP2 is partially relived by trichostatin A, an inhibitor of histone deacetylase activity, it is
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possible that MeCP2 mediates transcriptional repression independent of co-repressor recruitment
(Nan et al., 1998; Yu et al., 2000).
MeCP2 has been shown to associate with nucleosomal arrays by binding to linker DNA
between individual nucleosomes and mediating chromatin compaction, even in the absence of
methylated DNA, consistent with a proposed role for MeCP2 in mediating transcriptional
repression (Georgel et al., 2003; Nan et al., 1997). MeCP2-bound nucleosomal arrays exhibit
reduced enzymatic digestion of microccocal nuclease (MNase), indicative of reduced accessibility
to increased chromatin compaction. Furthermore, exogenous MeCP2 expression and
accumulation at DAPI+ nuclear chromocenters of Pmi28 mouse myoblasts is associated with a
decrease in the number of chromocenters that are visualized in the nucleus, which suggests that
MeCP2 can mediate the clustering of pericentromeric chromatin (Agarwal et al., 2011). The
expression of MeCP2 bearing RTT-associated missense mutations was correlated with a
decrease in MeCP2 accumulation and an increase in the number of chromocenters within the
nucleus, suggesting that up to two-thirds of RTT-associated missense mutations that were
assessed can impair the ability of MeCP2 to cluster pericentromeric chromatin in vivo. However,
these observations are limited by the use of artificial nucleosomal arrays in vitro, which are
performed under conditions that may promote non-specific binding of MeCP2 to DNA
(Thambirajah et al., 2012). Likewise, the exogenous overexpression and detection of MeCP2
accumulation at pericentromeric chromatin only represents one type of methyl-CpG-rich
chromatin structure in vivo that can be imaged by confocal microscopy. It remains unclear
whether MeCP2 directly compacts neuronal chromatin in vivo in order to mediate transcriptional
repression, particularly under physiological conditions and in the presence of other chromatin
modifiers and epigenetic marks.

MeCP2 as a Transcriptional Activator
Several gene expression studies have supported a role for MeCP2 in mediating
transcriptional activation. Previous studies identified MeCP2-mediated transcriptional changes in
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the hypothalamus and cerebellum of Mecp2-null and Mecp2-overexpression mice under the
assumption that true MeCP2 gene targets would show inverse changes between the two
conditions (Ben-Shachar et al., 2009; Chahrour et al., 2008; Chen et al., 2015). They found that,
although most gene expression changes were subtle, thousands of genes in the hypothalamus
were misregulated by the loss or gain of MeCP2 protein expression, and 85% of misregulated
genes were identified as being activated by MeCP2. Mechanistically, MeCP2 may mediate the
transcriptional activation of these genes through synergistic interactions with the transcriptional
activator CREB1, as both proteins were found to directly interact with each other and were found
at the promoters of activated genes, but not repressed genes (Chahrour et al., 2008). Thus
MeCP2 may promote the activation of genes through interactions with transcriptional activators.
By using RNA-spike ins to control for equivalent cell numbers among human ESCdifferentiated post-mitotic neurons, another study reported that global reductions in transcription
among MECP2-deficient neurons that worsened with time (2-4 weeks post-differentiation) (Li et
al., 2013a). Genes that were downregulated were expressed at substantially higher levels than
genes that were upregulated and exhibited higher ratios of hydroxymethyl-CpG/methyl-CpG,
suggestive of deficits in active transcription within MECP2-mutant neurons. These transcriptional
deficits were associated with morphological and physiological deficits observed in RTT patients
and mouse models, including decreases in soma size, a reduction in dendritic branch complexity,
and reduced action potential rates. Notably, these neurons also displayed reduced incorporation
of radiolabeled methionine over a 30-minute period, consistent with a global reduction in protein
translation rates. Many of the ribosomal proteins were also transcriptionally downregulated,
consistent with an additional study that also identified reductions in nascent transcription of
ribosomal RNAs using Mecp2-null ESC-derived neurons (Yazdani et al., 2012). Together, these
studies implicate MeCP2 in mediating transcriptional activation for a large number of genes that
are associated with the morphological and electrophysiological neuronal deficits observed in postmortem human RTT patients and Mecp2-mutant mice. However, a general mechanism by which
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MeCP2 may promote transcriptional activation to mediate proper neuronal morphology and
function still remains unclear.
Studies performed in vivo using Mecp2-mutant mice have proven to be equally
illuminating by revealing that MeCP2 modulates chromatin structure on a global scale, and these
changes may be consistent with transcriptional activation on a genome-wide scale. A recent highresolution imaging study in heterozygous Mecp2-null female mice reported that MeCP2-deficient
nuclei in CA1 pyramidal neurons are associated with an increase in chromatin compaction
(Linhoff et al., 2015). Interestingly, compaction in the absence of MeCP2 was only observed
among pyramidal neurons that typically express high levels of MeCP2. Cerebellar granule cells,
which have relatively smaller cell sizes and nuclear volumes, contain more heterochromatin, and
exhibit lower levels of MeCP2 expression, did not display a similar increase in chromatin
compaction. Chromatin compaction in MeCP2-deficient neurons was also associated with a
global increase and redistribution in H4K20me3, a marker of transcriptional repression, and
reduced S5 phosphorylation of RNA Polymerase II, a marker of transcriptional activity. This study
suggests that cell type-specific abundances of MeCP2 may modulate chromatin structure in
different cell types to promote transcriptional activity, lending support to MeCP2 functioning as a
transcriptional activator.
MeCP2 also competes with linker histone H1 through both in vitro nucleosomal arrays
and in vivo cellular FRAP assays, which may have global effects on the accessibility of chromatin
in vivo. Linker histone H1 can promote higher-order aggregation of chromatin fibers that may be
repressive (Bednar et al., 1998; Ghosh et al., 2008; Nan et al., 1997), and is traditionally
considered a transcriptional repressor (Bustin et al., 2005; Fan et al., 2005; Nishiyama et al.,
2012). Loss of MeCP2 chromatin binding in neurons leads to a doubling of linker histone H1
expression in neurons and may promote chromatin condensation (Ghosh et al., 2010; Ishibashi et
al., 2008; Skene et al., 2010). The high expression of MeCP2 in the brain, coupled with the 50%
decrease in linker histone H1 expression relative to other somatic tissues and cell types, may
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promote more open and uncondensed chromatin at transcriptionally active genes. Additional
evidence also supports MeCP2 in modulating neuronal chromatin structure that would be
consistent with transcriptional activation. Biochemical fractionation and isolation of rat brain
nuclear lysates reveals that most MeCP2 is enriched in soluble fractions of chromatin and is
found on nucleosome-bound DNA, suggesting that MeCP2 binds to more euchromatic and
nuclease-accessible regions of the genome (Thambirajah et al., 2012). Similarly, MNase
digestion of isolated cerebellar nuclei from Mecp2-null mice revealed a subtle decrease in the
accessibility of 5hmC-enriched chromatin when compared to wild-type mice, indicating that
MeCP2 promotes more nuclease-accessible chromatin structure at transcriptionally active genes
(Mellén et al., 2012).
Additionally, although MeCP2 exists as a monomeric protein in solution, MeCP2-bound
nucleosomal arrays form higher order structures mediated by MeCP2-MeCP2, MeCP2-DNAMeCP2, or DNA-MeCP2-DNA intermolecular contacts, which is consistent with studies that report
that MeCP2 mediates three-dimensional chromatin loops in vivo (Bednar et al., 1998; Klose and
Bird, 2004; Nikitina et al., 2007a, 2007b). Notably, MeCP2-dependent compaction and higherorder organization of nucleosomal arrays are also facilitated by domains outside of the MBD,
suggesting that other domains of MeCP2, including AT-hooks and the C-terminal tail, may also
interact with chromatin independent of a methylcytosine context (Baker et al., 2013; Heckman et
al., 2014; Nikitina et al., 2007b). In the neonatal brain, MeCP2 recruits the nucleosome remodeler
ATRX to imprinted gene loci such as H19/Igf2 and Gtl2/Dlk1, and remodels nucleosomes near
these loci to promote a more open, de-condensed chromatin structure (Kernohan et al., 2010,
2014). This allows linker DNA regions to be extended in length, exposing CTCF binding motifs
that help to maintain three-dimensional chromatin conformations required for proper gene
regulation at these imprinted loci. Although evidence supporting MeCP2 mediating three
dimensional chromatin conformations in adult mice has been limited at best (Horike et al., 2005),
the observation that ATRX is expressed in adult mice and is mislocalized to chromatin in Mecp2mutant mice suggests that three-dimensional interactions may occur in vivo.
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Other Proposed Mechanisms for MeCP2
MeCP2 has been shown to bind mRNA and siRNA with high affinity comparable to that of
methylated DNA, although these binding events are mutually exclusive (Jeffery and Nakielny,
2004). MeCP2 has thus been implicated in mediating alternative splicing (Maunakea et al., 2013;
Young et al., 2005), as an alternative hypothesis to explain the subtle gene expression changes
in the absence of MeCP2 function. Alternative splicing is critical for brain function, as various
transmembrane ion channels utilize various cell type-specific isoforms that are responsive to
different neuronal voltages and conductance in the plasma membrane. MeCP2 has been shown
to affect the activity of splicing mini-genes in HeLa cells, and changes in alternative splicing were
identified for a subset of genes in the cerebral cortex of Mecp2

308/y

mice (Young et al., 2005).

MeCP2 also directly interacts with Y box-binding protein 1 (YB1), a conserved RNA splicing factor
that forms a major component of messenger ribonucleoprotein particles (Young et al., 2005).
Another study that performed MeCP2 ChIP-seq in IMR90 cells found MeCP2 to be enriched at
alternatively spliced exons in a methyl-CpG dependent fashion, particularly those exons that are
included in the mature transcript (Maunakea et al., 2013). MeCP2 knockdown using siRNAs, as
well as trichostatin A treatment, results in the loss of MeCP2 binding at alternatively spliced
exons, leading to increased histone acetylation and an increase in the frequency of alternative
exon skipping. This supports a role for MeCP2 in binding to alternatively skipped exons and
maintaining local histone hypoacetylation to promote alternative exon inclusion into the final
mRNA transcript.
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Table 1.1: List of Mecp2 mouse models made to date
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Table 1.2: List of Mecp2 mouse conditional studies and associated phenotypes

FIGURE 1.1: Murine Mecp2 gene locus, alternative isoforms, and protein products
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FIGURE 1.2: Clinical and phenotypic severity of RTT-associated point mutations
(A) Locations of the eight most frequent MeCP2 missense and non-sense mutations associated
with RTT. MBD, Methyl-CpG Binding Domain; TRD, Transcriptional Repression Domain; NEO,
Neomycin cassette.
(B) Human RTT patient clinical severity associated with RTT-missense mutations depicted in (A).
(C) Phenotypic severity among mouse models bearing RTT-asssociated missense mutations.
Depicted is the median survival of various mouse models in weeks.
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CHAPTER 2: Loss of MeCP2 is associated with distinct expression changes in the
striatum, hypothalamus, and cerebellum
Adapted from: Zhao, Y.*, Goffin, D.*, Johnson, B.S.*, Zhou, Z. (2013) Loss of MeCP2 function is
associated with distinct gene expression changes in the striatum. Neurobiol. Dis. 59: 257-266.

ABSTRACT
Rett syndrome (RTT) is a neurodevelopmental disorder characterized by developmental
regression beginning 6–18 months after birth, followed by a lifetime of intellectual disability,
stereotyped behaviors, and motor deficits. RTT is caused by mutations in the gene encoding
MeCP2, a methyl-CpG binding protein believed to modulate gene transcription. Gene expression
studies of individual brain regions have reported that Mecp2 loss-of-function leads to both
activation or repression of its gene targets in mice. Conditional deletion of MeCP2 from different
brain regions has revealed unique insights into the role of these structures in mediating particular
RTT-like phenotypes. However, the function of MeCP2 in the striatum, a major brain region
involved in motor control and executive cognitive functions, has yet to be studied. Here, we
characterized the gene expression changes in the striatum of Mecp2 mutant mice. We found a
number of differentially expressed genes in the striatum of both constitutive Mecp2-null mice and
mice lacking MeCP2 only from forebrain GABAergic neurons. These changes only occurred when
MeCP2 expression levels had reached mature levels and RTT-like symptoms were manifest,
supporting a role for MeCP2 in maintaining proper brain function. Many of the gene expression
changes identified in the striatum have not previously been shown to change in the hypothalamus
or cerebellum. Bioinformatic analysis of differentially expressed genes in striatum as well as
hypothalamus and cerebellum revealed that loss of MeCP2 does not affect the global landscape
of gene expression. Additionally, we uncovered a number of differentially expressed genes in the
liver of Mecp2-null mice suggesting an important role for MeCP2 in non-neuronal tissues.
Collectively, our data suggest that the differential expression of genes following loss of MeCP2
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occurs in a tissue, or cell-type specific manner and thus MeCP2 function should be understood in
a cellular context.
INTRODUCTION
RTT is a severe X-linked neurological disorder that affects 1 in 10,000 – 15,000 females.
Patients with RTT experience a relatively normal first 6-18 months of life after which they enter a
period of developmental stagnation or regression. Subsequently, patients lose learned motor and
communication skills, and develop hand stereotypies and gait apraxia (Katz et al., 2012; Neul et
al., 2010). Approximately 95% of RTT cases are associated with mutations in the gene encoding
methyl-CpG binding protein 2 (MeCP2).
Genetic studies using Mecp2 knockout mice, or mice carrying RTT-associated mutations,
have established a causal role of MeCP2 in the etiology of RTT (Chen et al., 2001; Goffin et al.,
2012; Guy et al., 2001; Pelka et al., 2006; Shahbazian et al., 2002a). Conditional deletion of
Mecp2 from the mouse brain recapitulates the phenotypes observed in Mecp2-null mice such as
reduced brain and body weight, decreased locomotor activity, motor incoordination, gait and
breathing abnormalities (Chen et al., 2001; Guy et al., 2001). These studies demonstrate that
RTT is primarily a neurological disorder and that MeCP2 is indispensable for proper brain
function. Furthermore, conditional deletion of Mecp2 from specific brain regions or specific
population of brain cells have demonstrated that different symptoms of RTT may manifest
through loss of MeCP2 function from particular brain regions or cell types (Adachi et al., 2009;
Chao et al., 2010; Fyffe et al., 2008; Lioy et al., 2011; Samaco et al., 2009; Ward et al., 2011).
However, while specific neurotransmitter systems and neuronal populations play important roles
in the etiology of individual RTT-like phenotypes, the large-scale disruption of MeCP2 function is
required for the appearance of phenotypes that mimic constitutive Mecp2-null mice (Goffin and
Zhou, 2012).
MeCP2 is a highly abundant nuclear protein that binds methylated CpGs (5mC) in vitro
and in vivo (Skene et al., 2010). Through its interaction with co-repressor complexes, such as
Sin3A and histone deacetylases 2 (HDAC2), MeCP2 was originally postulated to repress gene
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transcription (Nan et al., 1997); however initial gene expression studies did not find significant
changes in gene expression upon loss of MeCP2 (Kriaucionis et al., 2006; Tudor et al., 2002). To
reduce the potentially confounding effects of cellular heterogeneity in the brain, other studies
examined gene expression changes using individual brain regions; these studies identified
hundreds to thousands of genes whose expression is affected by MeCP2 dysfunction in the
hypothalamus and cerebellum (Ben-Shachar et al., 2009; Chahrour et al., 2008). Notably, most of
these differentially expressed genes were down-regulated in Mecp2-null mice and up-regulated in
Mecp2-overexpressing mice, arguing against a primary role for MeCP2 in gene repression. This
additional role for MeCP2 in gene activation may result from the recruitment of CREB to MeCP2
(Chahrour et al., 2008) or the binding of MeCP2 to 5-hydroxymethylcytosine (5hmC), which is
enriched over active genes (Mellén et al., 2012; Szulwach et al., 2011). Since the pattern of 5mC
and 5hmC localization across the genome is cell-type dependent (Mellén et al., 2012), those
genes identified as differentially expressed in the hypothalamus and cerebellum may reflect the
composite changes across multiple cell types.
One brain region that has received little attention in the RTT field is the striatum. This
brain region serves as the input center for the basal ganglia, a subcortical region of the brain that
processes and integrates information associated with motor control and various executive
cognitive functions. Indeed, hand stereotypies, impaired motor coordination and disrupted
cognitive functions are common for all RTT patients. In addition, RTT patients often display a
volumetric decrease in the size of the striatum (Reiss et al., 1993; Subramaniam et al., 1997).
Deletion of MeCP2 from forebrain GABAergic neurons leads to the expression of several RTTlike phenotypes (Chao et al., 2010). However, the role the striatum plays in mediating these
phenotypes is not known. Additionally, the genes regulated by MeCP2 in the striatum have yet to
be defined. Given that 97-98% of striatal neurons are GABAergic medium spiny neurons (MSNs),
this cell homogeneity affords this region a unique advantage for the study of MeCP2-regulated
gene expression.
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In this study, we profiled gene expression changes in the striatum in mice following the
conditional deletion of MeCP2 from the striatum during early development and at an adult stage.
We identified 21 differentially expressed genes only in adult mice and not during development,
highlighting the importance of MeCP2 in maintenance of proper brain function. We also examined
gene expression changes in the striatum of constitutive Mecp2-null mice and found that 59 genes
are significantly down-regulated and 68 genes are significantly up-regulated in the absence of
MeCP2. We found that the majority of differentially expressed genes in the striatum are distinct
from those identified in the hypothalamus and cerebellum. Weighted gene co-expression network
analysis revealed that the overall transcriptome differs largely between brain regions rather than
between WT and Mecp2-null genotypes, indicating that the gene expression landscape is not
globally affected by loss of MeCP2. Together, our data suggests that MeCP2 regulates gene
expression in a region-specific manner, most likely driven by cell type, and that the aggregated
differences in gene expression within individual cells and regions lead to the pathogenesis of
RTT. Given that MeCP2 is a 5mC and 5hmC binding protein and these methylation patterns likely
differ between different cell types, we propose that the role of MeCP2 in regulating target gene
expression should be studied with individual cell types in consideration.
MATERIALS AND METHODS
Mouse strains, Sample collection, and RNA extraction
Experiments were conducted in accordance with the ethical guidelines of the National
Institutes of Health and with the approval of the Institutional Animal Care and Use Committee of
the University of Pennsylvania. Conditional deletion of Mecp2 from forebrain GABAergic neurons
was achieved by breeding Mecp2

flox/+

females (Chen et al., 2001) to transgenic Dlx5/6-cre males.

Constitutive Mecp2-null mice (Guy et al., 2001) were generated by breeding Mecp2

–/+

females to

WT males. All mice were maintained on the C57BL/6 background. Striata were dissected from
cKO mice at P7 and P90 and immediately frozen in liquid nitrogen. Striatal and liver tissue were
dissection from constitutive Mecp2-null mice at P60 and flash frozen in liquid nitrogen. RNA was
extracted using TRIzol reagent (Invitrogen Corporation, Carlsbad, CA, USA), DNase I treated,
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and purified using the miRNAeasy mini kit according to the manufacturer’s protocol (Qiagen,
Valencia, CA, USA).

Microarray Target Preparation and Hybridization
Microarray services were provided by the Penn Microarray Facility, including quality
control tests of the total RNA samples by Agilent Bioanalyzer and Nanodrop spectrophotometry.
All protocols were conducted as described in the Affymetrix GeneChip Expression Analysis
Technical Manual. Briefly, 100 ng of total RNA was converted to first-strand cDNA using reverse
transcriptase primed by poly(T) and random oligomers that incorporated the T7 promoter
sequence. Second-strand cDNA synthesis was followed by in vitro transcription with T7 RNA
polymerase for linear amplification of each transcript, and the resulting cRNA was converted to
cDNA, fragmented, assessed by Bioanalyzer, and biotinylated by terminal transferase end
labeling. cRNA yields and 5 µg of labeled cDNA was added to Affymetrix hybridization cocktails,
heated at 99ºC for 5 min and hybridized to Affymetrix Mouse Exon 1.0 ST GeneChips (for
constitutive Mecp2-null mice and their WT littermates) or Affymetrix GeneChip Mouse Gene 1.0
ST Arrays (for cKO mice and their WT littermates) according to manufacturers instructions.

Microarray Data Analysis
The bioinformatics analysis of all the microarray datasets used in this manuscript was
processed in the MAC terminal window and R environment. The raw CEL files of hypothalamus
(accession number GSE11150) and cerebellum (accession number GSE15574) datasets were
downloaded from the National Center for Biotechnology Information Gene Expression Omnibus
(GEO) database. Four methods were used to process the raw exon array data and to calculate
gene-level expression values. The Affymetrix Power Tools (APT) command line program was
used to process raw data using the robust multichip average method and generate gene-level
expression values based on the core probesets using median polish. The JETTA bioconductor
package was used to normalize raw data using the quantile method and to calculate gene-level
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expression values based on the core probesets using median polish. The last two methods
utilized the affy and xmapcore (exonmap) bioconductor packages. Raw data was processed
using the robust multichip average method. Probesets that mapped uniquely to gene exons using
the exmapcore package were used for subsequent analysis. Gene-level expression values were
calculated using either the median or mean value of all uniquely-mapped exon probsets.
Differentially expressed genes were identified using the limma bioconductor package. A linear
model was fitted for every gene, and the p-values of differentially expressed genes were
calculated using the empirical Bayes moderated t-test. Next, multiple comparisons were
processed to adjust the raw p-value of t-test using Benjamini and Hochberg’s method and to
generate the false discovery rate (FDR). The significance threshold was set at a fold change ≥1.2
with a FDR ≤ 0.05 for identifying differentially expressed genes between Mecp2-null mice and
their WT littermates. The significance threshold was set at a fold change ≥2 with a FDR ≤ 0.05 for
tissue and region-enriched genes between striatum, hypothalamus, cerebellum, and liver
datasets. Genes that were identified by at least one of the four methods described were
considered to be differentially expressed genes.
The GOEAST online software using default settings was used for Gene Ontology (GO)
enrichment analysis. Gene ID conversion was performed using the DAVID Bioinformatics
Resources.

Weighted Gene Co-expression Network Analysis (WGCNA)
The weighted gene co-expression network was built using the WGCNA package in the R
environment. The JETTA package was used to generate the gene expression profiles of WT and
constitutive Mecp2-null mice, and a network was constructed using all striatum, cerebellum, and
hypothalamus datasets. Network constructions were performed using the blockwise Modules
method in the WGCNA package. Using the scale-free topology criterion, the power of six was
chosen to construct the total network. Dynamic hybrid tree cutting was used to cut the
hierarchical clustering trees and to identify individual modules. The minimum module size was set
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to 30 genes and the minimum height for merging modules was set to 0.1. Default parameters
were used for other settings.

Quantitative Real-time PCR
For each sample, 1 µg of total RNA was digested with DNAseI (Invitrogen, Carlsbad, CA)
and reverse-transcribed by oligodT-priming using SuperScriptIII reverse transcriptase (Invitrogen,
Carlsbad, CA). The amount of each transcript of interest present in the sample was measured by
quantitative real-time PCR on 1/10th of the resulting cDNA using SYBR Green detection (Applied
Biosystems) on an ABI 7900HT instrument. Each sample was measured in triplicate using exonspanning qRT-PCR primers. GAPDH amplification served as an internal RNA control for relative
quantification.The following mouse primers were used for qRT-PCR analysis: Gapdh (F: 5’AATGGTGAAGGTCGGTGTG-3’; R: 5’-GTGGAGTCATACTGGAACATG-3’), Mecp2 (F: 5’CATACATAGGTCCCCGGTCA-3’; R: 5’- CAGGCAAAGCAGAAACATCA-3’), Irak1 (F: 5’GTCTTGGATAGCCTGCAACTG-3’; R: 5’-TGAGGGATTTGTCAGAGTGAAC-3’), Drd3 (F: 5’TTATCCACATCCCTGAAGCTG-3’; R: 5’-ACAGTGGGTATTAAGAACGTGAG-3’), Exph5 (F: 5’TCGGTCATCCTTTGCTTCAC-3’; R: 5’-AAGGTCTTACACGCTCATCG-3’), Satb1 (F: 5’TCTAGGAAGAGGAAGGCTTGG-3’; R: 5’-CGCAGAAAACTGGTAACATGG-3’), Dsg1c (F: 5’GGAGCTTAGAGTTAGAGTGATGG-3’; R: 5’-CAAGTTATTTGGCTCATCGGC-3’), Dlk1 (F: 5’TGTCAATGGAGTCTGCAAGG-3’; R: 5’-ATTCGTACTGGCCTTTCTCC-3’), Robo3 (F: 5’TTGTGACTAAGCCCCAGAAC-3’; R: 5’-CTGACTAGGGAAAAGCAGGAC-3’).

Data Deposition
The datasets that were generated and reported in this paper have been deposited into the
National Center for Biotechnology Information GEO database through accession number
GSE42895.
RESULTS
Differentially expressed genes in the striatum of Mecp2 conditional knockout mice
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The striatum serves as the major site of input and integration for cortical, thalamic, and midbrain
afferents in the basal ganglia, a brain region essential for maintaining proper sensorimotor and
executive cognitive functions. The manifestation of motor and cognitive disturbances in RTT,
together with the observed decreased striatal volume in RTT patients (Reiss et al., 1993;
Subramaniam et al., 1997), point to a possible role for the striatum in the etiology of RTT. A
causal role for the striatum in the pathogenesis of RTT, or a biochemical maker of striatal
dysfunction, however, has yet to be examined.
Given the potential role for MeCP2 in the repression and activation of gene transcription,
we examined whether loss of MeCP2 alters gene expression within the striatum. The striatum
affords a unique advantage for gene expression studies because it is composed primarily of
GABAergic MSNs. This homogeneity in cell type reduces the confounding effects that multiple
unique cell types with highly divergent gene transcriptional programs can have on gene
expression analyses (Heiman et al., 2008). Since altered neuronal activity caused by the loss of
MeCP2 from afferent inputs to the striatum may indirectly affect striatal gene expression, we
conditionally deleted MeCP2 from forebrain GABAergic neurons, including striatal MSNs, while
preserving expression in those neurons that provide inputs to the striatum. We achieved this by
breeding floxed Mecp2 mice (Mecp2

2lox/+

) (Chen et al., 2001) to mice expressing Cre-

recombinase localized to striatal MSNs and forebrain GABAergic interneurons (Dlx5/6-cre)
(Monory et al., 2006). The behavioral consequences of deletion of MeCP2 from forebrain
GABAergic neurons using Dlx5/6-cre have previously been determined (Chao et al., 2010).
These mice do not show any of the overt RTT-like phenotypes – such as hypoactivity, gait,
breathing difficulties or premature lethality – that are readily apparent in constitutive Mecp2-null
mice. However, behavioral characterization of these mice revealed phenotypic alterations
involving social interaction preference, motor coordination and repetitive behaviors (Chao et al.,
2010). To determine the efficiency of cre recombinase in the striatum of these mice, we
performed immunohistochemistry using an antibody directed against MeCP2 in the male progeny
of mice with the Mecp2

lox/y

; Dlx5/6-cre genotype (referred hereafter as cKO) and their Mecp2
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2lox/y

(WT) littermates. Indeed, we demonstrate a significant loss of MeCP2 immunoreactivity from the
striatum of cKO mice but not their WT littermates (Figure 2.1A). In addition, close examination of
MeCP2 expression revealed the existence of <1% of cells in the striatum (Figure 2.2).
RTT-like symptoms in mice manifest in an age-dependent manner. Mice show relatively normal
behavior during the early stages of postnatal development followed by the gradual appearance
and increased severity of RTT-like phenotypes. We therefore examined striatal gene expression
levels at two developmental time points: the first at P7 during early postnatal development when
MeCP2 protein levels are still increasing and the second following development at P90 when
MeCP2 protein levels have plateaued (Skene et al., 2010). In addition, behavioral testing has
previously shown that cKO mice exhibit motor deficits at this time point (Chao et al., 2010). We
therefore dissected the striatum from male cKO and WT littermates at P7 and P90 and obtained
genome-wide whole transcript coverage expression data using Affymetrix GeneChip Mouse Gene
1.0 ST Arrays (Gene Arrays). We first examined whether striatal gene expression changed over
the course of development from P7 to P90. Using the criteria of a fold-change of ≥ 1.2 with FDR ≤
0.05 we identified over 7,000 genes that were differentially expressed between P7 and P90 in
both WT and cKO samples (Figures 2.1B-C). These data demonstrate that there is a large-scale
reorganization of the striatal transcriptome across development and that this occurs to a similar
extent in both WT mice and mice lacking MeCP2 from striatal neurons.
We also compared gene expression changes between cKO mice and their WT littermates
at P7 and P90. During early postnatal development at P7 we did not detect any significant
differential gene expression between genotypes using the aforementioned criteria (Figure 2.1D).
In contrast, in adult mice at P90 we identified the differential expression of 21 genes in cKO mice
relative to WT littermates (Figure 2.1E, Table 2.1). These results demonstrate that the conditional
loss of MeCP2 from striatal neurons leads to changes in the expression of a small number of
genes only following postnatal development. Therefore, MeCP2 may not be required for striatal
gene regulation during the early stages of development, but rather plays a critical role in
maintaining proper brain function. In support of this hypothesis, conditional deletion of Mecp2
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from adult mice is sufficient to recapitulate a numerous RTT-like symptoms (Cheval et al., 2012;
McGraw et al., 2011; Nguyen et al., 2012) and restoration of MeCP2 in adult mice can reverse
RTT-like neurological phenotypes (Guy et al., 2007).

Differentially expressed genes in the striatum of Mecp2 constitutive knockout mice
The limited number of differentially expressed genes in the striatum of cKO mice is in
contrast to previous studies examining gene expression changes in the hypothalamus or
cerebellum of constitutive Mecp2-null mice where hundreds to thousands of genes are
differentially expressed (Ben-Shachar et al., 2009; Chahrour et al., 2008). This difference may
result from differences in cellular composition between brain regions, the identity of the mouse
model used, the array platform used or the cell autonomous and non-cell autonomous effects of
MeCP2. To address the possibility that the identity of the brain region mediates these differences,
we examined gene expression changes in the striatum of the same constitutive Mecp2-null mice
using the same Affymetrix GeneChip Mouse Exon 1.0 ST Arrays (Exon Array) used in previous
studies (Ben-Shachar et al., 2009; Chahrour et al., 2008). Striata were dissected from
symptomatic P60 Mecp2-null mice (Guy et al., 2001) and their WT littermates, and total RNA was
extracted, converted to cDNA and hybridized to individual exon arrays. Since exon arrays have
1.2 million probe sets with approximately 40 probes per gene, the calculation of gene expression
levels is a greater challenge than that required for gene arrays: that is, multiple probes will be
mapped to individual genes with varying intensities, leading to difficulty calculating the level of
gene expression. Multiple distinct, but related, methods have been developed to analyze exon
array data with respect to the calculation of gene expression levels. To analyze differentially
expressed genes in a comprehensive manner we applied four different methods to measure gene
expression levels: assessing expression level using the mean values from individual probes for a
given gene, the median values from individual probes for a given gene, the Affymetrix Power
Tools (APT) software package and the JETTA software package (Seok et al., 2012).
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Using these different methods, we have compiled four lists of genes that are differentially
expressed in the striatum of WT and Mecp2-null mice. These four lists of genes overlap with one
other to a large degree, but unique genes are also identified by each method. Using criteria of
fold change of ≥ 1.2 with FDR ≤ 0.05 we identified a total of 127 genes that are differentially
expressed in the striatum of Mecp2-null mice in at least one of the four approaches (68 upregulated genes, 59 down-regulated genes) (Supplementary Dataset S1). Of these, 67 were
identified using at least two of these analytical methods (Supplementary Dataset S1) and 56% of
those genes dysregulated in P90 cKO mice were also differentially expressed in Mecp2-null mice
(Table 2.1). Importantly, we find that Mecp2 is significantly down-regulated, whereas interleukin-1
receptor-associated kinase 1 (Irak1) is significantly up-regulated in Mecp2-null mice. Since the
Irak1 gene is located only 3 kb distal to Mecp2, this alteration is likely due to the altered genomic
environment caused by deletion of Mecp2 exons 3 and 4 (Urdinguio et al., 2008).
To verify the exon array analysis, we randomly selected six genes from our list of
differentially expressed genes (Exph5, Robo3, Drd3, Satb1, Dsg1c, and Dlk1) and analyzed their
mRNA levels in WT and Mecp2-null striatal tissues using quantitative real-time PCR (qRT-PCR).
We also included Mecp2 and Irak1 as positive controls. We found that all eight of these selected
genes show expression changes that are consistent with those seen in our exon array data
(Figure 2.3A), validating our approach in using exon array analysis to identify differentially
expressed genes in the striatum of Mecp2-null mice.
To characterize the major biological themes present in differentially expressed striatal
genes, we assigned Gene Ontology (GO) annotations to the genes and tested for significant
enrichment of functionally related terms (Figures 2.3B-C). As expected, most of the enriched
terms involve neural morphology or function. We found that the 59 down-regulated genes are
significantly enriched with functions associated with ion and chemical homeostasis (Figure 2.3B),
whereas the 68 genes up-regulated in Mecp2-null mice are highly enriched for functions
associated with transcriptional regulation, development and differentiation (Figure 2.3C).
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Therefore, the differentially expressed genes identified from the striatum are likely functionally
related to neuronal function.

Differentially expressed genes in the striatum are distinct from other brain regions
To determine whether gene expression changes upon loss of MeCP2 are consistent
across the brain regions, we compared the identified 127 differentially expressed striatal genes
with genes previously shown to be significantly altered by loss of MeCP2 (defined as those genes
showing fold change of ≥ 1.2 with FDR ≤ 0.05) in the hypothalamus (Chahrour et al., 2008) or
cerebellum (Ben-Shachar et al., 2009) between WT and Mecp2-null mice. Unsupervised
hierarchical clustering of differentially expressed genes between Mecp2-null and WT littermates
in these three brain regions revealed largely distinct classes of genes affected by the loss of
MeCP2 (Figure 2.4A). Comparison of those differentially expressed genes revealed that only a
small number of genes that are altered in all three brain regions (Figure 2.4 and Supplementary
Dataset S2). Indeed, only 2 genes (including Irak1) are commonly up-regulated between brain
regions (Figure 2.4B), whereas 3 genes (including Mecp2) are commonly down-regulated (Figure
2.4C). In addition, comparison between differentially expressed genes in the cerebellum of
Mecp2-null mice and their WT littermates identified using RNA-seq (Mellén et al., 2012) revealed
only three genes were commonly down-regulated (including Mecp2) in the striatum. Furthermore,
analysis of the GO terms for these differentially expressed genes yields a transcriptional
signature for the striatum that is different to that observed in the hypothalamus or cerebellum
(Figure 2.3B-C) (Ben-Shachar et al., 2009; Chahrour et al., 2008). These data support therefore
that MeCP2 regulates gene expression in a region-specific manner.

Similar gene co-expression networks in WT and Mecp2-null mice
Given the findings that MeCP2 binds to 5mC and 5hmC across the genome (Mellén et
al., 2012; Skene et al., 2010), it has been suggested that MeCP2 may affect global gene
transcription in addition to specific genes. To assess the global effect of MeCP2 on gene
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transcription, we analyzed gene expression level data from striatum, hypothalamus and
cerebellum in Mecp2-null mice and their WT littermates using hierarchical clustering algorithms.
We found that the overall gene expression profiles are clustered based on brain regions but not
genotypes (Figure 2.5A). These data demonstrate that the overall biochemical signature of an
individual brain region is maintained in the absence of MeCP2.
To gain higher-order and system level insight into how loss of MeCP2 affects the
expression of functionally related genes, we next applied weighted-gene co-expression network
analysis (WGCNA) to gene expression data from striatum, cerebellum and hypothalamus.
WGCNA examines groups of genes whose expression profiles are highly correlated across
samples and gives rise to gene modules containing subsets of genes with similar biochemical
and functional properties as well as anatomical localization (Johnson et al., 2009; Oldham et al.,
2008; Zhang and Horvath, 2005). This technique has recently been used to identify modules of
dysregulated genes in autism patients, providing evidence for convergent molecular pathologies
in ASD (Voineagu et al., 2011). We therefore constructed a co-expression network using the
entire data set, composed of both Mecp2-null mice and their WT littermate samples from striatum,
hypothalamus and cerebellum. Gene expression profiles were classified into nine modules (ME1 9) with the expression levels of each module summarized by the first principle component (the
module eigengene).
We first asked whether global differences in the organization of the brain transcriptome
exist between different brain regions. Indeed, eigengene values across all modules were
markedly different between the striatum, hypothalamus and cerebellum (Figures 2.5B and 2.6),
consistent with the existence of robust modules of co-expressed genes that are related to specific
cell types and reflect anatomical localization and functional divergence (Oldham et al., 2008). We
then sought to identify discrete groups of co-expressed genes showing transcriptional differences
between Mecp2-null mice and their WT littermates. We found no significant differences in module
eigengenes between WT and Mecp2-null mice across the striatum, hypothalamus or cerebellum
(Figures 2.5B and 2.6). Therefore, the loss of MeCP2 function does not alter the general
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organization and molecular distinctions of transcriptomes in different brain regions. Finally, we
wanted to determine whether those genes differentially expressed in the striatum were distributed
across modules or clustered together. We found that 70% of differentially expressed genes in the
striatum are clustered within three modules: 33% of genes within module 1, 25% in module 3 and
12% in module 4 (Figure 2.5C). These data suggest therefore that loss of MeCP2 from striatum
leads to alterations in genes that are functionally related to one another. The overall
transcriptome differs largely between brain regions rather than between WT and Mecp2-null
genotypes.

Evaluation of gene expression variation in Mecp2-null mice
MeCP2 has been suggested to organize global chromatin structure and tighten
transcriptional regulation by dampening transcriptional noise (Muotri et al., 2010; Skene et al.,
2010). This raises the possibility that loss of MeCP2 function may lead to the stochastic
dysregulation of genes within a given brain region across individual animals: that is, altered gene
expression profiles within different brain regions of Mecp2-null mice may reflect an increase in
inter-subject variance in gene expression. To examine this possibility we calculated the variance
for individual gene expression levels across animals in the striatum, hypothalamus and
cerebellum of Mecp2-null mice and their WT littermates. However, we found no significant
differences in gene expression variance in any of these three brain regions (Bartlett's test, Figure
2.7). To investigate the abundance of gene expression may override individual variation across
the transcriptome, we further classified all expressed genes into three groups based on their
expression levels (low, medium or high), and calculated expression variance within these
individual groups. Again, we found no significant differences in gene expression variance
between genotypes in any of these groups (Figure 2.8). These data indicate that increased
variance in gene expression levels is not the major contributor to the differential expression of
genes between Mecp2-null mice and their WT littermates. Therefore, loss of MeCP2 function is
unlikely to modulate gene expression levels through a stochastic disruption of gene regulation
50

processes; rather MeCP2 appears to modulate gene expression through a coordinated, cell-type
specific mechanism. Consistent with this, we found that MeCP2 also affects neuronal morphology
in a brain region- and cell type-specific manner (Wang et al., 2013).

Loss of MeCP2 function affects both neuronal and non-neuronal genes
Distinct gene expression changes occurring in different brain regions would be expected
if those genes were particularly enriched in a single brain region. To investigate this possibility,
we isolated liver tissue from Mecp2-null mice and normalized gene expression data from striatum,
hypothalamus and cerebellum to that of liver in order to identify region-enriched genes. We next
generated a classification scheme by a direct comparison of WT gene expression profiles
between our liver dataset and the datasets from striatum, hypothalamus, and cerebellum (Figure
2.9A). Genes exhibiting higher fold expression (fold change ≥ 2 with FDR ≤ 0.05) in the three
brain regions relative to liver were considered neuronal-enriched genes. Among these, those that
only appeared in a single brain region relative to the remaining two were considered specific brain
region-enriched genes. Using these criteria, we identified striatum- (622 genes), hypothalamus(1,109 genes) and cerebellum-enriched genes (714 genes) (Figure 2.9A and Supplementary
Dataset S3). To verify the fidelity of this classification scheme, we obtained the top 50 highly
expressed genes in the striatum from the Allen Mouse Brain Atlas and confirmed that 98% of the
genes from the atlas are present in our list of striatum-enriched genes (Supplementary Dataset
S4). A similar analysis with the previously published hypothalamus- and cerebellum-enriched
gene lists revealed 83% and 89% overlap, respectively.
We next examined whether genes differentially expressed between WT and Mecp2-null
mice were classified as brain region-enriched genes or demonstrated similar expression levels in
different brain regions. We found that the majority of genes deregulated in Mecp2-null datasets
tended to be those expressed across different brain regions or showed similar expression levels
in the liver. Indeed, only a small portion, 3 to 10%, of all differentially expressed genes, are
enriched in a single brain region (Figure 2.9A). Thus, brain region-specific differential gene
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expression in Mecp2-null mice is unlikely to be a consequence of the enrichment of those genes
in that particular brain region. Rather, other tissue-specific factors likely control this separation in
differential gene expression.
MeCP2 is ubiquitously expressed throughout the body although its function in nonneuronal tissues is not well understood (Shahbazian et al., 2002b). To examine whether loss of
Mecp2 function affects gene expression in non-neuronal tissues, we profiled gene expression
levels from the liver of Mecp2-null mice and their WT littermates. We found that 161 genes are
differentially expressed in the livers of Mecp2-null compared to their WT littermates (Figure 2.9B
and Supplementary Dataset S5). Of these genes, 73 are up-regulated and were enriched for lipid,
fatty acid and small molecule metabolism as determined by GO analysis (Figure 2.9C). Since
MeCP2 expression is relatively low in the liver (Shahbazian et al., 2002b), these expression
changes may be indirectly associated with MeCP2 due to general alterations in metabolism not
yet characterized in Mecp2-null mice. Nevertheless, these data suggest that Mecp2-null mice
may have altered liver metabolism consistent with a recent finding that mice lacking MeCP2 show
numerous alterations in liver metabolism (Pitcher et al., 2013). It is possible therefore that these
altered metabolic processes may also contribute to the pathology of RTT.
DISCUSSION
RTT is a devastating neurological disorder that leads to the manifestation of a number of
diverse symptoms including gait apraxia, loss of purposeful hand movements, respiratory
abnormalities and loss of communication. The particular symptoms observed in RTT suggest that
striatal dysfunction may play an important role in its etiology. Indeed, volumetric analyses of RTT
individuals have consistently identified a decrease in the size of the neostriatum, even when
taking into account the smaller brain size of these patients (Reiss et al., 1993; Subramaniam et
al., 1997). The striatum serves as the input center for the basal ganglia, a subcortical region of
the brain which processes and integrates information associated with learning and memory,
motor control and various executive cognitive functions. The conditional deletion of MeCP2 from
forebrain GABAergic neurons, including MSNs of the striatum, leads to the development of a
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number of symptoms in mice including impaired motor coordination, ataxia and social deficits
(Chao et al., 2010). The role that MeCP2 loss-of-function in the striatum plays in the development
of these symptoms, however, is unclear. Similarly, the identity of genes affected by loss of
MeCP2 in this region has not been investigated.
In order to examine changes in gene expression within the striatum we utilized two
mouse models: mice lacking MeCP2 only from forebrain GABAergic neurons including MSNs of
the striatum, and constitutive Mecp2-null mice. Using the first model, we profiled gene expression
changes in the striatum across development from P7 to P90. We found considerable changes in
the gene expression profiles of the striatum during these time points, with over 7,000 genes being
affected developmentally in both cKO mice and their WT littermates. In contrast, we observed
only a small number of differentially expressed genes between cKO mice and their WT
littermates. These alterations only occurred at P90 when MeCP2 levels are high and not during
early postnatal development. These data suggest therefore that MeCP2 is not required for striatal
gene regulation during early development; rather, MeCP2 appears to be essential for maintaining
proper brain function at later postnatal stages. Indeed, conditional deletion of Mecp2 from adult
mice is sufficient to recapitulate many RTT-like symptoms and altered hypothalamic gene
expression (Cheval et al., 2012; McGraw et al., 2011; Nguyen et al., 2012).
Notably, the number of differentially expressed genes in striatum is markedly different in
cKO striatum compared to those previously observed in hypothalamus and cerebellum of
constitutive Mecp2-null mice (Ben-Shachar et al., 2009; Chahrour et al., 2008). To address the
possibility that these differences were the result of different mouse models we repeated our
striatal gene expression studies using symptomatic Mecp2-null mice and exon arrays similar to
previous studies. Indeed, up to 127 genes were differentially expressed in symptomatic Mecp2null mice at P60 compared to WT littermates. The greater number of genes identified in the
striatum of Mecp2-null mice relative to cKO mice may result from differences in cell autonomous
and non-cell autonomous effects of MeCP2 loss-of-function. Most of the genes identified in cKO
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mice were also identified in Mecp2-null mice suggesting that they are indeed regulated by
MeCP2.
Among the small number of differentially expressed genes found in the striatum, the
majority of the affected genes were not identified in analyses of the hypothalamus or cerebellum.
These data suggest that MeCP2 regulates gene expression in a region- or cell-type-specific
manner. Furthermore, the majority of these region-specific changes in gene expression involve
genes that are typically expressed in multiple brain regions and non-neuronal cell types. Distinct
gene expression profiles in different brain regions are likely governed by local alterations to
chromatin structure in addition to cell-type specific 5mC and 5hmC localization (Mellén et al.,
2012; Szulwach et al., 2011). Thus region-specific alterations in gene expression may reflect
differential binding of MeCP2 to 5mC and 5hmC, respectively.
Our analysis of the gene expression changes in the striatum revealed considerably fewer
genes differentially expressed by loss of MeCP2 relative to the hypothalamus and cerebellum that
together exhibited > 2,000 genes differentially expressed (Ben-Shachar et al., 2009; Chahrour et
al., 2008). The larger number of genes altered in these two regions may reflect the greater
heterogeneity in cell types within these regions in comparison to the striatum that is primarily
composed of MSNs. It would be interesting to determine whether individual cell types, such as
Granule cells, Purkinje cells and Bergmann glia from the cerebellum, demonstrate a more
restricted alteration in gene transcription in Mecp2-null mice. Moreover, analysis of gene
expression at a systems level using WGCNA revealed modules of genes functionally and
anatomically classified based on brain region and are unaltered by loss of MeCP2. However,
those genes that are differentially expressed in the striatum cluster within discrete sets of
modules arguing that these genes are functionally related to one another. These findings suggest
that MeCP2 does not alter the gene expression landscape globally, but rather shows a brain
region- or cell-type-specific effect. Thus, while individual gene expression changes in individual
cell types may be small, the composite effects, however, lead to global disruption in brain function
and the pathogenesis of RTT.
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Most of the work regarding MeCP2 has centered around its function in the brain since
brain-specific deletion of MeCP2 is sufficient to recapitulate most RTT-like symptoms observed in
constitutive Mecp2-null mice (Chen et al., 2001; Guy et al., 2001). Although MeCP2 is
ubiquitously expressed, its function in other tissues remains unknown. In this study, we also
examined gene expression changes in the liver of symptomatic Mecp2-null mice and identified
161 genes that were differentially expressed, with 73 upregulated genes being enriched for lipid,
fatty acid and small molecule metabolism. These data may indicate that Mecp2-null mice may
have altered liver metabolic processes. Indeed, it has been suggested that Mecp2-null mice have
a metabolic disorder (Pitcher et al., 2013). Mecp2-null were found to have marked increases in
sera levels of triglycerides and cholesterol and decreased sera levels of insulin-like growth factor
binding-protein 2 (Pitcher et al., 2013). These alterations were associated with an increase in fat,
but not lean mass and insulin resistance (Pitcher et al., 2013). Since MeCP2 expression remains
low in the liver (Shahbazian et al., 2002b), it is not known whether these alterations in the
expression of genes related to metabolism in the liver are directly caused by loss of MeCP2
function in the liver, or are secondary to occur indirectly through altered metabolic pathways in
Mecp2-null mice. Further study into the function of MeCP2 in the liver and the greater
characterization of metabolic processes affected by loss of MeCP2 will provide greater insight
into the role of metabolism in the pathogenesis of RTT.
In summary, we identified a number of differentially expressed genes in the striatum of
Mecp2-null mice. These differentially expressed genes in the striatum were largely unique to
those previously identified in the cerebellum or hypothalamus. We have therefore uncovered a
previously under-appreciated feature of MeCP2 in regulating gene expression in a region-specific
manner within the brain. We demonstrate that differential gene expression in different regions of
the Mecp2-null brain do not occur due to region-specific expression or increased gene expression
variance or within a particular functional biochemical network. Differential gene expression is
likely caused by other region-specific mechanisms such as local differences in 5mC and 5hmC
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patterns. Our findings add new possibilities to the molecular function of MeCP2 and identify
genes that may be novel therapeutic targets for the treatment of RTT.
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CHAPTER 2 FIGURES

FIGURE 2.1: Gene expression changes in the striatum of Mecp2 conditional knockout
2lox/y
lox/y
mice. (A) Immunohistochemistry for MeCP2 expression in Mecp2
and Mecp2 ; Dlx5/6-cre
mice at P90. The presence of Dlx5/6 leads to a substantial loss of MeCP2 from striatum. Scale
bar corresponds to 500 µm.
(B) Volcano plots depicting fold-change and FDR-correct p-values for striatal gene expression
2lox/y
between P7 versus P90 in WT and Mecp2
; Dlx5/6-cre (cKO) mice.
(C) Volcano plots for gene expression changes between WT and cKO mice at P7 and P90. Green
dots represent genes showing a fold change of ≥ 1.2 with FDR ≤ 0.05 that were considered
differentially regulated
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FIGURE 2.2: Loss of MeCP2 from the striatum with expression of Dlx5/6-cre
2lox/y

lox/y

Immunohistochemistry for MeCP2 expression in Mecp2
and Mecp2 ; Dlx5/6-cre mice at
P90. The presence of Dlx5/6 leads to a substantial loss of MeCP2 from striatum although small
numbers of MeCP2-expressing cells remain. Scale bar corresponds to 100 µm.
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FIGURE 2.3: Gene expression changes in the striatum of Mecp2 constitutive knockout
mice
(A) Validation of differentially expressed genes in striatum of WT and constitutive knockout
(Mecp2-null) mice by quantitative real-time RT-PCR.
(B) Gene ontology (GO) analysis for genes enriched in the striatum of Mecp2-null mice compared
to their WT littermates.
(C) GO analysis for genes depleted in the striatum of Mecp2-null mice compared to their WT
littermates. The enrichment p-values were calculated by hypergeometric test and adjusted by
Yekutieli method using GOEAST software.
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FIGURE 2.4: Differential gene expression in different brain regions of Mecp2-null mice
(A) Heat map of the differentially expressed genes in striatum, hypothalamus and cerebellum of
Mecp2-null mice. Expression values are color-coded according to the legend to the right. The
dendrogram depicts unsupervised hierarchical clustering based on fold-changes.
(B) Venn diagram depicting the overlap between genes differentially up-regulated in striatum,
hypothalamus and cerebellum.
(C) Venn diagram depicting the overlap between genes differentially down-regulated in striatum,
hypothalamus and cerebellum.
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FIGURE 2.5: Gene expression network analysis in different brain regions of WT and
Mecp2-null mice
(A) Unsupervised hierarchical clustering of the gene expression profiles of striatum (ST),
hypothalamus (HY), and cerebellum (CE) in Mecp2-null (null) and WT mice.
(B, top) Heat map of the gene expression profiles in Mecp2-null and WT data sets across three
brain regions. (B, bottom) A representative module (ME6) of co-regulated genes generated
based on topological overlap of gene expression data from WT and KO mice. A clear separation
of eigengene values can be seen based on brain region but not genotype.
(C) Localization of differentially expressed genes within modules assigned using WGCNA in the
striatum.
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FIGURE 2.6: Weighted gene co-expression network analysis (WGCNA) in Mecp2-null and
wild-type mice
Gene expression profiles and module eigengene of the 8 modules in the co-expression network
constructed using the Mecp2-null and wild-type data sets.
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FIGURE 2.7: Gene expression variances between replicates in striatum, hypothalamus,
and cerebellum in Mecp2-null and wild type (WT) mice
Gene level expression profiles used in this analysis were generated by the mean (A), median (B),
APT (C), and JETTA (D) methods, respectively. Differentially expressed genes between Mecp2null and WT mice in striatum are labeled in red.
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FIGURE 2.8
Expression variances between replicates for the highly-expressed (red), intermediately-expressed
(grey), and lowly-expressed (green) genes in striatum (A), hypothalamus (B), cerebellum (C), and
liver (D) in Mecp2-null and wild type (WT) mice. Gene level expression profiles used in this
analysis were generated by the JETTA package.
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FIGURE 2.9 Distribution of differentially expressed genes in WT and Mecp2-null mice
(A) Genes differentially expressed in WT and KO tissues were separated into those that show
enrichment within their representative brain region, those enriched in brain versus liver, and those
that are not enriched.
(B) The number of genes up-regulated and down-regulated in liver in Mecp2-null mice compared
with WT littermates.
(C) Gene ontology (GO) analysis showing biological functions of the genes up-regulated in the
liver of Mecp2-null mice compared to their WT littermates. The enrichment p-values are
calculated by hypergeometric test and adjusted by Yekutieli method using GOEAST software.

65

CHAPTER 3: Biotin tagging of MeCP2 reveals contextual insights into the Rett
syndrome transcriptome
Adapted from: Johnson, B.S.*, Zhao, Y.*, Fasolino, M.D.*, Lamonica, J., Kim, Y.J., Wood, K.H.,
Bu, D., Cui, Y., Goffin, D., Kim, T.H., Zhou, Z. Biotin tagging of MeCP2 reveals contextual insights
into the Rett syndrome transcriptome. Manuscript in preparation.

ABSTRACT

Mutations in MECP2 are responsible for Rett syndrome (RTT), a severe X-linked
neurological disorder characterized by loss of developmental milestones, intellectual
disability and motor impairments. Molecular insight into how these mutations disrupt
neuronal function and contribute to RTT is impeded by the cellular heterogeneity of the
mammalian brain. We generated knock-in mice bearing frequent RTT mutations (T158M,
R106W) in conjunction with cell type-specific biotin tagging and profiled the
transcriptome of WT and mutant neurons across two distinct cell types and ages. We
found that MeCP2-dependent gene expression varies by age and cell type, and the
degree of transcriptional changes correlates with the severity of the RTT mutation. We
also provide evidence supporting post-transcriptional compensation of misregulated long
genes. Finally, we circumvent genetic mosaicism associated with female mouse models
of RTT and identify functionally distinct gene expression changes between neighboring
WT and mutant neurons, therefore providing key insights into RTT.
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INTRODUCTION
RTT is a progressive X-linked neurological disorder that represents one the most
common causes of mental disability among young girls, occurring in 1 out of every 10,000 female
births. Individuals with classic RTT appear asymptomatic until 6-18 months of age, after which
they experience a characteristic loss of acquired language, social, and psychomotor skills,
followed by the manifestation of stereotyped hand movements, hypotonia, breathing irregularities,
and, in a large majority of patients, seizures (Neul et al., 2010; Percy et al., 2010). Approximately
95% of RTT cases are genetically mapped to the X-linked gene that encodes Methyl-CpG binding
protein 2 (MeCP2), a ubiquitously expressed protein that is highly enriched in post-mitotic
neurons of the mammalian brain relative to other somatic cell types (Cuddapah et al., 2014;
Shahbazian et al., 2002b). The majority of RTT missense and nonsense mutations associated
with MECP2 are predominantly clustered in two functionally distinct protein domains that are
critical for MeCP2 function. The Methyl-CpG Binding Domain (MBD) allows MeCP2 to recognize
and bind to symmetrically methylated cytosines (Lewis et al., 1992; Nan et al., 1997). The
Transcriptional Repression Domain (TRD) mediates protein-protein interactions with histone
deacetylase-containing co-repressor complexes, including the NCoR-SMRT and mSin3A
complexes (Ebert et al., 2013; Lyst et al., 2013; Nan et al., 1998). Together these domains
implicate MeCP2 as a nuclear protein that is broadly distributed throughout chromatin and likely
mediates transcriptional repression (Nan et al., 1997; Skene et al., 2010), although transcriptional
activation has also been reported (Chahrour et al., 2008; Li et al., 2013a).
Although much research into RTT has primarily focused on hemizygous male mice, due
to the limits imposed by random X-inactivation in female mice, animal models bearing mutations
in Mecp2 faithfully recapitulate the pathophysiology of human RTT patients. Following apparently
normal post-natal development, Mecp2-null male mice progressively display abnormal gait and
hypoactivity, breathing irregularities, learning and memory impairments, and premature lethality,
which are accompanied by morphologial deficits and electrophysiological abnormalities in the
brain (Chen et al., 2001; Guy et al., 2001). Mecp2-mutant mice bearing RTT missense mutations
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further model the clinical variability associated with RTT, highlighting the individual molecular
contributions of the MBD and TRD towards RTT phenotypes. However, despite clear genetic
linkage and conserved pathophysiology, a mechanism by which MeCP2 loss of function
contributes to the cellular, synaptic, circuit, and behavioral deficits seen in RTT patients and
Mecp2 mouse models remains poorly understood.
The identification of transcriptional targets associated with MeCP2 dysfunction remains a
key step towards illuminating the molecular etiology of RTT. Previous studies have corroborated
that subtle gene expression changes occur among numerous genes that are misregulated in
Mecp2-mutant male mice and in cultured neurons lacking MeCP2. However, the phenotypic
consequences of such effects are unclear, having only been explored on a gene-specific basis
despite lists of misregulated genes that vary across multiple studies (Ben-Shachar et al., 2009;
Chahrour et al., 2008; Jordan et al., 2007; Kriaucionis et al., 2006; Li et al., 2013a; Nuber et al.,
2005; Sugino et al., 2014; Tudor et al., 2002; Urdinguio et al., 2008). Reports detailing MeCP2
binding to methylated cytosines (mCpG and mCpA), hydroxymethylated cytosines (hmCpG), and
GC-rich regions throughout the neuronal genome also remain conflicting, thus making the
identification of direct MeCP2 target genes difficult to ascertain (Chen et al., 2015; Cohen et al.,
2011; Gabel et al., 2015; Rube et al., 2016; Skene et al., 2010).
The complexity of studying MeCP2 transcriptional function is further confounded by the
heterogeneity of cellular transcriptomes and their diversity in the mammalian brain. The brain
comprises a myriad of intermixed cell types that differ in morphology, function, and
electrophysiological properties. Current studies are now beginning to uncover the distinctive
transcriptional and epigenomic programs that vary between different cell types in order to
maintain this cellular diversity (Fuzik et al., 2016; Mo et al., 2015; Tasic et al., 2016; Usoskin et
al., 2015). Genomic distributions of methylated and hydroxymethylated cytosines are cell typespecific, but our knowledge remains limited on whether MeCP2, despite its ubiquitous expression
throughout the brain, exerts transcriptional control in a cell type-dependent or independent
manner (Sugino et al., 2014). Addressing this heterogeneity and investigating transcriptional
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changes within the varying contexts of individual cell types may provide key insights into how
MeCP2 modulates gene expression.
Within individual cell types, RNA also exists as a heterogeneous pool of nuclear and
cytoplasmic transcripts at different stages of synthesis, processing and maturation, sub-cellular
localization, translation, and degradation. The bulk of protein-coding mRNAs are enriched in the
cytoplasm and subject to post-transcriptional regulation. In contrast, protein-coding RNAs in the
nucleus represent transcripts not yet heavily influenced by post-transcriptional regulation, and are
thus well suited for studying transcriptional dynamics in the cell (Bhatt et al., 2012; Djebali et al.,
2012). Measured gene expression changes using whole cell mRNA from individual brain regions
thus reflect composite profiles that easily obscure cell type-specific expression changes, which
may also impede an accurate assessment of MeCP2 function at the transcriptional level.
In this study, we addressed these issues by engineering a collection of genetically
modified mice whereby nuclear MeCP2 is “tagged” with biotin in a Cre-recombinase dependent
manner. To understand the molecular impact of RTT-associated mutations on cell type-specific
gene expression in vivo, we also developed tagged knockin mice bearing T158M or R106W RTT
missense mutations. When combined with Fluorescence-Activated Cell Sorting (FACS), this
strategy effectively circumvents the cellular heterogeneity of the mouse brain and allows isolation
of nuclei from cell types of interest. By examining MeCP2 differentially expressed genes (FDR <
0.05, herein DEGs) within the context of neuronal gene expression in the nucleus, we identified
transcriptional similarities and differences that correlate with the severity of the mutation in
different cell types and at different ages. Furthermore, we find that genome-wide transcriptional
deficits in the nucleus are balanced by post-transcriptional compensation of RNAs in a gene
length-dependent manner. Finally, our approach allows us to also circumvent genetic
heterogeneity associated with X-inactivation in heterozygous female mice and profile
transcriptional changes among neighboring WT and mutant neurons, thereby discerning cell
autonomous from non-cell autonomous transcriptional effects. This comprehensive survey across
different neuronal settings allows us to propose a contextualized model by which cell and non-cell
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autonomous transcriptional changes in different cell types contribute to the molecular severity of
neuronal deficits observed in RTT.
MATERIALS AND METHODS
Generation and Phenotypic Characterization of Mice
The targeting construct used for homologous recombination at the Mecp2 locus in murine ES
cells was cloned in two arms by PCR amplification of sv129 genomic DNA. The 5′ arm was PCR
amplified with 5′-AGGAGGTAGGTGGCATCCTT-3′ and 5′-CGTTTGATCACCATGACCTG-3′
primers, whereas the 3′ arm was PCR amplified with 5′-GAAATGGCTTCCCAAAAAGG-3′ and 5′AAAACGGCACCCAAAGTG-3′ primers. Restriction sites at the ends of each arm were created
using nested primers for cloning into a vector containing a loxP-flanked neomycin cassette (Neo)
and a diphtheria toxin A negative-selection cassette. QuikChange (Stratagene) insertional
mutagenesis was used to generate the Mecp2-Tavi targeting construct by inserting the Tavi tag
immediately upstream of the Mecp2 stop codon within the 5’ arm. The portion of the Tavi tag
containing the biotinylation consensus sequenced flanked by 5’ NaeI and 3’ BspHI restriction
sites was inserted through two rounds of mutagenesis (Round 1 Forward: 5’-GACCGAGAGAG
TTAGCGCCGGCCTGAACGACATCTTCGAGTCATGACTTTACATAGAGCG-3’, Round 1
Reverse: 5’-CGCTCTATGTAAAGTCATGACTCGAAGATGTCGTTCAGGCCGGCGCTAACTCT
CTCGGTC-3’; Round 2 Forward: 5’-CTGAACGACATCTTCGAGGCTCAGAAAATCGAATGGC
ACGAATCATGACTTTACATAGAG-3’, Round 2 Reverse: 5’-CTCTATGTAAAGTCATGATTCGT
GCCATTCGATTTTCTGAGCCTCGAAGATGTCGTTCAG-3’), whereas the portion of the tag
containing the TEV protease cleavage site was inserted upstream of the NaeI restriction site with
a third round of mutagenesis (Round 3 Forward: 5’-GACCGAGAGAGTTAGCGAAAACCTG
TATTTTCAGGGCGCCGGCCTGAACGACATC-3’, Round 3 Reverse: 5’-GATGTCGTTCAGGCC
GGCGCCCTGAAAATACAGGTTTTCGCTAACTCTCTCGGTC-3’). To generate Mecp2-Tavi
targeting constructs bearing independent RTT-associated point mutations, QuikChange sitedirected mutagenesis was used to mutate MeCP2 arginine 106 to tryptophan and MeCP2
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threonine 158 to methionine within the 3’arm and 5’arm, respectively. A single nucleotide at
codon T160 also underwent site-directed mutagenesis for a silent mutation to introduce a BstEII
restriction site to correctly identify targeted ES cells. To generate conditional BirA transgenic
mice, PCR primers containing AscI restriction sites and a Kozak consensus sequence were used
to subclone the BirA coding sequence and insert it downstream of the floxed Neo-STOP cassette
within pROSA26-1, a transgenic targeting vector that has previously been characterized.
After confirmation by Sanger sequencing and linearization with NotI (Mecp2-Tavi targeting
construct and its mutant variants) or SgfI (BirA targeting construct), the constructs were
electroporated into sv129-derived murine ES cells. Correctly targeted ES cells were
independently injected into C57BL/6 blastocysts and subsequently implanted into
pseudopregnant females. Agouti offspring were screened by PCR genotyping to confirm germline
transmission of the Mecp2-Tavi, Mecp2

T158M

-Tavi, Mecp2

R106W

-Tavi, and R26

cBirA

alleles. In the

case of the Mecp2-Tavi allele and its mutant variants, the resulting offspring were mated with
C57BL/6 EIIa-cre mice to ensure germline deletion of the floxed Neo cassette between Mecp2
exons 3 and 4.

Mouse lines
Dlx5/6-Cre mice (Stock 008199) were obtained from Jackson Laboratories. NeuroD6/NEX-Cre
mice were obtained with permission from the Nave Laboratory.

Animal Husbandry
Experiments were conducted in accordance with the ethical guidelines of the US National
Institutes of Health and with the approval of the Institutional Animal Care and Use Committee of
the University of Pennsylvania. All of the experiments described were performed using mice on a
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congenic sv129:C57BL/6 background with the knock-in/transgenic alleles backcrossed to
C57BL/6 mice (Charles River) for at least five generations, unless otherwise stated. Mice were
housed in a standard 12h light/12h dark cycle with access to ample amounts of food and water.
Mice bearing the Tavi tag were genotyped using a bipartite primer PCR-based strategy to detect
the Tavi tag at the 3’-end of the endogenous Mecp2 gene (Forward: 5’CACCCCGAAGCCACGAAACTC-3’, Reverse: 5’-TAAGACTCAGCCTATGGTCGCC-3’) and give
rise to a 318-bp product from the wild-type allele and a 388-bp product from the tagged allele.
Mice bearing the BirA transgene were genotyped using a tripartite primer PCR-based strategy to
detect the presence or absence of the CAG promoter at the Rosa26 locus (Forward:5’TGCTGCCTCCTGGCTTCTGAG-3’, Reverse #1: 5’-GGCGTACTTGGCATATGATACAC-3’,
Reverse #2: 5’-CACCTGTTCAATTCCCCTGCAG-3’) and give rise to a 173-bp product from the
wild-type allele and a 477-bp product from the transgene-bearing allele. Mice bearing Crerecombinase (either NeuroD6/NEX-Cre or Dlx5/6-Cre) were genotyped using PCR-based
strategies as previously described (REFERENCES).

Phenotypic Scoring
Phenotypic scoring was performed on a weekly basis for the absence or presence of RTT-like
symptoms as described previously.

Immunofluorescence and microscopy
Mice were anesthetized with 1.25% Avertin (wt/vol), transcardially perfused with 4%
paraformaldehyde (wt/vol) in 0.1M sodium-potassium phosphate buffered saline and postfixed
overnight at 4°C. Brains were coronally or sagittally sectioned at 20µm using a Leica CM3050 S
cryostat. Immunofluorescence on free-floating sections was performed as previously described,
except sections were permeabilized with 0.5% Triton without methanol for 20 minutes, and
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sections were blocked overnight with 10% Normal Goat Serum and 1:100 unconjugated goat antimouse IgG (Sigma M5899). The following primary antibodies were incubated at 4°C overnight:
rabbit anti-MeCP2 C-terminus (1:1000, in house), rabbit anti-nucleolin (1:1000, Abcam ab22758),
mouse anti-parvalbumin (1:500, Millipore MAB1572), rabbit anti-calretinin (1:1000, Swant
7699/3H), mouse anti-GAD67 (1:500, Millipore MAB5406), mouse anti-NeuN (1:500, Millipore
MAB377). For rat anti-somatostatin (1:250, Millipore MAB354MI), primary incubation was
performed for 48 hours at 4°C. Flourescence detection of primary antibodies was performed
using Alexa 488-conjugated goat anti-rabbit (1:1000, Invitrogen A11008), Alexa 488-conjugated
goat anti-mouse (1:1000, Invitrogen A11029), and Alexa 488 goat anti-rat (1:1000, Invitrogen
A11006). Fluorescence detection of biotin was performed simultaneously with secondary
antibody incubations, using Streptavidin Dylight 650 (1:1000, Fisher 84547) for fluorescence
microscopy and Streptavidin Dylight 550 (1:1000, Fisher 84542) for confocal microscopy.
Sections were counterstained with DAPI (1:1000, Affymetrix 14564) to visualize DNA before
mounting with Fluoromount G (SouthernBiotech). Images were acquired using a Leica DM5500B
fluorescent microscope with a Leica DFC360 FX digital camera (region-specific biotinylation,
quantification of neuronal cell type-specific markers) or a Leica TCS SP8 Multiphoton confocal
microscope (representative images of neuronal cell type specific markers, subcellular localization
of MeCP2). Images were acquired using identical settings for laser power, detector gain amplifier
offset and pinhole diameter in each channel. Image processing was performed using ImageJ and
Adobe Photoshop, including identical adjustments of brightness, contrast, and levels in individual
color channels for merged images across genotypes.

Quantitative western analysis
Quantitative western blot was performed using Odyssey Infrared Imaging System (Licor). Primary
antibodies include rabbit anti-MeCP2 C-terminus (1:4000, in house), mouse anti-MeCP2 Nterminus (1:4000, Sigma M7433), mouse anti-NeuN (1:500, Millipore MAB377), and rabbit anti73

Histone H3 (1:1000, Abcam ab1791). Secondary antibodies include anti-rabbit IRDye 680LT
(1:10,000, Licor), anti-mouse IRDye 800CW (Licor), Streptavidin Dylight 650 (1:10,000, Fisher
84547) and Streptavidin Dylight 800 (1:10,000, Fisher 21851). Quantification of protein
expression levels was carried out following Odyssey Infrared Imaging System protocols.

Co-immunoprecipitation using nuclear extracts
Tissues were mined on ice and homogenized in ice cold lysis buffer (10 mM HEPES pH 7.9,
1.5mM MgCl2, 10mM KCl, 0.5% NP-40, 0.2mM EDTA, protease inhibitors). Nuclei were pelleted,
washed and resuspended in nuclear extract (NE) buffer (20mM HEPES pH 7.9, 1.5mM MgCl2,
500mM KCl, 0.2mM EDTA, 10% glycerol, protease inhibitors). Nuclei were incubated in NE buffer
at 4°C for two hours with rotation. Samples were cleared by ultracentrifugation with a TLA 100.3
rotor (Beckman Optima TL) at 4°C for 30 minutes and the supernatant taken for nuclear extract.
Protein concentration was quantified using a modified Bradford assay (Bio-Rad). 1mg of nuclear
extract was adjusted to 300µl total volume with NE buffer to perform IP in duplicate. Protein G
Dynabeads or Streptavidin M-280 Dynabeads (Life Technologies) were washed three times in
PBS with 0.1% Tween-20 and 0.1% BSA. Nuclear extracts were cleared for 30 minutes at 4°C
with 25µl Protein G Dynabeads. For streptavidin pulldown, 50µl of Streptavidin M-280 Dynabeads
were added to the nuclear extract and incubated at 4°C for two hours with rotation. To test if the
Tavi tag was required for streptavidin pulldown, nuclear extracts were split and incubated with or
without 200U TEV protease (Invitrogen) in the absence of a reducing agent and without agitation
at 4°C for ≥ 4 hours prior to IP. For antibody immunopreciptiation, 5µg of (rabbit anti-MeCP2, in
house) was added to the nuclear extract and incubated overnight at 4°C with rotation. Protein G
beads were blocked in wash buffer overnight at 4°C with rotation. Blocked beads were then
incubated with antibody-bound nuclear extract for two hours at 4°C with rotation. Beads were
washed four times in PBS with 0.1% Tween-20 and split into two equal volumes. Each sample
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was resusptended in 25µl loading buffer with 50mM DTT and boiled for 10 minutes at 95°C prior
to loading on a 4-12% Bis-Tris NuPage gel (Life Technologies).

Chromatin immunoprecipitation
Forebrain tissues from male mice at 8 weeks were homogenized in cross-linking buffer (1%
formaldehyde (wt/vol), 10mM HEPES (pH 7.5), 100mM NaCl, 1mM EDTA, 1mM EGTA) and
cross-linked for 5 minutes at RT. After quenching with 125mM glycine, cross-linked tissue was
washed with ice-cold PBS and dounced with 16 strokes in lysis buffer (50mM HEPES (pH 7.5),
140mM NaCl, 1mM EDTA, 1mM EGTA, 10% glycerol (vol/vol), 0.5% NP-40 (vol/vol), and 0.25%
Triton X-100 (vol/vol) with protease inhibitors). Nulcei were pelleted, washed and resuspended in
chromatin buffer (10mM Tris-HCl (pH 8.0), 1mM EDTA, and 0.5mM EGTA with protease
inhibitors). Chromatin was sonicated using a Diagenode Bioruptor, and salt and detergent were
added to adjust the chromatin buffer to 0.5% Triton X-100, 150mM NaCl, 10mM EDTA, and 0.1%
sodium deoxycholate (DOC, vol/vol), and precleared at 4°C with Protein A Dynabeads
(Invitrogen). For immunoprecipitation, 3µg of purified rabbit anti-MeCP2 IgG (in house) or nonspecific rabbit IgG control (Millipore NI01) was incubated with 45µg of chromatin for 4 hours,
followed by an overnight incubation with pre-blocked Protein A Dynabeads, at 4°C with rotation.
Bead-bound chromatin was washed with low salt buffer (50mM HEPES pH 7.5, 150mM NaCl,
1mM EDTA, 1% Triton X-100, 0.1% DOC), high salt buffer (50mM HEPES pH 7.5, 500mM NaCl,
1mM EDTA, 1% Triton X-100, 0.1% DOC), LiCl buffer (50mM Tris-HCl pH 8.0, 150mM NaCl,
1mM EDTA, 0.5% NP-40, 0.5% DOC) and TE buffer (10mM Tris-HCl pH 8.0, 1mM EDTA).
Chromatin was eluted with elution buffer (50mM Tris-HCl pH 8.0, 10mM EDTA, and 1% SDS
-1

(wt/vol)), digested with proteinase K (0.5mg ml ), and reversed crosslinked at 65°C overnight.
After RNase A treatment, DNA fragments were extracted with phenol/chloroform and ethanolprecipitated.
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Quantitative real-time PCR (qPCR) analysis was carried out using SYBR green detection
(Life Technologies) on an ABI Prism 7900HT Real-Time PCR System (Applied Biosystems). The
percent input for each amplicon was determined by comparing the average threshold cycle of the
immunoprecipitated DNA to a standard curve generated using serial dilutions of the input DNA
and interpolating the “fraction of input” value for this sample.

RT-PCR and RNA-seq using RNA from FACS-isolated nuclei
Total RNA was prepared from FACS-isolated cortical nuclei of male mice at 6 weeks (TAVI,
T158M, R106W, 2-3 mice pooled per biological replicate, 4 replicates each), male mice at 12
weeks (TAVI, T158M, 2 mice pooled per biological replicate, 3 replicates each), and female mice
at 18 weeks (TAVI, T158M, R106W, single mouse per biological replicate, 2 replicates each).
Nuclei were isolated from fresh cortical tissue for FACS as previously described under ice-cold
and nuclease-free conditions. Mouse cortices were rapidly resected on ice and subjected to
dounce homogenization in homogenization buffer (0.32M sucrose, 5mM CaCl2, 3mM MgAc2,
10mM Tris-HCl pH 8.0, 0.1% Triton, 0.1mM EDTA, Roche Complete Protease Inhibitor without
EDTA). Homogenates were layered onto a sucrose cushion (1.8M sucrose, 10mM Tris-HCl pH
8.0, 3mM MgAc2 Roche Complete Protease Inhibitor without EDTA) and centrifuged at 25,000
rpm at 4°C for 2.5 hours using a Beckman SW25.1 swinging bucket rotor. Nuclei were
resuspended & washed once in blocking buffer (1x PBS, 0.5% BSA (Sigma A4503), RNasin Plus
RNase Inhibitor (Promega)) and pelleted using a tabletop centrifuge at 5000 RCF at 4°C for 10
6

minutes. Nuclei were resuspended in blocking buffer to a concentration of ~6x10 nuclei/ml,
blocked for 20 minutes at 4°C with rotation, then incubated with Streptavidin Dylight 650 (1:1000,
Fisher 84547) and Alexa 488-conjugated anti-NeuN antibody (1:1000, Millipore MAB377X) for 30
minutes at 4°C with rotation. After a 5-minute incubation with 1:1000 DAPI to enable singlet
detection during FACS, labeled nuclei were washed for an additional 30 minutes at 4°C with
blocking buffer, pelleted and resuspended in blocking buffer with 1% BSA. A BD Biosciences
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Influx cell sorter at the University of Pennsylvania Flow Cytometry and Cell Sorting Facility was
5

used to identify cell type-specific populations of nuclei, and 1.2 – 2.5 x10 singlet nuclei from
specified populations were directly sorted into Qiagen Buffer RLT Plus for immediate lysis and
stabilization of RNA transcripts. Total nuclear RNA was processed using the Qiagen AllPrep
DNA/RNA mini kit according to manufacturer instructions, with exception to the on-column
DNaseI treatment. RNA was eluted from RNeasy mini spin columns and treated with DNaseI
(Qiagen 79254) for 25 minutes at room temperature, then precipitated with glycogen/NaOAc and
stored in ethonal at -80°C. Ethanol precipitation of nuclear RNA was carried out to completion
prior to initiating RT-PCR or RNA-seq library construction.
To validate cell type-specific cortical nuclei populations, total RNA from a single aliquot of sorted
nuclei was converted to cDNA with random hexamers using the SuperScript III First-Strand
Synthesis System (Invitrogen). RT-PCR was performed on a ABI Prism 7900HT Real-Time PCR
System (Applied Biosystems) using exon-spanning Taqman gene expression assays to detect
mRNA transcripts for the following genes: CRE (Mr00635245_cn), Mecp2 (Mm01193537_g1),
Rbfox3 (Mm01248771_m1), Gfap (Mm01253033_m1), Aif1 (Mm00479862_g1), Mog
(Mm00447824_m1), Slc17a7 (Mm00812886_m1), Tbr1 (Mm00493433_m1), Gad1
(Mm04207432_g1), Slc35a1 (Mm00494138_m1), Ht3ar (Mm00442874_m1), Pvalb
(Mm00443100_m1), Sst (Mm00436671_m1), Pgk1 (Mm00435617_m1), Actb (Mm00607939_s1),
ß2m (Mm00437762_m1). A geometric mean was calculated to normalize mRNA expression
levels to multiple housekeeping genes (Actb, ß2m, and Pgk1), and cell type-enrichment for each
sorted population was determined relative to the total mixed population of DAPI+ nuclei.
For RNA-seq, the total amount of RNA isolated from a single aliquot of sorted nuclei was
used as input for library construction; hence differential gene expression comparisons between
FACS-isolated Mecp2 control and mutant neurons is performed using RNA from equivalent
numbers of neuronal nuclei. Total RNA was depleted of ribosomal RNAs, subjected to 5 minutes
of heat fragmentation, and converted to strand-specific cDNA libraries using the TruSeq Total
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RNA library prep kit with RiboZero depletion (Illumina). Multiplexed libraries were sequenced at
the University of Pennsylvania Next Generation Sequencing Core facility using an Illumina HiSeq
2000/2500 that typically yielded 30-40M total reads per library.

GRO-seq
Nuclei were isolated from fresh cortical tissue under ice-cold and nuclease-free
conditions as described in the preceding section. After ultracentrifugation, nuclei were
resuspended & washed once in PBS (1x PBS, RNasin Plus RNase Inhibitor (Promega)) and
pelleted using a tabletop centrifuge at 5000 RCF at 4°C for 10 minutes. Nuclei were resuspended
in PBS, pipetted through a 0.22µm filter and counted using a hemocytometer. Nuclei were then
6

6

pelleted, resuspended to a concentration of 5×10 - 10×10 nuclei/100µl in glycerol storage buffer
(50mM Tris pH 8.3, 40% glycerol, 5mM MgCl2, 0.1 mM), and flash frozen in liquid N2 for storage
until needed.
For each nuclear run-on (NRO), 100µl of nuclei was mixed with 46.5µl NRO Reaction
Buffer (10mM Tris pH 8.0, 5mM MgCl2, 1 mM DTT, 300mM KCl), 3.5µl Nucleoside Mix (50µM
ATP, 50µM GTP, 2µM CTP, 50µM Br-UTP, 0.4U/µl RNasin), and 50µl 2% Sarkosyl. The NRO
reaction was performed at 30°C for 5 minutes, then terminated by a 20 minute incubation with
DNAse I at 37°C, followed by a hour-long incubation with 225µl NRO Stop Buffer (20mM Tris, pH
7.4, 10mM EDTA, 2% SDS) and Proteinase K at 55°C. Phenol-extracted RNA was fragmented
with 0.2N NaOH, and BrU-RNA was isolated three consecutive times with BrdU-antibody beads,
with enzymatic TAP and PNK treatments to remove the cap and 3’-phosphate and to add a 5’phosphate, as well as Illumina TruSeq small RNA sample prep kit adapter ligations between BrURNA isolation steps as described in Core et al. 2008, Greer et al. 2016.

RNA-seq mapping and analysis
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The FASTQ files of each samples were mapped to the mouse mm10 genome by STAR
(version 2.3.0) using the parameters of "--outFilterMultimapNmax 1 --outFilterMismatchNmax 3".
The number of reads mapped to the whole gene body of each gene were counted using Perl
scripts generated in-house. All comparisons were performed by the edgeR and DEseq2 R
packages, and FDR < 0.05 was the criteria used to identify differentially expressed genes. For
each comparison, the results from edgeR and DESeq2 were merged to avoid method-based
biases. The mean fold changes and the mean FDRs generated from both methods were used for
generating plots and heatmaps.

Statistical Analyses
Statistical analyses were performed using Prism 6.0 (GraphPad Software) and R.
Individual statistical tests are stated in the figure legends.
RESULTS
Engineering a System to Genetically Biotinylate MeCP2 In Vivo
Biotin-mediated affinity tagging has been utilized in multiple cell and animal models for
genomic, biochemical, and imaging experimental approaches due to the strong and highly
-14

specific interaction between biotin and streptavidin protein (Kd = 4x10 M) (Boer et al., 2003;
Driegen et al., 2005; Kim et al., 2009; Malik and Henikoff, 2010; Ooi et al., 2010). To investigate
MeCP2 function within Cre-specified cell types, we engineered a short 23-amino acid Tavi (TEV
and Avidin-binding) affinity tag (Figure 3.1A). This tag comprises a 15-amino acid consensus
motif that is posttranslationally labeled with biotin in the presence of the E. coli biotin ligase BirA,
as well as a TEV protease cleavage site. We used homologous recombination to insert the Tavi
tag immediately upstream of the stop codon at the Mecp2 genomic locus, thereby generating
mice where endogenous MeCP2 is biotinylated.
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To biotinylate the tag in a conditional manner, we cloned the BirA gene into a separate
targeting construct. A CAG promoter and a floxed Neo-STOP cassete, which acts as a strong
attenuator of transcription, preceded the BirA gene, followed by an IRES sequence and a single
copy of GFP (CAG-loxP-Neo-STOP-loxP-BirA-IRES-GFP) (Figure 3.2A). This transgene was
targeted to the Rosa26 gene locus to generate conditional BirA mice (R26

STOP-BirA

). In a mouse

that expresses Cre recombinase within a genetically defined cell population, the STOP cassette
is removed, allowing BirA to be expressed and MeCP2-Tavi to be biotinylated (Figure 3.1B). We
tested this by using EIIa-Cre to excise the STOP cassette from the germline, allowing BirA to be
ubiquitously expressed throughout the body (R26

BirA

). Notably, R26

BirA

heterozygous and

homozygous mice remained viable, fertile, and devoid of gross abnormalities, consistent with
previously engineered transgenic mice that express BirA either ubiquitously or within restricted
tissues using cell type-specific promoters (Boer et al., 2003; Driegen et al., 2005). We crossed
R26

STOP-BirA/+

and R26

BirA/+

males to Mecp2

Tavi/+

female mice to produce male progeny and assess

the specificity of BirA expression and enzymatic activity. Whole brain nuclear extracts revealed
that MeCP2-Tavi is detected by streptavidin, and thus successfully biotinylated, only under
conditions where BirA is expressed (R26

BirA/+

;Mecp2

Tavi/y

) (Figure 3.1C). Biotinylation in vivo was

restricted to the Tavi tag as MeCP2 streptavidin signal was absent from both R26
nuclear lysates and R26

BirA/+

;Mecp2

Tavi/y

BirA/+

;Mecp2

+/y

lysates pre-treated with TEV protease to remove the Tavi

tag prior to immunoblotting (Figure 1C). Immunoprecipitation of MeCP2 from whole brain nuclear
extracts using streptavidin-coated magnetic beads yielded similar observations (Figure 3.2B).
Thus streptavidin specifically recognizes MeCP2 when it is attached to a biotinylated Tavi tag.
Normal MeCP2 function is perturbed through altered protein expression levels, reduced
binding to methylated DNA, or disrupted interactions with known co-repressor complexes and
leads to the appearance of RTT-like phenotypes in mice (Brown et al., 2015; Collins et al., 2004;
Ebert et al., 2013; Goffin et al., 2012; Lyst et al., 2013; Samaco et al., 2008). To determine if
MeCP2-Tavi remains functional in vivo, we assessed whole brain RNA and protein expression
levels from age-matched adult Mecp2

Tavi/y

and control Mecp2
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+/y

mice. Although RT-PCR detected

similar levels of Mecp2 mRNA, MeCP2 protein expression levels in Mecp2

Tavi/y

were reduced

compared to control mice (Figures 3.1D-F). However, immunofluorescence (IF) and confocal
imaging of cortical neurons from paraformaldehyde-fixed brains show that MeCP2-Tavi is
properly localized to the nucleus and concentrated at methyl-CpG-rich heterochromatic foci,
similar to untagged MeCP2 (Figure 3.1H). Because MeCP2 nuclear localization is considered a
proxy for MeCP2 binding to methylated DNA, it is unlikely that the Tavi tag interferes with
MeCP2’s ability to associate with chromatin in vivo. We performed MeCP2 chromatin
immunoprecipitation (ChIP) from Mecp2

+/y

and Mecp2

Tavi/y

neuronal chromatin and observed

similar levels of MeCP2 binding at methylated genomic regions by ChIP-qPCR regardless of
whether the protein was tagged or untagged (Figure 3.1G), indicating that the reduction in
MeCP2-Tavi protein expression likely affects nucleoplasmic, rather than chromatin-bound,
fractions of MeCP2-Tavi. Furthermore, the Tavi tag does not disrupt protein-protein interactions
because MeCP2-Tavi remains capable of interacting with known components of the Sin3a and
NCoR-SMRT co-repressor complexes (Figure 3.2C).
Mecp2

+/y

and Mecp2

Tavi/y

mice were grossly indistinguishable in terms of brain weight,

body weight, and lifespan (Figures 3.1K-N). We used a well-established scoring scheme that
assesses several age-dependent phenotypes commonly observed in Mecp2-mutant mice. Using
these criteria, the Mecp2

Tavi/y

mice were similar to Mecp2

+/y

mice and displayed no significant

increase in phenotypic score over an observational period of 20 weeks. Therefore, in the absence
of overt phenotypes typically associated with MeCP2 dysfunction, we conclude that Mecp2
mice appear functionally equivalent to Mecp2

+/y

Tavi/y

mice throughout the first 20 weeks of age.

MeCP2 Missense Mutations Recapitulate RTT-like Phenotypes in Mice
To investigate MeCP2 function using our genetic system, we examined missense
mutations within functional domains of MeCP2. Four of the eight most frequent mutations
associated with RTT are missense mutations, three of which are located in the methyl-CpG
binding domain of human MECP2 and include R106W (2.76% of RTT patients), R133C (4.24% of
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RTT patients), and T158M (8.79% of RTT patients) (Christodoulou et al., 2003). Clinicians have
observed that typical RTT patients carrying the R133C mutation are associated with milder RTT
symptoms, including better preservation of ambulation and speech, whereas patients carrying the
T158M or R106W mutation exhibit relatively more intermediate or severe symptoms,
respectively(Cuddapah et al., 2014). Interestingly, the clinical severity of these mutations appears
to scale with their effects on binding affinity to methylated DNA. In vitro studies have shown that
MeCP2 R133C binding to methylated CpGs is indistinguishable from WT MeCP2; in contrast,
MeCP2 T158M retains partial affinity, and MeCP2 R106W completely abolishes interactions
between the MBD and methylated CpGs (Ballestar et al., 2000; Brown et al., 2015; Ghosh et al.,
2008; Ho et al., 2008). We thus hypothesized that MeCP2-dependent gene expression changes
may also scale with a partial or complete loss of binding affinity to chromatin in vivo and
generated Mecp2

T158M-Tavi/y

and Mecp2

R106W-Tavi/y

mutant mice (Figure 3.1A).

To exclude the possibility that genetic manipulation of the Mecp2 locus could affect
MeCP2 expression when comparing between Mecp2
T158M), and Mecp2

R106W-Tavi/y

Tavi/y

(herein TAVI), Mecp2

T158M-Tavi/y

(herein

(herein R106W) mice, we engineered these mutations using the

same knock-in targeting construct that was used to create the control TAVI allele. Around 6
weeks of age when RTT-like symptoms begin to appear, mutant mice display significant
decreases in MeCP2 protein expression levels despite similar levels of mRNA expression when
compared to TAVI controls (Figures 3.1I-J, and 3.2D). Reduced protein stability and expression
have been similarly reported in other mouse models bearing RTT missense mutations in the
MBD, which include two independent mutant alleles of the T158 residue (Brown et al., 2015;
Goffin et al., 2012). Furthermore, relative expression of mutant MeCP2 protein declined over
early postnatal development starting from postnatal day 0 (P0), although both mutations
displayed different expression kinetics over time (Figures 3.1E-F). We found that the expression
of MeCP2 R106W is already reduced at P0 by ~50% and gradually declines with age. In contrast,
MeCP2 T158M is indistinguishable from MeCP2 TAVI at P0, but demonstrates a more variable
decline in protein expression over the same timeframe. However, MeCP2 T158M expression
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levels remained consistently higher than MeCP2 R106W expression levels at each age that was
examined.
To confirm the cellular localization of these mutant proteins, we performed IF and
confocal imaging on BirA-expressing Mecp2 mutant mice using a MeCP2 antibody and
streptavidin. By antibody staining, MeCP2 T158M and MeCP2 R106W were diffuse throughout
the nucleus and not properly localized to heterochromatic foci, which suggests that these
missense mutations reduce the ability of MeCP2 to bind methyl-CpGs in vivo. However,
streptavidin IF signal intensity was significantly reduced in T158M and R106W mice relative to
TAVI mice, consistent with reduced protein instability and requiring higher sensitivity of
fluorescence detection (Figure 3.2G). Although streptavidin staining confirmed a loss of MeCP2
localization to heterochromatic foci, this channel revealed a portion of mutant MeCP2 that is
redistributed to the nucleolus (Figure 3.2H), similar to a previous report that found exogenous
expression of GFP-tagged MeCP2 to be redistributed to the nucleolus upon deletion of the MBD
and concomitant loss of binding to chromatin (Kumar et al., 2008a). We attribute the discrepant
MeCP2 IF signal to the relatively small size of the streptavidin molecule (~50kDa) compared to a
~150kDa antibody, which is less affected by steric hindrance of masked epitopes.
In addition to reduced protein expression and loss of proper sub-nuclear localization,
T158M and R106W mice exhibited RTT-like phenotypes that are also seen in Mecp2-null mice
(KO), including decreased brain weight, decreased body weight, and an age-dependent increase
in phenotypic score (Figures 3.1K-N). Although lifespan was significantly reduced in all three
Mecp2 mutant mice relative to WT or TAVI control mice, the median survival of R106W mice
more closely resembled that of MeCP2 KO mice than T158M mice. Statistical analysis revealed a
significant difference in the survival curves of T158M (median survival = 14 weeks) and R106W
(median survival = 10 weeks) mice (Figure 3.1N). Taken together, we find that mutations within
the same methyl-CpG binding domain can differentially affect the severity of the RTT phenotype
in mice at a molecular and physiological level. Given that MeCP2 T158M is known to retain partial
affinity for methyl-CpGs in vitro, and that our T158M mice exhibit significantly higher MeCP2
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protein levels and longer survivability when compared to R106W mice, we infer that the T158M
missense mutation represents a partial loss-of-function allele. In contrast, the R106W missense
mutation, which abolishes affinity for methyl-CpGs in vitro and in mice exhibits lower MeCP2
protein levels and lower survivability on par with Mecp2-null mice, may represent a complete lossof-function allele.

Genetic Biotinylation Permits Cell Type-specific Transcriptional Profiling
Given that MeCP2 is an abundantly expressed nuclear protein present in all neurons of
the CNS (Shahbazian et al., 2002b; Skene et al., 2010), we utilized our genetic biotinylation
system for cell type-specific transcriptional profiling (Figure 3.3B). We used the NeuroD6/NEXCre line (Goebbels et al., 2006) to drive BirA expression in forebrain glutamatergic (excitatory)
neurons and verified that MeCP2-Tavi was biotinylated in the appropriate cell types of several
brain regions using fluorescence and confocal microscopy (Figures 3.3A, 3.4A-H). IF and
quantification of pan-neuronal (NeuN), pan-inhibitory (GAD67), and inhibitory-specific
(parvalumin, somatostatin, calretinin) neuronal markers in the somatosensory cortex of
Mecp2

Tavi/y

;R26

cBirA/+

;NEX

Cre/+

(NEX-Cre) mice indicates that biotinylation occurs in approximately

80% of NeuN+ cortical neurons which are also devoid of inhibitory markers, consistent with these
cells being excitatory neurons (Figure 3.4H).
Fluorescence-Activated Cell Sorting (FACS) of singlet DAPI+ cortical nuclei stained for
both NeuN and biotin also revealed a similar distribution of NeuN+Biotin+ (NEX-Cre blue, 85.2%
± 0.35) and NeuN+Biotin- (NEX-Cre red, 14.8% ± 0.35) nuclei, as well as a third population that
was NeuN-Biotin- (NEX-Cre gray) (Figure 3.3C). We sorted for 120,000 nuclei from each of the
three populations with high purity (98-99%) and isolated total nuclear RNA to perform real-time
PCR (RT-PCR) for several cell type-specific markers (Figure 3.3D). The detection of both Crerecombinase and glutamatergic-specific transcripts (Slc17a7, Tbr1) within NeuN+Biotin+ nuclei
confirmed that this population represents excitatory neurons. In contrast, NeuN+Biotin- nuclei,
which lacked Cre-recombinase expression and were exclusively enriched for GABAergic-specific
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transcripts (Gad1, Slc35a1, Ht3ar, Pvalb, Sst), were representative of a collection of inhibitory
interneuron subtypes. Finally, both NeuN+Biotin+ and NeuN+Biotin- populations were depleted of
non-neuronal astrocyte, microglia and oligodendrocyte markers (Gfap, Iba1, Mog, respectively),
which were restricted to the NeuN-Biotin- population. We independently confirmed these
observations by repeating these IF and RT-PCR experiments using
Mecp2

Tavi/y

;R26

cBirA/+

;Dlx5/6

Cre/+

(Dlx5/6-Cre) mice to drive BirA expression in GABAergic inhibitory

neurons and observed inverted but similar results to NEX-Cre mice (Figures 2A and S2A-J)
(Potter et al., 2009). We find that despite the known limitations associated with transgenic Cre
lines , MeCP2-Tavi can be precisely biotinylated in the appropriate cell types and used for cell
type-specific transcriptional profiling.
Phenotypes associated with the genetic removal of MeCP2 from specific brain regions or
cell types in mice are largely non-overlapping and likely reflect the neural circuit that is being
impaired, thus context-specific (Chao et al., 2010; Fyffe et al., 2008; He et al., 2014; Ito-Ishida et
al., 2015; Samaco et al., 2009). We therefore questioned whether MeCP2-dependent gene
expression changes in vivo were also context-specific given the differences in gene expression
between individual neuronal cell types, and whether these expression changes would be
conserved across independent Mecp2 mutant mice. We used the NEX-Cre driver to express BirA
in glutamatergic neurons of 6-week male T158M, R106W and control TAVI mice and sorted for
exact numbers of excitatory and inhibitory cortical nuclei via FACS. Because we consistently
obtained ~1ng of total RNA per 1000 neuronal nuclei, we extracted nuclear RNA (PolyA+ and
PolyA-) from 120,000 - 250,000 nuclei per sample to meet the minimum input requirements for
Illumina TruSeq Total RNA library preparation with RiboZero depletion. Stranded nuclear RNAseq (nucRNA-seq) libraries were sequenced 100PE to a mean depth of 30 million read-pairs per
replicate, and 90-95% of total reads could be uniquely mapped to the mouse Ensembl
GRCm38/mm10 genome assembly due to substantially lower levels of ribosomal RNAs in the
nucleus relative to the cytoplasm. We sequenced four biological replicates per genotype and cell
type, and replicates for each condition were well correlated (mean r = 0.975) (Figure 3.3E). We
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found that the majority of nucRNA-seq reads mapped to the gene body, with approximately
73.9% mapping to introns, 15.6% mapping to exons and the remaining 10.5% mapping to
intergenic regions. In total RNA preparations at steady state, intron-mapped reads originate from
chromatin-associated primary transcripts that are in the process of being transcribed by RNA
polymerase at the time of isolation and are considered a proxy for transcriptional activity. Given
that MeCP2 modulates gene expression in the nucleus, these nucRNA-seq datasets afford a
unique opportunity to study the effects of Mecp2 missense mutations on cell type-specific gene
expression profiles at the transcriptional level. Hence all genic-mapped reads (defined as total
intron- and exon-mapped reads across the gene body) were used for subsequent transcriptomic
analyses.

Nuclear Transcriptomes Reveal Functionally Relevant Transcriptional Dynamics Between
Cell Types
We first analyzed gene expression profiles from control excitatory and inhibitory neuronal
populations to confirm that a transcriptomic analysis of nuclear RNA using genic-mapped reads
was informative. Unsupervised hierarchical clustering of mapped read counts revealed that
replicate nuclear transcriptomes were strongly correlated and faithfully segregated according to
cell type (Figure 3.5A). Genic-mapped reads readily identified highly expressed genes specific to
individual cell types, many of which are obscured in traditional mRNA-seq datasets derived from
cellularly heterogeneous cortical tissue (Figure 3.3G). Using an FDR < 0.05 as the sole cutoff, we
identified 9,379 differentially expressed genes (DEGs) between the two neuronal populations
(Table 3.1 and Figure 3.3F), the majority (86.9%) of which comprised protein-coding genes.
Approximately half of these genes cell type-enriched genes were associated with Gene Ontology
(GO) terms expected of glutamatergic pyramidal cell function, whereas the remaining genes were
highly enriched for GO terms consistent with the role of metabolically active cortical interneurons
(Figures 3.6A-B). Surprisingly, more than 90% of cell type DEGs exhibited < 3 log2 fold change
and were more likely to be actively expressed in both cell types, albeit to varying degrees. This
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suggested that functional differences between excitatory and inhibitory neuronal populations of 6week old mice may be influenced by small differences in the expression of genes, and we
questioned whether this was reflected among GO annotations. We thus sorted significant GO
categories by the distribution of genes with low (FC < 1), moderate (1 ≤ FC < 3) or high (FC ≥ 3)
log2 fold enrichment and observed that certain distributions were indeed associated with
particular cellular functions (Figures 3.6A-B). Genes that are highly enriched in excitatory neurons
(FC ≥ 3), including the neurotrophins Bdnf and Gdnf, are associated with functions related to
secreted extracellular and transmembrane proteins involved in axonal projection and neuronal
development. In contrast, genes that are lowly enriched to excitatory neurons (FC < 1) are more
associated with intracellular kinase signaling cascades (Camk4a) and cytoskeletal remodeling.
Genes related to cell adhesion, calcium signaling and other synapse-related functions (Nrxn1,
Npas4) exhibited no strong bias across varying distributions of fold change. Within inhibitory
neurons, genes that are lowly enriched (FC < 1) were strongly associated with energy regulation
and cellular metabolism in mitochondria. However, highly enriched genes in inhibitory neurons
(FC ≥ 3) were also associated with secreted extracellular proteins such as Ngf and Reln.
Recent studies have demonstrated that in contrast to other genes, neuronal genes tend
to be exceptionally long, rendering them susceptible to transcriptional deficits associated with
neurodevelopmental and neuropsychiatric disorders, including RTT (Gabel et al., 2015; Sugino et
al., 2014; Zylka et al., 2015). Interestingly, we noticed that the excitatory-enriched genes (EXC
median = 50.6kb), as well as their respective GO categories, had significantly longer median
gene lengths than their inhibitory equivalents (INH median = 21.2kb) (Figures 3.6A-C). This
suggests that different neuronal cell types may emphasize the transcription of different gene
lengths as a consequence of cellular function. To elucidate how neuronal gene lengths behave
with respect to excitatory and inhibitory neuronal gene transcription, we measured the linear
correlation between gene lengths and detectable FPKM measurements for all Ensembl-annotated
protein-coding genes. Linear and local regression analysis revealed that longer gene lengths
were positively associated with increasing gene expression in both cell types, as expected of the
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neuronal lineage (Figures 3.6F-G). Pearson correlations among biological replicates were
significantly weaker within inhibitory neurons when compared to excitatory neurons, especially
among the most active genes that likely comprise the bulk of the cellular transcriptome. When we
partitioned the actively expressed genes by cell type enriched genes, we found an anti-correlation
between gene length and gene expression among inhibitory-enriched genes in both cell types
(Figures 3.6H-I). However, among excitatory-enriched genes, as well as constitutive genes that
were not differentially expressed across both cell types, excitatory neurons transcribed
increasingly longer genes at higher expression levels, and this correlation was absent in inhibitory
neurons. Given that actively expressed genes largely overlap between excitatory and inhibitory
neurons and hence display a similar cumulative distribution of gene lengths (Figures 3.6D-E), the
cell type-dependent correlations among cell type-enriched gene lengths and expression levels
are unlikely to be artifacts associated with the FPKM normalization of read counts. We thus
conclude that neuronal cell types display different transcriptional dynamics with regards to gene
length in order to carry out cell-specific functions. Therefore, the combined use of intron- and
exon-mapped reads from nuclear RNA can yield unique insights about the transcriptional status
of neurons in vivo.

Protein-Coding Genes are More Severely Affected in R106W than T158M Mice
We next compared nuclear gene expression profiles between age-matched mutant
(T158M, R106W) and control (TAVI) mice to identify and characterize differentially expressed
genes associated with the appearance of RTT-like phenotypes (Figure 3.7A, summarized in
Table 3.1). From both excitatory and inhibitory neurons, we identified a combined total of 223
T158M and 1,069 R106W unique DEGs in 6-week old mutant mice, indicating that the number of
misregulated genes positively scales with the severity of the Mecp2 mutation. Mecp2 was not
among the list of differentially expressed genes in either cell type, confirming that the missense
mutations do not affect Mecp2 expression at the transcriptional level. Between the two cell types,
we identified more DEGs in the inhibitory neurons of R106W mice and in the excitatory neurons
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of T158M mice (Figure 3.7B). Although the predominantly affected cell type is disparate between
Mecp2 mutant lines, the number and percentage of T158M DEGs that encompass R106W DEGs
-156

is greater in inhibitory (nshared = 109 genes, 74.7% of T158M DEGs; Hypergeometric p = 1.98e

)
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than excitatory (nshared = 75 genes, 38.1% of T158M DEGs; Hypergeometric p = 3.34e )
neurons. Notably, all of the genes shared between both genotypes were misregulated in the
same direction and likely reflect more direct targets of MeCP2 (Figure 3.7C). The Ensembl
genome annotation revealed that ≥90% of MeCP2 DEGs comprise protein-coding genes, which
was significantly higher than the percentage of protein-coding genes from genomic (60.4%),
actively expressed (77.7-78.3%) and cell type-enriched (86.2-87.7%) gene distributions (Figure
3.5C). Given that protein-coding genes are overrepresented among transcriptional deficits
associated with mutant MeCP2, we excluded non-coding genes from further analysis.
The most common feature associated with MeCP2-dependent transcriptional
dysregulation is the subtle changes in gene expression, and this was reflected among excitatory
and inhibitory neurons of both Mecp2 mutant mice (Table 3.1). However, we questioned whether
MeCP2 R106W impacts gene expression to a greater extent than MeCP2 T158M, and we tested
this by comparing the fold change distribution amongst differentially expressed genes between
Mecp2 mutant mice. To account for the disproportionate number of DEGs, we limited our analysis
to protein-coding genes that were shared across genotypes. Among this subset, the median fold
change was consistently and significantly higher in R106W mice, and upregulated and
downregulated genes were similarly affected by the severity of the Mecp2 mutation in both cell
types (Figure 3D). The differences between both mutant genotypes were more striking in
inhibitory neurons, and a cumulative distribution of T158M and R106W fold change values
confirmed a significant rightward shift for the R106W curve across all shared genes in inhibitory
neurons (Kolmogorov Smirnov p = 1.316e-5) (Figure 3.7E). R106W values in excitatory neurons
also displayed a rightward shift relative to T158M, but the difference was not as robust
(Kolmogorov Smirnov p = 0.105). Together, these data suggest that the number of differentially
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expressed genes and the degree to which genes are misregulated is influenced by Mecp2
mutations that differentially impact MeCP2 affinity for methylated DNA.

MeCP2 DEGs Are Typically Low Expressing Cell Type-Enriched Genes
We next examined MeCP2-dependent gene expression changes within the context of
how genes are typically expressed in excitatory and inhibitory neurons. Most genes were
selectively misregulated in a single cell type as only 20 genes (6.2% of total T158M) and 114
genes (10.7% of total R106W) were misregulated in both excitatory and inhibitory neurons
(Figure 3.7F). This degree of overlap is relatively low when compared to the 8,197 protein-coding
genes (74.2% of total) that are actively expressed in both cell types. Because the transcriptional
changes associated with mutant MeCP2 were cell-specific, we questioned whether there was an
association between MeCP2 DEGs and cell type-enriched genes. In each instance, the majority
of MeCP2 DEGs (approx. 70-80%) were significantly associated with cell type-enriched genes
(Chi-square p < 2.2e-16 per comparison; Table 3.1 and Figure 3.7G). In excitatory neurons,
~50% of all T158M and R106W DEGs were classified as excitatory-enriched genes. In inhibitory
neurons, T158M DEGs exhibited a stronger enrichment for excitatory-enriched genes, whereas
R106W DEGs were equally enriched for both excitatory- and inhibitory-enriched genes (Figure
3.7G).
Recent studies have linked MeCP2 function to gene repression that is coincident with gene length
across multiple Mecp2 mouse models (Gabel et al., 2015). Given that we established an
association between cell type-enriched genes and gene lengths in excitatory and inhibitory
neurons (Figure 3.6E-F), we next assessed the lengths of differentially expressed protein-coding
genes in T158M and R106W mice. MeCP2 DEGs were cumulatively longer than active
expressed genes within their respective cell type (Figure 3.8A-B). Among the four lists of MeCP2
DEGs, three had median gene lengths >80kb, with 43-51% of DEGs having gene lengths
exceeding 100kb. However, R106W DEGs in inhibitory neurons were significantly shorter with a
median length of 40.5kb, and only 26% of genes had gene lengths greater than 100kb. We
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partitioned DEG lengths by cell type enriched genes and found that the constitutive and inhibitoryenriched genes, which are significantly shorter than excitatory-enriched genes, were driving the
reduced lengths of R106W DEGs in inhibitory neurons (Figure 3.8B).
Curiously, we did not detect differences in gene lengths among constitutive, excitatoryand inhibitory-enriched genes with the remaining MeCP2 DEGs despite clear differences among
active expressed genes. Given that cell type-enriched genes are associated with different gene
lengths that vary by level of expression in each cell type (see Figure 3.6E-F), we hypothesized
that MeCP2 DEGs reflected genes that are typically expressed at low levels where gene lengths
are more likely to be equal between constitutive, excitatory- and inhibitory-enriched genes. We
thus assessed the relative expression levels of these genes by comparing the log2 FPKM
distribution of MeCP2 DEGs in control TAVI neurons to the distribution of active expressed genes
within each cell type (Figure 3.8C). The FPKM of most T158M and R106W DEGs fell below the
median of actively expressed genes in both cell types, with many DEGs falling below our cutoff
for active expressed genes altogether. This suggests that MeCP2 DEGs are genes that are either
lowly expressed or infrequently transcribed, regardless of the severity of the mutation.
Interestingly, active expressed genes comprised a higher percentage of R106W DEGs (EXC =
69.2%, INH = 43%) than T158M DEGs (EXC = 52.5%, INH = 40.2%) and were primarily
downregulated in R106W mice in both excitatory and inhibitory neurons (Wilcoxon Rank Sum
two-tailed p-value, EXC = 8.878e-09, INH = 7.208e-07). In contrast, we did not detect a
significant difference in the expression level of upregulated genes between genotypes in either
cell type (Wilcoxon Rank Sum two-tailed p-value, EXC = 0.994, INH = 0.9976).
We further tested the association between MeCP2 DEGs and expression levels by
dividing active expressed genes into four equally sized bins and determined DEG enrichment
(Figure 3.8C). DEGs in both mutant genotypes were significantly enriched in the bottom 25

th

percentile of active expressed genes (Fisher Exact one-tailed p-value (Odds Ratio), T158M EXC
= 1.11e-07 (3.1), T158M INH = 2.03e-04 (3.2), R106W EXC = 4.04e-08 (2.0), R106W INH =
1.50e-02 (1.3)). This association was noticeably stronger in T158M neurons in contrast to R106W
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neurons, where DEGs were more evenly distributed across multiple expression bins in both cell
th

types. We also observed a negative correlation between DEG enrichment in the 25 expression
percentile and the total number of misregulated genes found in each genotype and cell type
(Pearson r = -0.982, p = 0.01849). Thus the T158M mutation appears to affect low-expressing
genes in contrast to the R106W mutation, which affects genes found at higher expression levels
in addition to low-expressing genes. Given the severity of the phenotypes with respect to the
T158M and R106W mutations, this suggests that active expressed genes become more
frequently misregulated as MeCP2 function becomes increasingly compromised and the number
of DEGs increases in both excitatory and inhibitory neurons.

Upregulated and Downregulated Genes Are Associated With Discrete Gene Functions
Because downregulated genes accounted for the differences in FPKM expression level
between T158M and R106W DEGs, we questioned whether upregulated or downregulated DEGs
were associated with functionally distinct groups of genes and, if so, whether these functions
would be unique to each cell type. This was supported by the observation that the direction in
which MeCP2 DEGs were predominantly misregulated was coincident with cell type. Excitatory
neurons encompassed more downregulated genes whereas inhibitory neurons encompassed
more upregulated genes, and this trend was preserved among shared DEGs between both
mutant genotypes (nEXC = 69, 65.2% downregulated; nINH = 107, 64.5% upregulated).
Furthermore, upregulated and downregulated genes exhibited distinct preferences for excitatoryor inhibitory-enriched genes in both R106W (Fisher’s Exact Test, EXC two-tailed p = 6.057e-13,
INH two-tailed p = 3.09e-04) and T158M mice (Fisher’s Exact Test, EXC two-tailed p = 3.479e02; Figure 3.8D).
Among excitatory neurons, we found that excitatory-enriched genes were preferentially
downregulated and inhibitory-enriched genes were preferentially upregulated in both mutant
genotypes (Figure 3.8D). We further characterized these preferences by performing Gene Set
Enrichment Analysis (GSEA) using an FDR cutoff < 0.1 to identify gene functions associated with
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upregulated and downregulated genes. GSEA revealed that the majority of upregulated genes in
both mutant genotypes were primarily associated with transcriptional regulation (Figure 3.7H-I).
Examples of the leading edge genes within these functional annotations included DNA-binding
transcriptional activators (Fos, Irf8, Egr1, Ikzf2, Barx2), co-activators (Sertad1), and repressors
(Tcf7l1, Tshz1, Bhlhe40, Btg2), as well as chromatin remodelers (Eya1, Eya4, Ezh2) and
membrane associated receptors that participate in intracellular signaling cascades with
transcriptional outcomes (MET, Bmpr1b, Htr1b). In contrast, gene functions associated with
downregulated genes were exclusively found within R106W excitatory neurons and were highly
enriched for genes encoding post-synaptic membrane proteins, including Na
+

K (Kcna6, Kcnip2, Kcnip4, Kcna1b, Kcnn3, Kcnk13) Ca

2+

2+

(Scn3b, Scn7a,),

(Cacng2, Cacna1g, Cacng4), and Cl

-

channels (Gabra3, Gabra5, Glra3), synaptic scaffolding proteins (Dlgap2, Dlgap3, Dlgap4,
Shank2, Nrxn2), and ionotropic glutamate recepeptors (Grin3a, Grik5), among others (Figure
3.7H).
Surprisingly, R106W inhibitory neurons demonstrated the same underlying transcriptional
preference for upregulated inhibitory-enriched genes and downregulated excitatory-enriched
genes (Figure 3.8D). A number of chromatin remodelers and activity-dependent transcriptional
activators were detected, including those that were upregulated (Creb5, Etv1, Tead1, Eya1) and
downregulated (Nr4a3, Npas1, Arc, Ube2b). However, GSEA functional annotations of MeCP2
DEGs were notably distinct from excitatory neurons due to the different transcriptional
environment of interneurons. Gene functions associated with upregulated genes were related to
cellular metabolism and respiration, DNA damage and repair (Mgmt, Nabp1, Parpbp, Uvssa), cell
surface membrane and secreted proteins (Reck, Slit1, Sema5a, Fzd6, Shh), cytoskeletal/scaffold
proteins (Rhoj, Palld), and proteins that mediate intracellular signaling cascades (Nsmf, Gfra1,
Abca1). Although downregulated gene functions were not identified using our established FDR
cutoff, a more permissive cutoff (FDR < 0.25) revealed gene functions associated with postsynaptic membrane functions, such as Shank1, Reln, Homer1, and Frmpd4.
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Transcriptional Dysregulation in T158M Mice Increases With Age
RTT is a progressive disorder with clinical symptoms and phenotypes that worsen over
time. Although differentially expressed genes are known to increase in Mecp2-null mice with age,
we questioned whether the same would be observed for a hypomorphic mutation such as T158M
(Jordan et al., 2007). We thus aged T158M an additional 6 weeks and transcriptionally profiled
excitatory and inhibitory neuronal nuclei from 12 week old mice. Although we observed an
increase in the number of differentially expressed genes with age, the magnitude of the increase
was surprising. T158M DEGs increased from 197 to 5889 coding and non-coding genes in
excitatory neurons, and from 758 to 8086 coding and non-coding genes from inhibitory neurons
(Figure 3.9A).
In addition to the increased number of DEGs, aged T158M mice exhibited extensive
overlap in DEGs shared across cell types, in contrast to younger T158M and R106W animals
(Figure 3.9B). The distribution of cell type-enriched gene lengths among aged T158M DEGs
closely matched the distribution across active expressed genes, which suggests that the majority
of T158M DEGs were affecting genes expressed at higher levels. We found that aged T158M
DEGs misregulated across both cell types were typically expressed at higher levels than genes
misregulated in a single cell type, which were expressed at lower levels (Figure 3.11C). Another
striking feature of aged T158M DEGs was the strong association that was observed between the
direction of transcriptional change and gene length. Many long genes > 100kb in length were
downregulated, whereas many genes ≤ 100kb in length were upregulated (Figures 3.9B-C),
which conflicts with recent studies implicating MeCP2 in length-dependent repression of long
genes and is further addressed in the proceeding section.
Finally, we compared differentially expressed genes between 6 week T158M and R106W
neurons and 12 week T158M neurons. In both excitatory and inhibitory neurons, the majority of
DEGs at 6 weeks were also detected among DEGs at 12 weeks for each cell type, and the
degree of change was consistently larger in aged T158M excitatory and inhibitory neurons
relative to 6 week neurons (Figures 3.9D-F). Interestingly, aged T158M DEGs overlapped with a
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larger proportion of DEGs in R106W mutant neurons at 6 weeks (EXC: 57.3%, INH: 50.7%) than
T158M mutant neurons at 6 weeks (EXC: 44.4%, INH: 23.5%). This indicates that Mecp2-mutant
neurons are more likely to share DEGs based on the degree of phenotypic severity, rather than
simply being of the same genotype or mutation.

Global Transcription of Long Genes is Reduced and Leads To Post-transcriptional
Upregulation of Long Gene RNA
Several recent studies have demonstrated that MeCP2 is involved in the transcriptional
repression of long genes, which are preferentially upregulated in the neurons of multiple MeCP2deficient model systems (Gabel et al., 2015; Sugino et al., 2014). We sought to reproduce this
result in our own mutant mice, focusing specifically on the R106W mutation. As a positive control,
we isolated whole cell RNA from 6-week cortical tissue as described (Gabel et al., 2015), as well
as unsorted nuclear RNA from the same biological samples. After sequencing and mapping
reads, we sorted and binned protein-coding genes according to gene length and measured the
mean fold change between our control and mutant mice for both whole cell and nuclear RNA
fractions. We observed a similar length-dependent increase in the mean expression of long
genes from whole cell RNA as previously described (Gabel et al., 2015). However, we discovered
a striking inversion of this trend with nuclear RNA, which revealed that genes ≤ 100kb in length
were upregulated and genes > 100kb in length were downregulated in a length-dependent
manner (Figure 3.10A). To confirm that the gene expression changes observed in nuclear RNA
fractions represented true transcriptional changes, we used GRO-seq to profile and map nascent
RNA transcripts from isolated cortical nuclei of 6-week TAVI and R106W mice, and repeated the
length-dependent analysis (Core et al., 2008). Within mutant nuclei, we found a predominant
increase in nascent transcription for genes ≤ 100kb in length, and a predominant lengthdependent decrease in nascent transcription of genes > 100kb in length (Figure 3.10B), similar to
what was observed in nuclear RNA. Genes that were upregulated in nascent and nuclear RNA
fractions were cumulatively shorter relative to genes upregulated in whole cell RNA (Kolmogorov95

Smirnov two-tailed p-value < 2.2e-16 for both comparisons), and the inverse was observed for
downregulated genes (Kolmogorov-Smirnov two-tailed p-value < 2.2e-16 for both comparisons,
Figure 3.10C). We observed a weak but positive correlation among log2 fold changes for each
gene across both nascent and whole cell RNA fractions (Pearson’s r = 0.134) that indicates that
changes in expression at the transcriptional level are minimized at the post-transcriptional level
(Figure 3.10D). Hence we find that global gene expression changes in Mecp2-mutant mice differ
between subcellular compartments and that nuclear RNA more accurately reflects the
transcriptional landscape associated with MeCP2 deficiency.

Gene Length-Dependent Transcriptional Differences Correlate with Disease Severity
We next asked if we could identify global length-dependent transcriptional changes that
correlate with phenotypic severity pertaining to age and genotype, analogous to what was found
for FDR-controlled MeCP2 DEGs (see Figures 3.6 and 3.7). Similar to nascent and nuclear RNA
fractions from whole cortical tissue, sorted nuclear RNA from both excitatory and inhibitory mutant
neurons displayed length-dependent upregulation of genes ≤ 100kb in length and downregulation
of genes > 100kb in length. Although we observed a significant increase in the overall degree of
gene misregulation from 6 to 12 weeks of age, we did not detect a notable difference in lengthdependent transcriptional changes between T158M and R106W neurons at 6 weeks of age in
either cell type (Figures 3.11G and 3.11I).
We reasoned that differences in Pol II transcriptional activity at the gene body might
underlie transcriptional differences between T158M and R106W mutant neurons at the same
biological age, which would require an ability to detect nascent RNA transcripts that correlate with
transcriptional activity. We thus used our GRO-seq dataset to identify genes in sorted neurons
that met the aforementioned criteria (Figure 3.10E) and repeated the length-dependent analysis
of 6-week and 12-week samples using this gene filter. Between 6-week T158M and R106W
excitatory and inhibitory neurons, GRO-seq-filtered genes revealed a striking difference in mean
fold change among downregulated genes > 100kb in gene length (Figures 3.10F-I). The
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difference in magnitude originated from T158M mutant neurons, whose fold changes were
considerably smaller than R106W mutant neurons after filtering (Figures 3.10G, 3.10I, 3.11H, and
3.11J). Furthermore, this effect was only observed among samples at the same biological age
and did not have a noticeable impact on fold changes from 12-week T158M samples. Hence,
transcriptional downregulation of genes >100kb in gene length specifically correlates with
differences in the severity of Mecp2 missense mutations at the methyl-CpG binding domain.

A Female RTT Mouse Model Reveals Cell and Non-Cell Autonomous DEGs
Among heterozygous female mice bearing a mutant Mecp2 allele, random X-inactivation
leads to both genetic mosaicism among neuronal populations and phenotypic variability. As a
result, the majority of RTT molecular research is performed using hemizygous male mice,
whereas the majority of studies involving female mice are limited to behavioral assessments and
immunohistological correlates (Lyst and Bird, 2015). The ability to label and isolate WT and
mutant neurons from heterozygous female mice for transcriptional profiling may yield new
molecular insights into RTT etiology and MeCP2 function in the CNS.
As a proof-of-principle, we generated heterozygous TAVI (Mecp2
T158M (Mecp2

Tavi/T158M-Tavi

;R26

cBirA/+

;NEX

Cre/+

), and R106W (Mecp2

Tavi/+

;R26

Tavi/R106W-Tavi

cBirA/+

;R26

;NEX

cBirA/+

Cre/+

;NEX

),

Cre/+

female mice that each carried one copy of the Mecp2-Tavi allele. We aged female mice to 18
weeks for phenotypic characterization prior to FACS isolation of cortical nuclei. Similar to male
mice, the phenotypic scores of TAVI female mice remained comparatively low at 3 and 4 months
of age, whereas T158M and R106W female mice both displayed significantly higher phenotypic
scores (Figure 3.12B). This confirms that the Mecp2-Tavi allele is functionally equivalent to the
wild-type Mecp2 allele and that an increase in phenotypic score only occurs when bearing one
the Mecp2 missense mutations.
Using FACS isolation of cortical nuclei, we could distinguish wild-type (denoted as
TAVIWT, T158MWT, R106WWT) and mutant (denoted as T158MMUT, R106WMUT) populations
derived from a single female cortex because of the reduced levels of MeCP2 protein within
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mutant neurons (Figures 3.12A and 3.13A). Interestingly, we found that the amount of biotinylated
MeCP2-Tavi detected in mutant neurons was significantly higher in T158M than R106W mice
(29.1% vs. 20.8%, Student’s t-test; p = 0.038; Figure 3.12C). This indicated that MeCP2 T158M is
present at higher protein expression levels than MeCP2 R106W in the neurons of older female
mice and is reminiscent of mutant MeCP2 protein expression levels in younger male mice.
Among excitatory neurons, TAVI, T158M, and R106W mice displayed similar mean X-inactivation
ratios (53.1% TAVIWT, 42.6% T158MWT, 49.2% R106WWT) and did not display skewed Xinactivation > 75% (Figure 3.12D).
Nuclear RNA-seq from these sorted populations revealed striking differences between
female mutant mice. We first identified differentially expressed genes in T158MWT/MUT and
R106WWT/MUT excitatory neuronal populations by comparing them to TAVIWT, revealing a total of
526 and 678 unique protein-coding genes, respectively (Table 3.1). By comparing the distribution
of DEGs detected between WT and mutant neurons, we found that 5.3% of T158M DEGs and
43.4% of R106W DEGs were non-cell autonomous gene expression changes, revealing a
surprising mutation-specific transcriptional vulnerability of WT neurons in RTT (Figure 3.12E and
3.13B). We further visualized the differences between sorted female populations using principal
component space to plot the first two major axes of variation (PC1 vs. PC2) (Figure 3.12F). PC1
sufficiently separated R106W-derivied populations from the remaining genotypes and likely
reflected the presence of non-cell autonomous DEGs among both wild-type and mutant neurons.
PC2 further separated neuronal populations by Mecp2 allele status (wild-type vs. mutant
neurons) irrespective of genotype, suggesting that Mecp2 mutants induce cell autonomous
transcriptional changes that distinguish mutant neurons from neighboring wild-type neurons.
Against PC1 and PC2, T158MWT neurons closely resembled that of TAVIWT, which indicates that
adjacent positioning to mutant neurons is not sufficient to generate the degree of non-cell
autonomous transcriptional changes apparent in R106W mice. As PC1 accounts for twice the
amount of variation as PC2 and similarly affects both wild-type and mutant neurons, these data
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suggest that non-cell autonomous transcriptional changes in R106W female mice may be
extensive.
Given that R106WMUT clusters away from R106WWT, we questioned whether non-cell
autonomous DEGs represented a molecularly distinct group from cell autonomous DEGs. We
further assessed the distribution of fold changes among cell and non-cell autonomous DEGs in
R106W mice and observed that cell autonomous DEGs, which are more likely mediated by
mutant MeCP2, had significantly smaller fold changes than non-cell autonomous DEGs (Wilxoxon
Rank Sum, p = 1.077e-07) (Figure 3.13C). However, we did not detect a difference in absolute
fold change between non-cell autonomous DEGs that are present in both R106WWT and
R106WMUT neurons (Wilcoxon Signed Rank; p = 0.2461). Upregulated cell autonomous DEGs
were also cumulatively longer in gene length than non-cell autonomous DEGs (Figure 3.13D).
GSEA functional enrichment revealed that non-cell autonomous gene expression changes were
enriched for several early and late response genes that are known to link neuronal activity to
gene expression and affect synaptic plasticity, including Bdnf and Igf1, which are known to
stimulate signaling pathways that lead to the activation of immediate early gene expression such
as Npas4 and Fos (Figure 3.13E). The majority of molecules that were upregulated appeared to
be neuroprotective; thus these non-cell autonomous changes may be promoting cell health, likely
in response to abnormal neuronal network activity. In contrast, cell autonomous DEGs were
enriched for upregulated transcriptional regulators and downregulated G-protein coupled
receptors, similar to what we observed in 6 week male excitatory neurons (Figure 3.12J). Thus
non-cell autonomous and cell autonomous DEGs reflect functionally different cellular processes.
We identified 194 protein-coding genes shared between T158M and R106W female
mice, 193 of which were misregulated in the same direction (Figure 3.12G). Among 194 genes,
149 (76.8%) were considered cell autonomous in both mutant mice, whereas 9 genes (4.6%)
were considered non-cell autonomous in both mutant mice, indicating that cell autonomous
transcriptional changes are more likely to shared across genotypes (Fisher’s Exact Test, p =
2.43e-05, Figure 3.12H). The remaining 36 genes (18.5%) were found to be cell autonomous in
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one genotype and non-cell autonomous in the other. The majority of these genes (n = 34) were
cell autonomous in T158M mice and non-cell autonomous in R106W mice and thus reflect a
limitation of detecting non-cell autonomous DEGs in the absence of transcriptionally vulnerable
T158MWT neurons.
We next sought to determine whether shared DEGs were more severely affected in
R106W than T158M female mice, similar to what was observed with 6-week old male mice.
Among shared DEGs in 18-week female mice (n = 185 genes, excluding genes that are
exclusively non-cell autonomous), protein-coding genes were indeed more severely affected in
R106W than T158M mice (Wilcoxon Signed Rank; p = 0.02711, Figure 3.12I). In contrast to
younger male mice, this effect was limited to upregulated genes (Wilcoxon Signed Rank; p =
0.002995), whereas downregulated genes were similarly affected across genotypes (Wilcoxon
Signed Rank; p = 0.3952). We next tested whether these genotype-specific differences occur in a
cell autonomous fashion, and thus are likely to be mediated by MeCP2. Using genes that are
considered cell autonomous in both genotypes (n = 149 genes), we did not detect a difference in
absolute fold change between T158M and R106W mice (Wilcoxon Signed Rank; p = 0.5272,
Figure 3.12I). However, among the 36 genes that are non-cell autonomous in at least one
genotype, we again observed that these shared genes were more severely affected in R106W
than T158M mice (Wilcoxon Signed Rank; p = 4.593e-05, Figure 3.12I), including both
upregulated (Wilcoxon Signed Rank; p = 0.007751) and downregulated genes (Wilcoxon Signed
Rank; p = 0.001356).
Finally, GSEA functional analysis of shared genes between T158M and R106W mutant
neurons revealed upregulated genes to be associated with transcriptional regulators and
downregulated genes to be associated with transmembrane ion channels, strikingly similar to
what was observed in younger 6-week male excitatory neurons. Thus, similar pathogenic
processes may be occurring in the excitatory neurons of both RTT male and female mice.
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DISCUSSION
In this study, we performed a comprehensive transcriptome analysis of FACS-isolated
Mecp2-mutant neuronal nuclei across different cellular and subcellular contexts. This was
accomplished through the development of a novel genetic strategy that allows for cell typespecific biotinylation of Tavi-tagged MeCP2 and RTT-associated mutant variants in vivo. Although
similar methods have been developed to biotinylate tagged proteins in mice and other eukaryotic
systems, biotinylation typically occurs either ubiquitously throughout the organism or is restricted
to a single cell type (Boer et al., 2003; Driegen et al., 2005; Kim et al., 2009; Malik and Henikoff,
2010; Ooi et al., 2010). The coupling of biotinylation with Cre-Lox technology powerfully extends
the use and flexibility of the Tavi tag in vivo for ChIP, protein-protein co-immunoprecipitations and
transcriptional profiling in different cell types based on the availability of existing Cre mouse lines
(Gong et al., 2007). Furthermore, this system can be expanded to any protein-coding gene
because the small size of the Tavi tag (66 nucleotides) makes it ideal for targeted insertion using
CRISPER-Cas9 technology (Yang et al., 2013).

Genome-wide Transcriptional Changes in RTT are Post-Transcriptionally Compensated
In contrast to whole cell RNA, which is enriched for cytoplasmic mRNAs subject to posttranscriptional regulation and degradation, nuclear RNA provides a better correlate of
transcriptional dynamics in the cell (Bhatt et al., 2012; Djebali et al., 2012; Werner and
Ruthenburg, 2015). Because MeCP2 is a predominantly nuclear protein, nuclear RNA from
Mecp2-mutant mice may reveal transcriptional effects that are obscured from whole cell or
translating mRNA preparations. We demonstrated that, in the absence of MeCP2 function using
two independent RTT-associated missense mutations, protein-coding genes ≤ 100kb in length
are preferentially upregulated while protein-coding genes > 100kb in length are preferentially
downregulated in both unsorted and sorted neuronal nuclei, and the degree of misregulation
occurs in a length-dependent manner that increases with age. Using GRO-seq to measure levels
of nascent RNA synthesis genome-wide, we confirmed that these changes occur at the
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transcriptional level. Sorted nuclei also revealed that these changes occur in both excitatory and
inhibitory neurons, and the degree of misregulation was considerably smaller in inhibitory neurons
than excitatory neurons at 6 weeks of age. We posit that this may somehow relate to the strong
positive correlations between gene length and expression level in excitatory neurons that are
notably diminished in inhibitory neurons.
These observations run counter to several recent reports that have identified lengthdependent upregulation of long genes > 100kb in different neuronal cell types and brain regions
of multiple Mecp2 models, along with the functional interpretation that MeCP2 is biased towards
the repression of long genes (Brown et al., 2015; Gabel et al., 2015; Sugino et al., 2014).
However, cortical whole cell RNA preparations using our mutant mice were also able to
reproduce the same length-dependent upregulation of long genes > 100kb, similar to these
studies. We found that mean expression changes in whole cell RNA negatively correlate with that
of nuclear and nascent RNA fractions. In addition, whole cell RNA displayed cumulatively shorter
downregulated genes and longer upregulated genes in opposition to changes observed in the
nucleus. The apparent discrepancy between subcellular compartments suggests that in the
absence of MeCP2 function, subtle length-dependent transcriptional changes in the nuclear
transcriptome are biologically relevant and likely subject to post-transcriptional compensation that
acts to minimize these changes. Although it remains unclear whether such compensation of
transcriptional deficits is truly beneficial or pathological in its own right, this mechanism could
underlie the stabilization, and at times subtle improvement, of symptoms that patients experience
after the initial onset of developmental stagnation and regression associated with RTT (Neul et
al., 2010). Identifying the molecular players that underlie this compensation may thus yield a
novel class of interventional therapeutics that can be administered prior to or during the initial
phase of RTT and minimize its clinical impact.

Transcriptional Profiling in Female RTT Mouse Models
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Importantly, our genetic strategy overcomes a previously insurmountable barrier for
research into RTT, and allows for the separation and isolation of genetically mosaic neuronal
nuclei from heterozygous female mice for transcriptional profiling. In males, excitatory neurons at
6 weeks of age displayed DEGs whose numbers scaled with the molecular severity of the
mutation, whereas neurons at 12 weeks of age displayed thousands of DEGs that were
significantly length-dependent. Despite the advanced age of the females used in this study (18
weeks), female mutant neurons displayed an intermediate number of DEGs that scaled with the
severity of the mutation, although to a lesser extent than what was observed in males.
Transcriptional profiling of excitatory neurons from both T158M and R106W heterozygous mice
thus supports the notion that female mutant neurons are on a pathological timeline that is distinct
from male mutant neurons, which is likely due to the presence of adjacent wild-type neurons.
However, it remains unclear to what extent transcriptional changes may be shaped by the
availability of wild-type neurons that provide trophic support. Further experiments assessing
multiple females that encompass a wide range of X-inactivation ratios at multiple time points, and
perhaps across multiple cell types, will be required to resolve this issue.
A significant advantage of this approach is the ability to distinguish cell autonomous
effects from molecularly distinct non-cell autonomous effects at the transcriptional level, which
may better inform genotype-phenotype correlations among Mecp2 mutations. Post-mortem brains
from RTT patients exhibit reduced dendritic arborization and defects in spine density and
morphology, which are recapitulated in Mecp2-null animal models and are characteristic of
deficits in synaptic plasticity and neuronal network activity (Armstrong, 2005; Chapleau et al.,
2009; Goffin et al., 2012; Wang et al., 2013). By comparing two mutations with different molecular
severities, we discovered that both wild-type and mutant neurons were susceptible to non-cell
autonomous gene expression changes in R106W, but not T158M, mice. Many of these non-cell
autonomous changes were associated with upregulated genes that link neuronal activity to gene
expression and help promote synaptic plasticity. Two of these genes (Bdnf and Igf1) encode
neuroprotective peptides that improve RTT synaptic, cellular, and behavioral phenotypes and are
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currently being tested in clinical trials (Castro et al., 2014; Chang et al., 2006; Khwaja et al.,
2014). The absence of these non-cell autonomous changes in T158M mice could indicate that
neurons expressing the R106W allele are more prone to synaptic or circuit abnormalities than
neurons expressing the T158M allele in vivo. Thus, the severe synaptic plasticity deficits that are
commonly observed in Mecp2-null mice might not be fully recapitulated across the broad
spectrum of RTT-associated mutations that may differentially impact synaptic or circuit
abnormalities contributing to RTT clinical severity.
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Table 3.1: List of active expressed genes, cell type-enriched genes, and Mecp2 differentially
expressed genes derived from sorted nuclear RNA in Chapter 3. Protein-coding genes are
considered only.

CHAPTER 3 FIGURES

FIGURE 3.1: Design, Utilization, and Characterization of Mecp2Tavi mice and
Associated RTT Variants
(A) Schematic of the targeting strategy used for generating Tavi-tagged knock-in mice at the
endogenous Mecp2 genomic locus (top). Schematic of translated Tavi-tagged protein products
that display the placement of the R106W or T158M missense mutations along with associated
genotype and shorthand abbreviations (bottom). MBD, Methyl-CpG Binding Domain; TRD,
Transcriptional Repression Domain; NEO, Neomycin cassette.
(B) Diagram of the mouse breeding strategy required to biotinylate the Tavi tag in a Credependent manner.
(C) Representative western blot analysis detailing genotype/conditions under which the Tavi tag
is biotinylated using whole brain nuclear extracts treated with or without TEV protease. Blot is
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probed with antibodies against the MeCP2 N-terminus, the Tavi tag, and NeuN, and probed with
streptavidin for biotin detection.
(D) Western blot comparing MeCP2 protein expression between wild-type untagged and tagged
mice at 20 weeks of age. Blot is probed with antibodies against MeCP2 C-terminus and TBP.
(E) Relative protein expression quantification of western blot in (D) (n = 3; Student t-test).
(F) Relative expression of MeCP2 mRNA between wild-type untagged and tagged mice at 20
weeks of age using RT-PCR (n = 3; Student t-test)
(G) ChIP-PCR signal of MeCP2 binding at highly methylated repetitive elements using antibodies
against the MeCP2 C-terminus or normal rabbit IgG. (n=3, Student t-test).
(H) Representative images depicting immunofluorescent detection of biotinylated MeCP2 and
RTT variants in cortical tissue of untagged (WT) and tagged (TAVI, T158M, R106W) male mice at
6 weeks of age using an antibody against the MeCP2 C-terminus and streptavidin for biotin
detection. Scale bars represent 10 µm.
(I) Representative western blot comparing MeCP2 relative protein expression levels in the brain
between Tavi-tagged control (TAVI) and mutant (T158M, R106W) male mice at 6 weeks of age.
Blot is probed with antibodies against the MeCP2 C-terminus and TBP.
(J) Relative protein expression quantification of western blot in (I) (n = 4, Student t-test).
(K) Brain weights from untagged (WT, KO) and tagged (TAVI, T158M, R106W) male mice at 6
weeks of age (nWT = 20, nTAVI = 11, nKO = 6, nT158M = 6, nR106W = 12;F = 20.05, P < 0.0001, one
way ANOVA).
(L) RTT-like phenotypic presentation over postnatal age in untagged (WT, KO) and tagged (TAVI,
T158M, R106W) male mice. Data points over time consist of at least 6 observations each. Total
number of mice assessed: nWT = 31, nTAVI = 23, nKO = 15, nT158M = 14, nR106W = 28.
(M) Body weight presentation over postnatal age in untagged (WT, KO) and tagged (TAVI,
T158M, R106W) male mice. Data points consist of at least 6 observations each. Total number of
mice assessed: nWT = 31, nTAVI = 23, nKO = 15, nT158M = 14, nR106W = 28.
(N) Kaplan-Meier survival curve for untagged (WT, KO) and tagged (TAVI, T158M, R106W) male
2
mice (nWT = 31, nTAVI = 23, nKO = 17, nT158M = 39, nR106W = 26; χ = 109.3, df = 4, P < 0.0001,
Mantel-Cox).
*P < 0.5, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s. = not significant; All data depicts mean ±
SEM. See also Figure 3.2.
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FIGURE 3.2: Extended Data for Figure 3.1
(A) Schematic of the targeting strategy used for generating conditional BirA transgenic mice at
the Rosa26 genomic locus.
(B) Western blot detailing genotype/conditions under which the Tavi tag is biotinylated and
amenable to be isolated via antibody- or streptavidin-mediated pulldown. Whole brain nuclear
extracts treated with or without TEV protease were used. Immunoprecipitation was performed
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with antibody against the MeCP2 C-terminus. Blot is probed with antibodies against the MeCP2
N-terminus and the Tavi tag.
(C) Streptavidin-mediated pulldown of biotinylated MeCP2-TAVI and interacting NCoR corepressor components. Blot was probed with antibodies against the MeCP2 C-terminus, HDAC3,
TBLR1, and streptavidin for biotin detection.
(D) Relative expression of MeCP2 mRNA between wild-type untagged and tagged mice at 6
weeks of age using RT-PCR (n=3-4 per genotype, one way ANOVA).
(E) Representative western blot comparing MeCP2 relative protein expression levels in the brain
between Tavi-tagged control (TAVI) and mutant (T158M, R106W) male mice at 0, 1, 2, and 3
weeks of age. Blot is probed with antibodies against the MeCP2 C-terminus and TBP.
(F) Quantification of western blots depicted in (E) (n = 3-4 per genotype).
(G) Representative images depicting immunofluorescent detection of biotinylated MeCP2 RTT
variants in cortical tissue of untagged (WT) and tagged (T158M, R106W) male mice at 6 weeks of
age using an antibody against the MeCP2 C-terminus and streptavidin for biotin detection. Scale
bars represent 10µm.
(H) Representative images depicting immunofluorescent spatial colocalization of biotinylated
MeCP2 RTT variants and nucleoli in cortical tissue of untagged (WT) and tagged (T158M,
R106W) male mice at 6 weeks of age using an antibody against nucleolin and streptavidin for
biotin detection. Scale bars represent 10µm.
*P < 0.5, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s. = not significant.
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FIGURE 3.3: Cell type-specific transcriptional profiling of neuronal nuclei
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(A) Representative immunofluorescent detection of biotinylated MeCP2-Tavi protein within Crespecified neuronal populations of the mouse hippocampus using an antibody against the MeCP2
C-terminus and streptavidin for biotin detection. See Figure 3.4A-B for additional brain regions.
Scale bars represent 100µm.
(B) Schematic of cortical nuclei isolation and preparation for Fluorescence-Activated Cell Sorting
(FACS).
(C) FACS analysis of labeled cortical nuclei populations. Data shown is representative of nine
independent experiments using NEX-Cre mice. Percentages indicate the mean distribution of
neurons that are biotin+ (excitatory; 85.2% ± 0.35) or biotin- (inhibitory; 14.8% ± 0.35). See
Figure 3.4I-J for reverse experiment.
(D) RT-PCR validation of FACS-isolated populations depicted in (C).
(E) Pearson correlation of replicate sequencing libraries using nuclear RNA from FACS-isolated
populations depicted in (C). Colors correspond to excitatory-enriched (blue) and inhibitoryenriched (red) genes identified through differential expression analysis of excitatory and inhibitory
neurons.
(F) Pearson correlation of excitatory- and inhibitory-specific RNA-seq libraries depicted in (E).
Data shown is representative of 4 biological replicates. Note lower pearson correlation and clear
dispersal of cell type-specific genes.
(G) Browser snapshot of Dlgap1 genomic locus in both excitatory and inhibitory neurons of TAVI
male mice at 6 weeks of age. Both RefSeq and Ensembl gene annotations are shown.
*P < 0.5, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s. = not significant; All data depicts mean ±
SEM. See also Figure 3.4.
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FIGURE 3.4: Validation of MeCP2-Tavi biotinylation in different cell types
(A,B) Representative immunofluorescent detection of biotinylated MeCP2-Tavi protein within Crespecified neuronal populations of the (A) mouse cortex and (B) mouse striatum using an antibody
against the MeCP2 C-terminus and streptavidin for biotin detection. Scale bars represent 100µm.
(C) Representative confocal images depicting Cre-mediated biotinylation in NeuN+ neurons.
Scale bars represent 50µm.
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(D) Representative confocal images depicting Cre-mediated biotinylation in Gad67+ interneurons.
Scale bars represent 50µm.
(E) Representative confocal images depicting Cre-mediated biotinylation in Parvalbumin+
interneurons. Scale bars represent 50µm.
(F) Representative confocal images depicting Cre-mediated biotinylation in Somatostatin+
interneurons. Scale bars represent 50µm.
(G) Representative confocal images depicting Cre-mediated biotinylation in Calretinin+
interneurons. Scale bars represent 50µm.
(H) Quantification of Cre-mediated biotinylatin in NeuN+, Parvalbumin+, or Calretinin+ neurons (n
= 3, Student’s t-test).
(I) FACS analysis of labeled cortical nuclei populations. Data shown is representative of three
independent experiments using Dlx5/6-Cre mice. Percentages indicate the mean distribution of
neurons that are biotin+ (inhibitory; 14.2% ± 0.4) or biotin- (excitatory; 85.8% ± 0.4).
(I) RT-PCR validation of FACS-isolated populations depicted in (C).
*P < 0.5, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s. = not significant. All data depicts mean ±
SEM.
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FIGURE 3.5: Validation of cell types by RNA-seq, and gene class distribution
among DEGs
(A) Unsupervised hierarchical clustering and heatmap depicting correlations between 6 week
excitatory and inhibitory neuronal nuclei from TAVI mice.
(B) Unsupervised hierarchical clustering and heatmap depicting correlations between 12 week
excitatory and inhibitory neuronal nuclei from TAVI mice.
(C) Distribution of coding and non-coding genes differentially expressed genes (DEGs) in
excitatory and inhibitory neurons of T158M and R106W male mice, compared to genomic,
expressed, or cell type-enriched genes in each cell type.
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FIGURE 3.6: Characterization of EXC and INH neuronal gene expression
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(A) Gene ontology for excitatory-enriched genes and their median gene lengths, sorted by level of
enrichment (low, moderate, high) relative to inhibitory neurons.
(B) Gene ontology for inhibitory-enriched genes and their median gene lengths, sorted by level of
enrichment (low, moderate, high) relative to excitatory neurons.
(C) Boxplot depicting gene lengths of excitatory- and inhibitory-enriched genes (Wilcoxon Rank
Sum test)
(D) Cumulative distribution function of excitatory-enriched and inhibitory-enriched gene lengths (P
-16
< 2.2e , Kolmogorov-Smirnov test)
(E) Area-proportional Venn diagram depicting proportion of active expressed genes in excitatory
and inhibitory neurons that overlap.
(F) Smoothed scatterplot depicting correlation between gene length and log2 FPKM for all proteincoding genes in excitatory neurons (Pearson r = 0.23).
(G) Smoothed scatterplot depicting correlation between gene length and log2 FPKM for all
protein-coding genes in excitatory neurons (Pearson r = 0.18).
(H) Scatterplot depicting correlation between gene length and log2 FPKM among all active
expressed genes in excitatory neurons (depicted in C), parsed by constitutive (black), excitatory(blue), or inhibitory-enriched genes (red).
(I) Scatterplot depicting correlation between gene length and log2 FPKM among all active
expressed genes in inhibitory neurons (depicted in C), parsed by constitutive (black), excitatory(blue), or inhibitory-enriched genes (red).
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FIGURE 3.7: T158M and R106W differentially expressed genes at 6 weeks of age
(A) FACS isolation of cortical excitatory and inhibitory neuronal nuclei from hemizygous
mice bearing the tagged wild-type (Mecp2Tavi/y) or RTT mutant allele (Mecp2T158M-Tavi/y,
Mecp2R106W-Tavi/y).
(B) Total number of differentially expressed genes (DEGs) identified within cortical
excitatory or inhibitory neurons of RTT mutant mice.
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(C) Heatmap displaying gene expression log2 fold changes within excitatory and
inhibitory neurons of T158M and R106W mutant mice (comparison across genotype).
(D) Boxplots comparing the median fold changes between overlapping genes of T158M
and R106W neurons depicted in (C).
(E) Cumulative distribution function of the magnitude fold changes between T158M and
R106W overlapping genes depicted in (C).
(F) Heatmap displaying gene expression log2 fold changes within excitatory and
inhibitory neurons of T158M and R106W mutant mice (comparison across cell type).
(G) Fraction of protein-coding DEGs that are also classified as constitutive, excitatory- or
inhibitory-enriched genes across two independent RTT mouse models (Chi-square test)
(H) Enrichment map of gene ontology associations using pre-ranked Gene Set
Enrichment Analysis (GSEA) with differentially expressed genes from R106W excitatory
neurons (P < 0.01, FDR < 0.1). Blue represents gene sets associated with
downregulated genes. Yellow represents gene sets associated with upregulated genes.
Line weight denotes the extent of gene overlap between connected nodes.
(I) Enrichment map of gene ontology associations using pre-ranked GSEA with
differentially expressed genes from T158M excitatory neurons (P < 0.01, FDR < 0.1).
Blue represents gene sets associated with downregulated genes. Yellow represents
gene sets associated with upregulated genes. Line weight denotes the extent of gene
overlap between connected nodes.
*P < 0.5, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s. = not significant. See also Figure
3.8.
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FIGURE 3.8: Additional expression features of T158M and R106W DEGs
(A) Cumulative distribution functions of protein-coding gene lengths between T158M and R106W
male DEGs compared to the active expressed genes in their respective cell type.
(B) Box plots depicting protein-coding gene lengths among T158M and R106W male DEGs
compared to the active expressed genes in their respective cell type, parsed by constitutive
(black), excitatory- (blue), or inhibitory-enriched genes (red).
(C) Left, Boxplots comparing log2 FPKM distributions between T158M and R106W neurons.
Additional boxplot shows distribution of shared genes between genotypes (immediately adjacent)
and active expressed genes for each cell type. Right, Bubble plot depicting significant enrichment
of DEGs across different expression quartiles as determined through Fisher’s Exact Test. Area of
circle scales with statistical significance. Q1 represents top 25% of active expressed genes (high
expression), Q4 represents bottom 25% of active expressed genes (low expression).
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(D) Bar graphs depicting percentage of DEGs that are preferentially upregulated or
downregulated for each genotype/cell type. Statistically significant associations are depicted in
red (Fisher’s Exact Test).
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FIGURE 3.9: T158M differentially expressed genes at 12 weeks of age
(A) Total number of differentially expressed genes (DEGs) identified within cortical
excitatory or inhibitory neurons of RTT mutant mice.
(B) Heatmap displaying gene expression log2 fold changes within excitatory and
inhibitory neurons of T158M and R106W mutant mice (comparison across cell type, left)
and associated gene lengths (right).
(C) Browser snapshot of Nrxn3 genomic locus in both excitatory and inhibitory neurons
of TAVI and T158M male mice at 6 and 12 weeks of age. Note reduction in intronmapped reads at the Nrxn3 gene among T158M neurons at 12 weeks of age, which are
absent at 6 weeks of age.
(D) Area-proportional Venn diagram comparing MeCP2 DEG overlap between aged
T158M, young T158M, and young R106W mice for excitatory (top) and inhibitory
neurons (bottom).
(E) Boxplots comparing the median fold changes between overlapping genes in young
and aged T158M neurons depicted in (D) (Wilcoxon Signed Rank test).
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(F) Boxplots comparing the median fold changes between overlapping genes in young
R106W and aged T158M neurons depicted in (D) (Wilcoxon Signed Rank test).
*P < 0.5, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s. = not significant. See also Figure
3.11.
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FIGURE 3.10: Genome-wide length-dependent transcriptional changes in RTT
mutant mice
(A) Genome-wide changes in gene expression of R106W mice (n = 2) compared to TAVI
mice (n = 2) at 6 weeks of age, as assessed by RNA-seq analysis of whole cell (green)
or nuclear (magenta) RNA extracted from the same cortical tissue samples. Lines
represent mean fold change in expression for genes binned according to gene length
(200 gene bins, 40 gene step) as described in (Gabel et al., 2015). Ribbon represents
the SEM of genes in each bin.
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(B) Same as in (A), but using nascent RNA from global nuclear run-on sequencing
(GRO-seq).
(C) Cumulative distribution function of gene lengths for all upregulated and
downregulated coding genes used in (A) and (B) among nascent (n = 10,951 genes),
nuclear (n = 13,400 genes), and whole cell (n = 13,400 genes) RNA fractions. (P < 2.2e16 for each nascent or nuclear RNA versus whole cell RNA comparison, KolmogorovSmirnov test).
(D) Scatterplot comparing log2 fold changes between nascent and whole cell RNA
fractions.
(E) Area-proportional Venn diagram revealing proportions of genome-wide gene
expression changes in nuclear RNA fractions (sorted excitatory neurons, whole cortical
tissue) that are also transcriptionally engaged with RNA polymerase given their overlap
with nascent RNA fractions.
(F) Mean fold change in gene expression of sorted excitatory neurons from young
R106W (red; n = 4), young T158M (orange, n = 4) and aged T158M mice (n = 2) using
transcriptionally engaged genes binned according to gene length.
(G) Genome-wide Kolmogorov-Smirnov maximum distance (D^+) between cumulative
distributions of log2 fold changes among young T158M and R106W sorted excitatory
neurons. See Figure 3.11 for more details.
(H) Same as in (F), but using sorted inhibitory neurons.
(I) Same as in (G), but using sorted inhibitory neurons. See Figure 3.11 for more details.
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FIGURE 3.11: Genome-wide length-dependent transcriptional changes in RTT
mutant mice (Extended)
(A) Cumulative distribution functions of protein-coding gene lengths among aged T158M male
DEGs compared to the active expressed genes in their respective cell type.
125

(B) Box plots depicting protein-coding gene lengths among aged T158M male DEGs compared to
the active expressed genes in their respective cell type, parsed by constitutive (black), excitatory(blue), or inhibitory-enriched genes (red).
(C) Boxplots comparing log2 FPKM distributions (expression levels) of 12 week T158M DEGs that
are either shared between or specific to excitatory and inhibitory neurons (Wilcox Rank Sum
Test).
(D) Smoothed scatterplot depicting correlation between gene length and log2 fold change for all
protein-coding genes from nascent RNA fractions (Whole Cortex GRO-seq).
(E) Smoothed scatterplot depicting correlation between gene length and log2 fold change for all
protein-coding genes from nuclear RNA fractions (Whole Cortex nuclear RNA-seq).
(F) Smoothed scatterplot depicting correlation between gene length and log2 fold change for all
protein-coding genes from whole cell RNA fractions (Whole Cortex RNA-seq).
(G) Mean fold change in gene expression of sorted excitatory neurons from young R106W (red; n
= 4), young T158M (orange, n = 4) and aged T158M mice (n = 2). Not sorted for transcriptionally
engaged (GRO-seq detected) genes.
(H) Genome-wide Kolmogorov-Smirnov maximum distance (D^+) between cumulative
distributions of log2 fold changes among young T158M and R106W sorted excitatory neurons.
(I) Mean fold change in gene expression of sorted inhibitory neurons from young R106W (red; n =
4), young T158M (orange, n = 4) and aged T158M mice (n = 2). Not sorted for transcriptionallyengaged (GRO-seq detected) genes.
(J) Genome-wide Kolmogorov-Smirnov maximum distance (D^+) between cumulative
distributions of log2 fold changes among young T158M and R106W sorted inhibitory neurons.
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FIGURE 3.12: Transcriptional profiling of genetically mosaic neurons in RTT
female mice
(A) FACS isolation of genetically-mosaic cortical excitatory neuronal nuclei from heterozygous
Tavi/+
Tavi/T158M-Tavi
female mice bearing the tagged wild-type (Mecp2
) or RTT mutant allele (Mecp2
,
Tavi/R106W-Tavi
Mecp2
).
(B) RTT-like phenotypic presentation over postnatal age in tagged TAVI (n = 12), T158M (n = 4),
and R106W (n = 9) female mice (F = 41.14 (Genotype), P < 0.0001, two way ANOVA).
(C) Quantification of biotin signal from FACS-isolated populations depicted in (A) (nT158M = 4,
nR106W = 9, Student t-test).
(D) Distribution of X-inactivation among cortical excitatory neurons from FACS-isolated nuclei as
a percentage of the WT population. Data points in red highlight samples that were used for highthroughput sequencing.
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(E) Bar graph depicting the total distribution of unique cell and non-cell autonomous DEGs
between T158M and R106W female excitatory neurons.
(F) Principal components analysis of WT and MUT populations isolated from TAVI, T158M, and
R106W female mice.
(G) Left, Heatmap displaying the total number of unique gene expression log2 fold changes
detected from both WT and MUT populations in either T158M or R106W female excitatory
neurons. Note genes that overlap across genotypes (n = 194). Right, Heatmap displaying the
distribution of cell (Cell Aut.) and non-cell autonomous (Non-Cell) DEGs.
(H) Proportion of cell autonomous and non-cell autonomous genes that overlap between T158M
and R106W female excitatory neurons.
(I) Boxplots comparing the median fold changes between total, cell autonomous, and non-cell
autonomous overlapping genes between T158M and R106W female excitatory neurons. (onetailed Wilcoxon Signed Rank test)
(J) Enrichment map of gene ontology associations using pre-ranked Gene Set Enrichment
Analysis (GSEA) with shared DEGs between T158M and R106W female excitatory neurons (P <
0.01, FDR < 0.1). Blue represents gene sets associated with downregulated genes. Yellow
represents gene sets associated with upregulated genes. Line weight denotes the extent of gene
overlap between connected nodes.
*P < 0.5, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s. = not significant. See also Figure 3.13.
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FIGURE 3.13: Cell and non-cell autonomous transcriptional changes are
molecularly distinct processes
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(A) Left, Browser snapshot of X-inactivation control genomic locus in both WT and MUT neurons
of TAVI, T158M, and R106W female mice at 18 weeks of age. Right, Percentage of reads
detected with wild-type or knockin allele for each sorted population.
(B) Heatmap displaying the total gene expression log2 fold changes detected in both WT and
MUT populations of T158M or R106W female excitatory neurons.
(C) Boxplot comparing the magnitude of log2 fold change among cell and non-cell autonomous
genes (Wilcoxon Rank Sum test).
(D) Cumulative distribution function comparing the gene lengths among cell and non-cell
autonomous genes (Wilcoxon Rank Sum test).
(E) Enrichment map of gene ontology associations using pre-ranked Gene Set Enrichment
Analysis (GSEA) with non-cell autonomous DEGs in R106W female excitatory neurons (P < 0.01,
FDR < 0.1). Blue represents gene sets associated with downregulated genes. Yellow represents
gene sets associated with upregulated genes. Line weight denotes the extent of gene overlap
between connected nodes.
(F) Enrichment map of gene ontology associations using pre-ranked Gene Set Enrichment
Analysis (GSEA) with cell autonomous DEGs in R106W female excitatory neurons (P < 0.01,
FDR < 0.1). Blue represents gene sets associated with downregulated genes. Yellow represents
gene sets associated with upregulated genes. Line weight denotes the extent of gene overlap
between connected nodes.
(G) Mean fold change in gene expression of sorted WT or MUT excitatory neurons from T158M
(orange; n = 2) or R106W (red, n = 2). Not sorted for transcriptionally-engaged (GRO-seq
detected) genes.
(H) Mean fold change in gene expression of sorted WT or MUT excitatory neurons from T158M
(orange; n = 2) or R106W (red, n = 2) mice using transcriptionally engaged genes binned
according to gene length.
*P < 0.5, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s. = not significant.
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CHAPTER 4: Discussion, Implications, and Future Directions

4

General Summary of Dissertation Work
Despite two decades of strong genetic and experimental evidence linking MeCP2 to RTT

and associated clinical symptoms and cellular phenotypes, the mechanistic function of this
protein still remains unclear. Many studies have attempted to ascribe a function through MeCP2dependent gene expression changes by using whole tissue mRNA extracted from Mecp2-null
male mice for profiling. However, the limited numbers of consistent gene expression changes
across multiple studies and the subtle degree to which these genes are misregulated have
hindered efforts to define a consistent molecular role for MeCP2 in RTT. Recent studies are
beginning to illuminate the extensive heterogeneity and complexity of gene expression and
regulation at the cellular and subcellular level, especially in the brain. This diversity, coupled with
the clinical variability of RTT-associated mutations among patients that are predominantly female,
argues for a more context-specific experimental approach towards investigating MeCP2 function
that is only now being appreciated.
In Chapter 2, I began to address these issues of cellular heterogeneity by profiling gene
expression in Mecp2-null mice within the striatum, a brain region whose neurons comprise a
single cell type (>95% medium spiny neurons). By comparing gene expression changes in the
striatum to additional neuronal (hypothalamus, cerebellum) and non-neuronal (liver) tissues, I
largely demonstrated that most expression changes are specific to individual brain regions,
although the affected genes are typically expressed throughout the brain, and questioned
whether this would apply to individual cell types as well.
In Chapter 3, I significantly expanded upon the previous study by developing a novel
genetic strategy that allows for cell type-specific transcriptional profiling and investigation of
MeCP2 function across multiple neuronal contexts. I also developed an allelic series of Mecp2mutant mice bearing RTT-associated missense mutations. By combining Cre-mediated biotin
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tagging of MeCP2 and RTT-associated mutant variants in vivo with RNA sequencing from FACSpurified neuronal nuclei of adult mice, I was able to 1) identify transcriptional changes in cortical
excitatory and inhibitory neurons, 2) investigate how these changes scale with moderate to
severe impairments in binding to methylated DNA, 3) observe how these changes relate to
neuronal gene expression in a physiological context, and 4) distinguish molecularly distinct cell
autonomous and non-cell autonomous transcriptional effects within genetically mosaic female
mice. Taken together, these findings allow me to explore a speculative model whereby
transcriptional deficits in the absence of MeCP2 binding lead to the neuronal and circuit level
deficits observed in RTT patients and Mecp2 animal models, with mechanistic implications for
MeCP2 in modulating neuronal plasticity in a physiological context.

4.1

MBD MISSENSE MUTATIONS MODEL RETT SYNDROME IN MICE
4.1.1

Summary of Findings

I developed knockin mice bearing RTT-associated missense mutations that either
partially (T158M) or completely abolish (R106W) MeCP2’s ability to bind to methylated DNA.
These mice closely resembled Mecp2-null mice in the severity and onset of most gross
phenotypes, consistent with the increased phenotypic severity of mutations in the MBD
(Cuddapah et al., 2014). However, R106W mice closely resembled Mecp2-null mice in terms of
lifespan, whereas the T158M mice were more mildly affected and survived an additional 4 weeks;
thus these mice phenotypically correlate with the degree of molecular impairment.
4.1.1

Broader Significance

Both typical and atypical RTT patients bearing these two mutations also exhibit a similar
relationship to what I observed among mice, and are associated with intermediate (T158M) and
severe (R106W) clinical diagnostic scores. Experimental studies comparing the phenotypic
effects of RTT mutations further corroborate these observations on a molecular scale.
Biochemically, the MBD is the most structured domain of MeCP2. Interdomain interactions, which
include the ASX-ST motif, help stabilize MBD structure and are required for forming and
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maintaining hydrogen bond interactions with methyl groups on DNA (Ghosh et al., 2008; Ho et al.,
2008). Both mutations are predicted to introduce hydrophobic charges that destabilize (T158M) or
completely disrupt (R106W) the local topology and hydrophilic environment of the ASX-ST motif,
contributing to reduced affinity for methylated DNA. EMSA studies report that the R106W
mutation consistently abolishes affinity for methylated DNA, whereas the T158M mutation exhibits
partial to severe reductions in affinity relative to wild-type protein in vitro (Ballestar et al., 2000;
Brown et al., 2015; Ghosh et al., 2008). The R106W mutation in particular also disrupts MeCP2’s
ability to compact nucleosomes, mediate higher-order structures of nucleosomal arrays, and
confer MNase resistance in vitro (Nikitina et al., 2007b). Molecular FRAP studies also report an
increase in the nuclear mobility and diffusion kinetics of MeCP2 bearing these two mutations, and
this occurs to a greater extent with the R106W than the T158M mutation, indicative of reduced
association with chromatin in vivo (Kumar et al., 2008b; Schmiedeberg et al., 2009). Finally,
transcriptional repressor assays using methylated reporter constructs report a partial loss of
repressive activity when Drosophila S2 cells are transfected with MeCP2 T158M in contrast to
MeCP2 R106W, which displays a complete loss of activity concomitant with a complete loss of
methyl-CpG binding (Kudo et al., 2001).

4.2

EXCITATORY AND INHIBITORY NEURONS DISPLAY CELL TYPE-

SPECIFIC TRANSCRIPTIONAL DYNAMICS
4.2.1

Summary of Findings

The genetic strategies that I developed to both separate and profile nuclear gene
expression in cortical excitatory and inhibitory neurons allowed me to 1) identify genes whose
expression is enriched in a particular cell type over the other, and 2) determine how neuronal
genes, and particularly excitatory- and inhibitory-enriched genes, are typically expressed within
an unperturbed physiological context. Previous studies have demonstrated that neuronallyexpressed genes tend to be longer in gene length relative to genes expressed in other somatic
tissues and cell types (Gabel et al., 2015; King et al., 2013; Zylka et al., 2015). I confirmed as
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such among genes expressed in excitatory and inhibitory cortical neurons of adult mice, which
were significantly longer than genomic distributions of gene length. The same was true for
excitatory- and inhibitory-enriched genes, which tended to be cumulatively longer and shorter in
gene lengths, respectively.
However, I observed additional cell-specific behaviors among active expressed genes in
each cell type that have not been previously characterized. Excitatory and inhibitory neurons
largely express the same group of genes. These include genes whose expression is lowly or
moderately enriched (log2 FC < 3) in one cell type as opposed to the other. The manner in which
these genes are expressed, however, is dramatically different. Short inhibitory-enriched genes,
which are associated with cellular respiration and energy metabolism, are expressed in a lengthdependent manner in both excitatory and inhibitory neurons, which would be expected of
metabolically active neurons regardless of subtype. It is likely that these genes are more highly
expressed in inhibitory neurons because, as mitochondria-rich cell types, they have perpetual role
in dynamically suppressing the activity of excitatory neurons to maintain overall network
homeostasis in the brain (Kann et al., 2014; Maffei and Fontanini, 2009). In contrast, long
excitatory-enriched genes are positively correlated with the level of gene expression exclusively
within excitatory neurons; this relationship is completely absent in inhibitory neurons. Excitatoryenriched genes encode proteins that promote axogenesis (signaling molecules, actin-associated
proteins), are localized to the plasma membrane (synaptic proteins, ion channels,
transmembrane receptors) and extracellular matrix (secreted and cell adhesion molecules,
integrins), and participate in intracellular signaling cascades (protein kinases and phosphatases).
Thus these genes are consistent with the role of cortical pyramidal neurons that undergo
extensive changes in synaptic plasticity at the plasma membrane in response to neuronal circuit
activity (Beaulieu, 1993; Emes et al., 2008; Holtmaat and Svoboda, 2009).
4.2.2

Broader Significance

Because excitatory- and inhibitory-enriched genes and their associated functions are
consistent with the known roles of these two broad cortical cell types, I posit that excitatory
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neurons exhibit a strong positive association between gene length and expression level in order
to carry out an assortment of cell-specific functions required for proper neuronal activity in the
brain. I would thus expect cortical pyramidal neurons to be particularly sensitive to factors that
perturb this length-dependent transcriptional regulation, which is supported by the effects of DNA
supercoiling and topoisomerase inhibition on mammalian cells (King et al., 2013; Kouzine et al.,
2013; Mabb et al., 2014; Madabhushi et al., 2015; Naughton et al., 2013; Puc et al., 2015).
Topoisomerases are enzymes that relieve the torsional stress associated with DNA
supercoiling, which occur as a consequence of both cell division and gene transcription (Chen et
al., 2013; Tsao et al., 1989; Wang, 2002). Cultured cortical neurons treated with 300µm
topotecan, a reversible TOP1 inhibitor, display impairments in excitatory synapse formation and
function and deficits in inhibitory synapse function, leading to overall reduced spontaneous
network activity without compromising cellular health. These effects are caused by an inability to
resolve DNA supercoiling at particularly long genes, leading to impaired transcriptional elongation
of RNA polymerase II and length-dependent downregulation of neuronal genes important for
synaptic function, many of which include genes associated with autism. In addition to lengthdependent transcription, topoisomerase 1 has also been shown to be required for liganddependent androgen receptor-mediated enhancer activation in prostate cancer cells by relieving
torsional strain required for productive elongation of eRNAs (Puc et al., 2015). Immediate early
gene activation and expression in depolarized primary cortical neurons also requires the
production of double-stranded breaks by topoisomerase IIβ to relieve torsional strain and mediate
synaptic changes (Madabhushi et al., 2015). Beyond the role of topoisomerases, these studies
support the notion that high efficiency of transcriptional elongation may promote the expression of
neuronal genes.
Notably, transcriptional elongation of genes can be impeded by well-ordered
nucleosomes along the gene body, which increases the frequency of productively elongating Pol
II pausing across the gene body in eukaryotic yeast cells (Churchman and Weissman, 2011).
Increases in torsional stress can also destabilize well-order nucleosomes in Drosophila S2 cells
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and lead to increased nucleosome turnover, which may impact overall chromatin structure at
certain genes (Teves and Henikoff, 2014). Alternatively, high efficiency of transcriptional
elongation may be promoted by participating in long-range chromatin interactions within
transcriptionally active topologically associating domains (TADs) or other active sites of
transcription in the nucleus (Dixon et al., 2012; Osborne et al., 2004). Transcriptional activity and
elongation can also effect changes in large-scale chromatin structure by promoting large regions
of positive or negative supercoiling of DNA that help to establish broad topological domains of
condensed or decondensed chromatin, respectively (Naughton et al., 2013).
The complex interplay being chromatin structure and the transcriptional elongation of
long genes in pyramidal neurons is particularly interesting in light of studies that detect significant
genetic risk associations among chromatin modifiers, transcriptional regulators, and synaptic
genes in autism, schizophrenia, and intellectual disability (Cotney et al., 2015; De Rubeis et al.,
2014; Iossifov et al., 2014). I conclude that excitatory neurons promote the length-dependent
expression of long genes required for overall synaptic function at the plasma membrane and may
be particularly sensitive to chromatin-mediated barriers of efficient transcriptional elongation.

4.3

DOWNREGULATED GENES MODULATE RETT PHENOTYPES
4.3.1

Summary of Findings

Using aged-matched T158M and R106W mutant male mice at the onset of overt RTT
phenotypes, I sequenced nuclear RNA from cortical excitatory and inhibitory neurons. Genomewide, when MeCP2 function is generally impaired, the expression of long genes is predominantly
downregulated in a length-dependent manner. This argues for MeCP2 in promoting the
expression of long genes, regardless of cortical cell type. The degree to which long genes are
downregulated correlates with the degree of MeCP2 impairment, which I defined—through the
use of two RTT-associated missense mutations in the MBD—as MeCP2’s ability to bind to
methylated cytosines and, by proxy, chromatin in vivo. Furthermore, genome-wide differences
between these two mutations were only detected among genes that can produce de novo RNA
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transcripts from isolated cortical nuclei using GRO-seq, i.e. genes that are transcriptionally
engaged with RNA Polymerase II. Thus, the active transcription of long genes in excitatory and
inhibitory neurons is sensitive to differences in MeCP2’s ability to bind to chromatin in vivo.
Finally, the degree to which genes are downregulated worsens with age, which correlates with
the progressive worsening of phenotypes when T158M mice are aged an additional 6 weeks.
Upon initiating this study, I hypothesized that MeCP2 DEGs (FDR < 0.05) would reveal
genes that are most sensitive to the effects of MeCP2 binding. Expression features among FDRcontrolled genes that correlate with MeCP2 impairment may thus provide refined insight into the
types of genes that MeCP2 may mechanistically modulate. Consistent with genome-wide
observations and my hypothesis, I found that aged-matched R106W mice exhibited more DEGs
than T158M mice. Similarly, genes that are shared between both genotypes are more
misregulated in R106W mice. The severity between these two mutations also correlated with the
ability to discern functional enrichment from downregulated DEGs in age-matched mice (Gene
Set Enrichment Analysis, FDR < 0.10). Functional terms could only be statistically inferred from
the R106W genotype and suggested a mutation-specific loss of ion channel, glutamate receptor
and synaptic function among excitatory neurons. Interestingly, these terms were also identified
among downregulated genes in aged female T158M and R106W excitatory neurons. Taken
together, observations from FDR-controlled DEGs suggest that the cell autonomous loss of
synaptic genes that localize to the somatodendritic or post-synaptic compartment correlates with
RTT phenotypic severity, which occurs in both male and female neurons and depends on
MeCP2’s ability to bind to methylated DNA. This is in particular agreement with genome-wide
transcriptional observations in excitatory neurons, where the global downregulation of long genes
would be expected to significantly impact synaptic functions (described in 4.2.1).

4.3.2

Broader Significance

Given the strong similarities with topoisomerase 1 inhibition and length-dependent
transcriptional downregulation of long genes that lead to synaptic deficits, the transcriptional
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effects that are observed in T158M and R106W neurons likely underlie the neuronal deficits
observed in both RTT patients and mouse models, which include reduced dendritic branching,
reduced number and function of glutamatergic synapses, and reduced hypoexcitability of
excitatory pyramidal neurons. In the context of excitatory neurons, it is remarkable that the
degree of MeCP2 impairment across mutations correlates with the degree of transcriptional
deficits, which may ultimately modulate the degree of synaptic phenotypes and help explain the
spectrum of clinical severity among RTT patient mutations. Differences in synaptic impairments
across mutations would explain why the R106W female mice have non-cell autonomous gene
expression changes in contrast to T158M female mice. Many of the genes associated with noncell autonomous changes are neuroprotective and help ameliorate RTT-mediated neuronal and
behavioral phenotypes in mice. Synaptic function in excitatory neurons, and overall neuronal
network activity, may be more severely compromised in R106W mice than T158M mice, leading
to the upregulation of genes that help to boost neuronal synaptic plasticity.
The differences in transcriptional deficits that correlate with MeCP2 impairment are likely
due to the differences in the affinity of MeCP2 T158M and MeCP2 R106W for methylated DNA in
vivo, rather than reduced protein expression levels. Experimental evidence in our lab supports the
notion that MeCP2 is a stable protein when bound to chromatin, and that mutations that disrupt
binding to chromatin (the primary effect) leads to increased protein instability and turnover (the
secondary effect) (J. Lamonica, personal communications). Several knockin Mecp2 mouse
models bearing RTT-associated mutations in the MBD also show reduced protein stability (Brown
et al., 2015; Goffin et al., 2012). When considered together with our knockin mice, MBDassociated mutations demonstrate a positive correlation between increased ability to bind to
methylated DNA and increased protein stability, which lends support to our hypothesis. This
correlation therefore establishes that MeCP2 protein expression levels among RTT-associated
mutations in the MBD may serve as a general readout for residual binding to chromatin. Under
this assumption, the T158M mutation has a higher residual binding capacity to chromatin than the
R106W mutation, which I consistently observed in both male and female mice. This is in
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agreement with molecular FRAP studies in live cells which demonstrate that, in contrast to wildtype MeCP2 residence time on chromatin (~15 seconds), MeCP2 T158M spends ~4 seconds on
chromatin, whereas MeCP2 R106W spends < 2.5 seconds on chromatin (Schmiedeberg et al.,
2009).
Given the importance of length-dependent transcription in excitatory neurons that I
previously established (see section 4.2), I propose that MeCP2 promotes chromatin-mediated
increases in the efficiency of transcriptional elongation by directly binding to long neuronal genes.
This may be consistent with MeCP2 being chromatin-bound and localized within highly nucleaseaccessible regions in the brain (Rube et al., 2016; Thambirajah et al., 2012). Bisulfite-sequencing
of neurons do show that gene body methylation in both CpG and CpA contexts are found at
neuronal genes, and MeCP2 ChIP-seq displays increased read density at long genes over
methyl-CpG and methyl-CpA sites (Baubec et al., 2013; Chen et al., 2015; Gabel et al., 2015).
The increase in MeCP2 expression mirrors the increase in methyl-CpA deposition as neurons
mature and undergo synaptogenesis, and methyl-CpA density increases as genes increase in
length (Chen et al., 2015; Gabel et al., 2015; Lister et al., 2013; Mo et al., 2015; Skene et al.,
2010). Methyl-CpG density also increases as gene length increases, but to a much lesser extent
than methyl-CpA, likely owing to its relatively higher abundance in the genome (Gabel et al.,
2015). The high density of methyl-CpG and methyl-CpA over gene bodies may therefore lead to
increased cooperative binding of MeCP2 to long neuronal genes (Baubec et al., 2013; Ghosh et
al., 2010).
One method in which MeCP2 binding may promote increased transcriptional efficiency is
through promoting more open and de-condensed chromatin structures and long genes. Such
chromatin arrangements are more favorable for nucleosome sliding and remodeling, which is
required to remove barriers for efficient transcriptional elongation (Bell et al., 2011; Churchman
and Weissman, 2011; Clapier and Cairns, 2009; Zentner et al., 2013). This is supported by
observations from a recent high-resolution in vivo imaging study of genetically mosaic neurons in
Mecp2-null female mice (Linhoff et al., 2015). In this study, they found that Mecp2-null
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hippocampal CA1 neurons display a 20% increase in chromatin compaction in vivo. This was
concomitant with an increase in global H4K20me3, which correlates with transcriptional
repression at gene promoters and silencing of repetitive elements at pericentromeric chromatin
(Schotta et al., 2004; Wang et al., 2008), and a decrease in S5-phosphorylated RNAP II, which
suggests lower transcriptional activity in Mecp2-null neurons. This condensation is likely mediated
by the increase in linker histone H1 expression, which can compete with MeCP2 for chromatin
binding and which doubles in expression in the absence of MeCP2 (Ghosh et al., 2010; Ishibashi
et al., 2008; Skene et al., 2010). Notably, linker histone H1 also inhibits Dnmt3a-mediated de
novo methylation at linker DNA (Takeshima et al., 2008) and exhibits higher affinity for linker DNA
than MeCP2 by salt extraction (Nikitina et al., 2007b). The high levels of MeCP2 in the brain may
thus displace transcriptionally repressive linker histone H1 bound to chromatin, and, through
recruitment of interacting proteins, promote a more open chromatin environment at long neuronal
genes that is not only transcriptionally efficient and leads to higher levels of gene expression, but
may be more open to activity-dependent methylation changes that are important for learning,
memory, and synaptic plasticity (Feng et al., 2010; Wu et al., 2010; Zovkic et al., 2013).
In a recent review of the RTT research field, Adrian Bird and colleagues proposed that
“for a model of MeCP2 function to properly describe the pathology of RTT, it must explain how
the same syndrome can arise from both null mutations and missense mutations predominantly in
two discrete regions of the protein” (Lyst and Bird, 2015). Thus a mechanistic model of RTT must
also be able to explain the severe phenotypic effects associated with mutations in the MBD of
MeCP2, and the relatively milder phenotypic effects and onset of symptoms associated with
mutations in the TRD of MeCP2. Using these criteria, the downregulation of long genes in
neurons, which is dependent on differences in binding affinity using our T158M and R106W mice,
may not be sufficient to initiate the onset of RTT symptoms. This is because missense mutations
in the TRD of MeCP2, as well as C-terminal truncations, lead to a more gradual onset of RTT
phenotypes over time without effecting changes in binding affinity to methylated DNA (Cuddapah
et al., 2014). Given the correlations I established between transcriptional and phenotypic deficits,
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the gradual onset of RTT phenotypes associated with these milder mutations must be
accompanied by the gradual transcriptional downregulation of long genes. This is consistent with
the progressive nature of RTT and the extensive increase in transcriptional deficits among
neurons as T158M mice age over time. Thus a mechanistic model of RTT must also be
consistent with the notion that long genes can be transcriptionally downregulated in the absence
of mutations that disrupt MeCP2’s affinity for methylated DNA. For this to occur, mutations that do
affect MeCP2 binding to methylated DNA, chromatin, and potentially long genes (such as the
T158M and R106W mutations) must increase the rate at which the symptoms progress, which is
consistent with the reduced survival of R106W in comparison to T158M mice. Under this set of
rules, the transcriptional efficiency of long neuronal genes is likely reduced in response to some
other opposing instigating factor that initiates RTT phenotypes (discussed in more detail in
section 4.4.2). MeCP2 binding to long neuronal genes may thus act to buffer that response,
leading to an increase in transcriptional efficiency and proper neuronal function.
Although MeCP2 binding may be necessary to increase transcriptional efficiency, it may
not be sufficient, and other functional aspect of MeCP2 may need to be considered in order to
briefly speculate on a mechanism. The only phenotype that correlated with molecular severity
between T158M mice and R106W mice was life span. As an aside, this suggests that the
transcriptional efficiency of long neuronal genes may be particularly important for HoxB1+
neuronal function in the brainstem and spinal cord. This neuronal population helps mediate
autonomic functions such as respiration and heart rate that are frequently affected in both RTT
patients, and lifespan, which is severely affected in HoxB1+ conditional Mecp2 mice (Ward et al.,
2011). Most published Mecp2 knockin mice have significantly longer life spans than Mecp2-null
mice; the only two mouse models that closely resemble the Mecp2-null (11 weeks) and R106W
(10 weeks) mice in reduced survival are R111G mice (11 weeks) and R270X mice (12 weeks)
(Baker et al., 2013; Heckman et al., 2014). Of the two, R111G mutation resides in the MBD and
severely disrupts binding to methylated DNA; hence the reduction in lifespan is not as surprising.
The R270X is a C-terminal truncation that disrupts an AT-hook domain required to form higher
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order oligomeric structures among nucleosomal arrays (Baker et al., 2013). In addition to a rapid
onset of phenotypes that closely resemble Mecp2-null mice, this mutation retains MBD binding to
methylated DNA in vitro and chromatin in vivo, exhibits no compensatory doubling of linker
histone H1 expression, disrupts transcriptional repression activity by the TRD domain, and
markedly reduces ATRX localization to pericentromeric chromatin in the nucleus (Baker et al.,
2013).
Given a model where transcriptional downregulation of long genes correlates with
phenotypes such as lifespan and is dependent on binding affinity, the R270X mutation suggests
that the NCoR-SMRT interaction, and transcriptional repressor activity of MeCP2 in general, may
be indispensible for promoting the expression of long neuronal genes. The ability to organize
chromatin structure at long genes, perhaps through direct recruitment of the ATP-dependent
chromatin remodeler and helicase ATRX, may be sufficient to increase transcriptional efficiency
of long genes. Perhaps MeCP2 promotes de-condensation of chromatin at long neuronal genes
in order to recruit ATRX, which subsequently maintains a more transcriptionally active
environment though its nucleosome remodeling activity to increase the transcriptional efficiency
of these genes. Such an environment may promote three-dimensional chromatin contacts that
maintain the length-dependent expression of genes. Additional work should thus use HiC to
investigate genome-wide three dimensional nuclear organization and chromatin structure in
various Mecp2-mutant mouse models, which can now be performed at the single cell level and in
intact nuclei for high resolution mapping (Nagano et al., 2013, 2015; Rao et al., 2014).
An A140V mouse model of x-linked mental retardation, which disrupts the ATRX
interaction in mice without affecting MeCP2 binding or transcriptional repressor activity, has been
shown to display reduced cell packing density and reduced dendritic complexity, similar to
Mecp2-mutant mice (Jentarra et al., 2010). However, this mouse model also shows normal life
span, weight gain, and other gross physiological features that distinguish it from Mecp2-mutant
mice, suggesting that the molecular mechanisms between these two proteins are not clearly
understood. Alternatively, if the transcriptional efficiency among long genes is reduced in the
142

A140V mouse model, perhaps the transcriptional downregulation of long genes alone may not be
sufficient to mediate the gross clinical symptoms observed in RTT (discussed in more detail in
section 4.4.2). Further work will be required to generate additional mutations in Mecp2 for cell
type-specific nuclear RNA sequencing and phenotypic assessment.
Together, these nuclear RNA sequencing experiments strongly implicate MeCP2 in
facilitating the expression of long genes within adult neurons at the transcriptional level of gene
regulation, with is consistent with prior studies using mouse brains as well as human-derived
embryonic stem cells (Ben-Shachar et al., 2009; Chahrour et al., 2008; Li et al., 2013a). Although
MeCP2 may exert effects akin to a transcriptional activator, further work will be required to
determine the exact mechanism by which this occurs.

4.4

UPREGULATED GENES INITIATE RETT PHENOTYPES
4.4.1

Summary of Findings

Using aged-matched T158M and R106W mutant male mice at the onset of overt RTT
phenotypes, I sequenced nuclear RNA from cortical excitatory and inhibitory neurons. Genomewide, when MeCP2 function is generally impaired, the expression of short genes is predominantly
upregulated in a length-dependent manner. This argues for MeCP2 in promoting the repression
of short genes, regardless of cortical cell type. The degree to which short genes are upregulated
does not correlate with the degree of MeCP2 impairment, in contrast to downregulated genes.
Furthermore, genome-wide differences between these two mutations were not detected among
genes that are transcriptionally engaged with RNA Polymerase II. Thus the active transcription of
short genes in both excitatory and inhibitory neurons is indifferent, rather than sensitive, to the
differences in MeCP2’s ability to bind to chromatin in vivo; any change to MeCP2 binding or
function may result in the upregulation of these genes. However, the degree to which genes are
upregulated still worsens with age, which correlates with the progressive worsening of
phenotypes when T158M mice are aged an additional 6 weeks.
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The most striking feature observed among FDR-controlled upregulated genes was the
similarity in molecular features between aged-matched T158M and R106W neurons. Upregulated
DEGs in both cell types are typically low expressing, inhibitory-enriched genes (see section
4.2.1). However, the distributions of expression levels are similar between T158M and R106W
mutant neurons, in contrast to the mutation-specific differences in expression levels among
downregulated genes. This suggests that genes that are upregulated in the absence of MeCP2
function may lie upstream of the transcriptional consequences associated with RTT phenotypes.
Furthermore, upregulated DEGs in both T158M and R106W excitatory neurons were similarly
enriched for transcriptional regulators of gene expression. This association was also detected
among cell autonomous DEGs in aged female T158M and R106W excitatory neurons, and was
absent among non-cell autonomous DEGs. Taken together, this suggests that MeCP2 normally
represses inhibitory-enriched transcriptional regulators, and that the cell autonomous derepression of these genes occurs upstream of RTT-associated transcriptional effects. This is in
agreement with genome-wide observations, where the increase in expression of inhibitoryenriched transcription factors, regardless of MeCP2 molecular severity, could promote the global
expression of inhibitory-enriched genes, which are typically short in gene length (described in
4.2.1).

4.4.2

Broader Significance

Given the proposed roll for transcriptionally downregulated genes in modulating RTT
phenotypes (see section 4.3.2) the ectopic expression of inhibitory-enriched transcription factors
within excitatory neurons may serve the role of the “instigating factor” and have pronounced
effects on the transcriptional efficiency of long neuronal genes in vivo. In excitatory neurons,
these factors may act to negatively regulate the expression of long neuronal genes, such as by
disrupting three-dimensional chromatin conformations that are mediated by precise combinations
of transcription factors (Fullwood et al., 2009; Métivier et al., 2003). The strength with which these
instigating factors downregulate long genes may rely on the accessibility of transcription factor
sites at promoters or along the gene body of neuronal genes, which may be physically occluded
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by MeCP2 occupancy itself, or by MeCP2 remodeling of nucleosome positioning with accessory
factors (such as ATRX) (Kernohan et al., 2010, 2014; Thambirajah et al., 2012). Furthermore, as
these instigating factors are continually expressed with time, the intranuclear protein
concentration of these transcription factors will increase, which may lead to the formation of novel
CTCF-mediated chromatin interactions across long neuronal gene bodies that can block RNA
Polymerase II transcriptional elongation across a gene (Mayer et al., 2015). This likely explains
the progressive but extensive downregulation of long neuronal genes that are observed among
aged T158M mice in contrast to younger mice.
Through the association I established between cell type-enriched genes and gene
lengths, these ectopically expressed inhibitory-enriched transcription factors are likely responsible
for the genome-wide length-dependent increase in the transcription of short genes. These genes,
which are similarly affected in both T158M and R106W mutant neurons regardless of GRO-seq
gene filtering, most likely represent the transcriptional upregulation of inhibitory-enriched genes
which tend to be shorter in gene length and would likely be responsive to the increased
expression of their transcription factors. Given that inhibitory-enriched genes are associated with
cellular respiration, metabolism, and mitochondrial function, the length-dependent transcription of
these genes may be associated with mitochondrial abnormalities that have been observed in
neurons of both post-mortem RTT patients and Mecp2 mutant mice (Belichenko et al., 2009;
Cornford et al., 1994; Großer et al., 2012), and would be consistent with reports in recent years
that highlight the similarities in clinical features between RTT and metabolic or mitochondrial
disorders (Buchovecky et al., 2013; De Filippis et al., 2015; Filosa et al., 2015; Müller and Can,
2014; Valenti et al., 2014).
Given my genome-wide observations, the same transcriptional mechanisms described
above may also apply to inhibitory neurons. However, because these inhibitory-enriched
transcription factors are being de-repressed in an inhibitory cell type, this might only result in
strengthening pre-existing chromatin conformations, leading to an increase in the already high
expression of inhibitory expressed genes. This likely explains why the majority of DEGs in 6 week
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T158M and R106W interneurons are upregulated, in contrast to excitatory neurons where genes
are predominantly downregulated. The transcriptional effects on long genes may not be as robust
in interneurons because this cell type does not exhibit the same length-dependent transcriptional
dynamics as excitatory neurons do for long neuronal genes.
The low expression of these instigating transcription factors suggest that these genes are
infrequently transcribed, which supports a mechanism for these genes being de-repressed in the
absence of MeCP2 function. Not surprisingly, this would require MeCP2’s interactions with
NCoR-SMRT and Sin3a histone deacetylase co-repressor complexes. However, models of corepressor function are continually evolving. Rather than contributing to long-term gene
repression, which is likely maintained by histone post-translational modifications such as
H3K27me3 and H3K9me3, co-repressor activity can be a dynamically regulated process to
quickly modulate the expression of genes and the chromatin environment (Perissi et al., 2010).
This is consistent with genome-wide studies of histone deacetylase (HDAC) and histone
acetyltransferase (HAT) occupancy in human cells, which found that the majority of HDACS in the
human genome function to reset chromatin by removing acetylation at active genes, including
genes that may be primed for activation due to the presence of H3K4me3 (Perissi et al., 2010;
Wang et al., 2009).
One of the mechanisms by which this can occur is through the cyclic recruitment of corepressor complexes to genes. Cyclic recruitment to lowly expressed genes may result in a gene
promoter transitioning between an active acetylated “expression” state, and an inactive
deacetylated “repressed” state (Raj and van Oudenaarden, 2008). This can lead to stochastic
transcriptional “bursts” of gene expression whose frequency can be regulated by signaling
pathways that produce biologically-relevant outcomes (Raj and van Oudenaarden, 2008; Raj et
al., 2006) and can occur in mammalian tissues in vivo (Bahar Halpern et al., 2015; Featherstone
et al., 2016). In neurons, stochastic regulation of gene expression may be beneficial for
modulating the activity-dependent expression of ion channels that affect the intrinsic excitability of
pyramidal neurons, which are known to vary in electrophysiological properties from cell to cell
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(Fuzik et al., 2016). In support of this notion, biophysical measurements of networked mitrial cells
in the mouse olfactory bulb reveal that increases in the heterogeneity of intrinsic firing properties
between individual cells were associated with a two-fold increase in the amount of information
that could be processed by these neuronal networks (Padmanabhan and Urban, 2010).
Thus, a model supporting the ectopic upregulation of inhibitory-enriched genes in the
absence of MeCP2 function may also support a role for MeCP2 in regulating stochastic gene
expression, which can effect changes that affect overall neuronal network activity (Blackman et
al., 2012; Maffei and Fontanini, 2009; Nguyen et al., 2012; Qiu et al., 2012; Zhong et al., 2012).
Such a model incorporates a controlled de-repression of inhibitory-enriched transcription factors
that act to negatively regulate long neuronal genes in response to excessive neuronal activity.
Notably, MeCP2 is phosphorylated at S421 and S424 and dephosphorylated at S80 in an activitydependent manner, which are thought to alter its affinity for methylated DNA and chromatin in
vivo (Cohen et al., 2011; Tao et al., 2009; Zhou et al., 2006). Under this cyclic repression model,
subtle changes in MeCP2’s binding affinity, such as those mediated by phosphorylating and
dephosphorylating events, would increase its rate of dissociation from chromatin. I expect the
effect would be strongest among genes with low densities of methyl-CpG or methyl-CpA, in
contrast to long neuronal genes with have high densities of methyl-CpG or high methyl-CpA. This
model predicts that physiological activity-dependent changes in MeCP2 binding affinity for
methylated DNA are subtle, as T158M and R106W mutations, which partially or fully reduce
MeCP2’s affinity for methylated DNA, show the same genome-wide upregulation of genes despite
their strong differences in molecular severity.
Together, these nuclear RNA sequencing experiments indicate that MeCP2 mutations
induce the ectopic expression transcriptional regulators within adult neurons that may act to
initiate RTT symptoms. This requires the transcriptional repressor activity of MeCP2, which is well
established in the RTT field and can be regulated in an activity dependent manner (Ebert et al.,
2013; Lyst et al., 2013; Nan et al., 1997, 1998; Tao et al., 2009). Alterations to MeCP2 binding, or
to its ability to interact and recruit HDAC-containing co-repressor complexes, may lead to the
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same upregulation of these transcriptional regulators. Therefore, the increased expression of
these transcription factors is also consistent with the mutational spectrum of RTT. Interestingly,
this likely explains why the aforementioned A140V mouse model does not display extensive RTT
phenotypes. The A140V mutation, which has been directly compared the R106W mutation in
heterologous cells, does not alter MeCP2 binding, nor does it affect MeCP2-mediated
transcriptional repression (Kudo et al., 2002; Nan et al., 2007). This provides strong genetic
evidence supporting the upregulation of these transcriptional regulators as instigators of the RTT
phenotype. Further work will be necessary to determine if the pathological upregulation of these
instigators is part of a much larger physiological role for MeCP2 in mediating stochastic gene
expression to effect changes in synaptic plasticity.

4.5

POST-TRANSCRIPTIONAL COMPENSATION OF RETT PHENOTYPES
4.5.1

Summary of Findings

In an effort to repeat the findings of several recent reports detailing length-dependent
repression of long genes by MeCP2 (Brown et al., 2015; Gabel et al., 2015; Sugino et al., 2014), I
performed a genome-wide analysis assessing the mean log2 fold change among T158M and
R106W mice using both nascent RNA (chromatin-associated), nuclear RNA (chromatinassociated + nucleoplasm), and whole cell RNA (chromatin-associated + nucleoplasm +
cytoplasm). I found that, though whole cell RNA recapitulated the length-dependent increase in
the expression of long genes that was described in the aforementioned studies, nascent and
nuclear RNA fractions show the opposite trend. In the nucleus, long genes are predominantly
downregulated, whereas short genes are predominantly upregulated. These results show that
MeCP2-mediated gene expression changes in the nucleus reflect true transcriptional changes by
MeCP2, whereas MeCP2-mediated gene expression changes using whole cell RNA reflect
products of post-transcriptional compensation.
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4.5.2

Broader Significance

Multiple studies have corroborated the extensive differences in transcriptome profiles
between subcellular compartments (Bhatt et al., 2012; Djebali et al., 2012; Trask et al., 2009;
Werner and Ruthenburg, 2015). However, the extensive length-dependent differences in gene
expression between nascent, nuclear, and whole cell RNA fractions indicate that MeCP2
mediates biologically relevant transcriptional changes on a genome-wide scale that the cell
actively attempts to minimize. Although alterations to nuclear export may account for some of the
differences in fold change between subcellular compartments, I think a more likely mechanism
lies among ribonucleoprotein (RNP) granules in the cytoplasm. Neurons make extensive use of
post-transcriptional regulatory processes to mediate activity-dependent translation at dendrites,
synaptic terminals, and other areas of the cell (Buxbaum et al., 2015). RNP granules are nonmembranous organelle structures that serve key roles in mRNA homeostasis (Li et al., 2013b),
participating in the localization, modification, and decay of mRNAs, especially during times of
cellular stress. RNP granules include P-bodies, which represent sites of mRNA degradation,
translational repression, non-translating mRNAs and RNA-binding proteins (Jain and Parker,
2013). Another class of RNP granule includes stress granules, which are sites where
translationally stalled or inert RNAs can be stored in the cytoplasm until needed, especially during
translational perturbations (Anderson and Kedersha, 2008).
Given these structures, it’s likely that short genes are exhibiting higher mRNA turnover
and being degraded more frequently miRNA-mediated mechanisms that ultimately target these
short RNAs to P-bodies for degradation. Likewise, stress granules may accumulate in the
cytoplasm to reduce mRNA turnover and mediate the cytoplasmic retention of long synaptic
genes as a way of conserving a limited resource to maintain overall neuronal function. The
incorporation of long genes into stress granules may be of particular relevance to RTT, which
exhibit severe translational deficiencies that are associated with synaptic deficits in plasticity and
are thought to underlie the small soma size of neurons; likewise, Mecp2-null ESC-derived
neurons also display reduced ribonucleotide incorporation of ribosomal RNAs in the nucleus,
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which would lead to an overall cellular decrease in ribosomal content (Li et al., 2013a; Yazdani et
al., 2012).
However, it remains unknown whether post-transcriptional compensation is truly
beneficial, or whether it is effectual in minimizing RTT phenotypes. It would also be interesting to
know how this process is initiated and regulated, particularly during the regression phase of RTT
and onset of symptoms. Of extreme interest, supplementary figure 2a and 2b of (Gabel et al.,
2015) performed genome-wide analysis on Mecp2-null, R270X, and G273X mouse models at 4
week and 9 weeks of age using whole cell RNA. Interestingly, although Mecp2-null mice show a
mean decrease in the expression of short genes at both 4 weeks and 9 weeks of age, the R270X
and G273X mouse models show a mean increase in the expression of short genes at 4 weeks of
age, which are then downregulated (compensated) by 9 weeks of age. This suggests that posttranscriptional compensation in the cytoplasm initiates during the onset of RTT phenotypes.
It also remains an open question whether post-transcriptionally compensated RNAs in
Mecp2-mutant neurons are translated at levels similar to wild-type neurons, or whether these long
neuronal RNAs are sequestered but remain quiescent given the cell autonomous deficiency of
ribosomal RNAs and translational activity. More work is needed to understand the dynamics of
translational regulation in Mecp2-mutant neurons.

4.6

IT’S ALL ABOUT CONTEXT: A MODEL FOR MECP2 IN RETT

SYNDROME
4.6.1

The Model

Within the context of an excitatory pyramidal neuron, and at basal conditions, MeCP2
remains stably bound to long excitatory-enriched neuronal genes with high densities of methylCpG/CpA (modulator genes) to promote efficient and stable expression, which may occur through
increasing nucleosome mobility along gene bodies or participation in three dimensional chromatin
structures. At the same time, MeCP2 dynamically binds to genes encoding inhibitory-enriched
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transcriptional regulators with low densities of methyl-CpG/CpA (instigator genes) in order to
mediate their stochastic expression.
In response to normal neuronal activity, MeCP2 is post-translationally phosphorylated to
subtly reduce its binding affinity for methylated DNA. This decreases its residence time with
chromatin, leading to the stochastic upregulation and expression of instigators, which then act to
negatively regulate the expression of modulator genes. However, MeCP2 remains largely bound
at modulator genes because of higher densities of methyl-CpG/CpA and cooperative binding with
other surrounding MeCP2 molecules that promote higher-order structures. Given that the
distribution of methyl-CpG does not strongly correlate with expression level (Lister et al., 2013;
Mo et al., 2015), modulator genes with high levels of CpG-bound MeCP2 and high transcriptional
activity (Group A modulators) are easily able to buffer the negative effects of the instigators.
However, because methyl-CpA is positively correlated with gene repression (Mo et al., 2015), the
presence of MeCP2 may keep these types of modulator genes from being fully repressed and
results in relatively low levels of transcriptional activity (Group B modulators). The paucity of high
transcriptional activity among Group B modulator genes makes these genes particularly
susceptible to stochastic influences of instigators, resulting in the stochastic downregulation of
Group B modulators. After a certain amount of time, the system resets, de-phosphorylated
MeCP2 resumes its normal dynamic binding at instigator genes, and Group B modulator genes
either return to baseline, or are epigenetically modified to retain the new expression state.
In response to excessive amounts of neuronal activity, MeCP2 is post-translationally
phosphorylated genome-wide, resulting in global decreases in binding affinity. The proportion of
MeCP2 that gets phosphorylated may increase given how long neuronal activity persists, and the
global reduction in binding affinity may be enough to overcome the influence of high density
methyl-CpG/CpA and cooperative binding. Again, this results in the stochastic upregulation and
expression of instigators, which then act to negatively regulate the expression of modulator
genes. However, Group A and Group B modulators are now partially or fully depleted of MeCP2,
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depending on the degree of neuronal activity, and are thus fully susceptible to the negative
regulatory effects of instigators. This leads to a global downregulation of neuronal and synaptic
genes related to neuronal plasticity in order to scale back the excessive excitatory input that the
neuron is receiving. After neuronal activity has passed, the system resets, de-phosphorylated
MeCP2 resumes its normal dynamic binding at instigator genes, and Group A and B modulator
genes either to baseline, or are epigenetically modified to retain the new expression state.
In a T158M RTT neuron, MeCP2’s residence time with chromatin is constitutively
reduced regardless of neuronal activity, leading to the constitutive upregulation and expression of
instigators, which then act to negatively regulate the expression of modulator genes. However,
although MeCP2 T158M exhibits significantly reduced binding to methylated DNA, it still has a
high enough residence with chromatin to exhibit partial binding to Group A and Group B
modulators. The expression of Group B modulators is consistently downregulated because of
their increased sensitivity to the negative influences of instigators. Group A modulators, exhibit a
partial buffering capacity against instigators due to partial binding by MeCP2 T158M, but are still
more resistant to instigators because of their higher levels of transcriptional activity. However, as
the amount of instigator protein increases over time, Group A modulators gradually decrease in
transcriptional activity, with lower expressing genes being more susceptible to downregulation
than higher expressing genes. This results in a gradual downregulation of long neuronal genes
over time.
In a R106W RTT neuron, MeCP2’s residence time with chromatin is constitutively
reduced regardless of neuronal activity, leading to the constitutive upregulation and expression of
instigators, which then act to negatively regulate the expression of modulator genes. However,
MeCP2 R106W exhibits no affinity for methylated DNA and minimal residence with chromatin.
The transcriptional activity of Group B modulators is consistently downregulated because of their
increased sensitivity to the negative influences of instigators. Group A modulators have no
buffering capacity against instigators aside from higher levels of transcriptional activity. However,
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as the amount of instigator protein increases over time, Group A modulators more rapidly
decrease in transcriptional activity, with lower expressing genes being more susceptible to
downregulation than higher expressing genes. This results in a faster rate of downregulation of
long neuronal genes over time, especially when compared to T158M RTT neurons. The rapid
downregulation or change in network activity may induce the expression of immediate early
genes and secretory molecules in an effort to compensate and stimulate synaptic plasticity
processes.

4.6.2

Implications

This model has potential implications for how neurons may respond to neuronal activity at
the transcriptional level. Given that mRNA abundance does not strongly correlate with protein
abundance, Group B modulators may encode genes that are very efficient at being translated into
protein, which can occur with stochastically expressed genes (Raj and van Oudenaarden, 2008).
Thus these genes may encode proteins whose expression at the plasma membrane can be
dynamically regulated at the transcriptional level. In the context of the datasets generated in this
study, Group B modulators represent the R106W downregulated DEGs, which were significantly
enriched for ion channels and transporter activity. Transcriptional changes in genes encoding ion
channels are known to occur in response to neuronal activity; furthermore, neurons use activitydependent feedback mechanisms to regulate receptors and overall membrane conductances
(O’Leary et al., 2014). Computational models show that the most efficient way for homeostatic
mechanisms to occur is to have a “master regulator” that can both detect changes in neuronal
activity and alter neuronal conductance in response (O’Leary et al., 2014). One type of
homeostatic feedback mechanism is called synaptic scaling, an activity-dependent and
transcription-mediated process that scales the expression of ion channels to change the neuron’s
long-term intrinsic excitability until a sense of balance is reached (Turrigiano, 2011). Interestingly,
MeCP2 has been implicated in synaptic scaling, as MeCP2-deficient neurons demonstrate a
failure to scale their neuronal conductance in line with excessive or diminished neuronal activity
(Blackman et al., 2012; Qiu et al., 2012; Zhong et al., 2012). Furthermore, this requires MeCP2
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phosphorylation on S421 and S424, and thus requires a reduction in MeCP2 affinity for chromatin
in vivo (Zhong et al., 2012).
Therefore, the model that I propose to explain the observations I see within T158M and
R106W mice also provides a novel transcriptional mechanism for how MeCP2-mediated synaptic
scaling could occur through activation of a negative feedback circuit in response to neuronal
activity.

4.6.3

Therapeutic Significance

The existence of post-transcriptionally compensated whole cell RNA, which is enriched
for cytoplasmic polyadenylated and ribosome-associated RNAs and is thus used in nearly every
transcriptional study involving MeCP2 (Ben-Shachar et al., 2009; Chahrour et al., 2008;
Colantuoni et al., 2001; Jordan et al., 2007; Kriaucionis et al., 2006; Li et al., 2013a; Mellén et al.,
2012; Nuber et al., 2005; Sugino et al., 2014; Tudor et al., 2002; Urdinguio et al., 2008), may
force a re-assessment as to how MeCP2 should be studied in the future, and does caution the
practice of inferring protein function from changes in gene expression. For example, the existence
of post-transcriptional mechanisms to minimize MeCP2-mediated changes may explain why
some RTT patients, after experience the regressive phase of the syndrome, enter a pseudostationary phase where they partially recover lost developmental skills, and may underlie the
slower rate of symptom onset in female, rather than male mice. However, by assuming from
whole cell preparations that MeCP2 mediates transcriptional repression, advocating the use of
topoisomerase inhibitors to treat RTT patients may do more potential harm than good.

4.7

LIMITATIONS ASSOCIATED WITH WORK

One potential limitation with this work includes the phenotypic characterization of the
T158M and R106W mice. Although these mice exhibit extensive differences in molecular and
transcriptional phenotypes, the physiological and behavioral characterization of these mice is
limited and lacking. More robust behavioral characterizations are required to identify additional
physiological and behavioral phenotypes that correlate with transcriptional changes. This is
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especially important for female mice, which are now ideal for investigating how behavioral and
phenotypic changes correlate with changes in X-inactivation ratios of wild-type and mutant
neurons, especially when R106W mice are more prone to non-cell autonomous changes than
T158M mice. This may unveil new molecular mechanisms that correlate with X-inactivation and
the non-cell autonomous promotion of cellular health, using genetics to lead to the identification of
novel secreted molecules for future therapeutic use.
Another limitation involves the cortical cell types that were profiled. Although two
transcriptionally distinct cell types were isolated, “excitatory” and “inhibitory” neurons are arbitrary
classification schemes in the broadest sense. These two cell types encompass a rich and
extraordinarily wide variety of cell types that are only now coming to light with the advent of new
technology, including single cell sequencing (Fuzik et al., 2016; Tasic et al., 2016; Usoskin et al.,
2015). Each individual neuron is its own cell type, reflecting a unique electrophysiological
signature and gene expression profile that is functionally distinct from another neuron of the same
“cell type” (Fuzik et al., 2016). Thus many of the cell type-specific associations I discovered may
only represent transcriptional dynamics among a functionally heterogeneous group of cells at a
population level. Future studies will be needed to determine how these dynamics are reflected at
the single cell level, which also has the advantage of expanding the number of cell types being
profiled at any one time for more accurate comparisons and biological insights. Single cell
sequencing may be especially important for MeCP2, given the large amount of variability in
transcriptional activity that is observed at the population level.
Another limitation is the lack of MeCP2 binding sites to confirm whether many of the
hypotheses I generated in this dissertation holds true. This could not be helped given the
extensive amount of time I spent over the years trying to optimize cell type-specific MeCP2 ChiPseq. This has been a major limitation for the RTT field, given the global distribution of MeCP2.
However, I believe that the difficulty results from the biology of the protein itself, and limitations on
how ChIP is traditionally performed. The model that I propose in this dissertation predicts that,
although MeCP2 may be found throughout the genome, its binding may be highly dynamic, and
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its resident interactions with chromatin may differ depending on gene length, methylation density,
and cell type in order to dynamically modulate gene expression in response to neuronal activity.
Therefore, traditional methods of ChIP may not be sufficient to capture this dynamic binding of
MeCP2. Novel strategies that assess binding dynamics of proteins over time, such as competitive
ChIP, may be the path going forward to test how differences in MeCP2 binding affinity and
dynamics can influence gene expression in an activity-dependent manner, or in response to RTTassociated mutations.
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